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ABSTRACT 
Magnetic resonance imaging (MRI) is the leading imaging technique for disease diagnos-
tics. MRI contrast agents facilitate MRI technique to obtain tissue-specific image with improved 
sensitivity and signal-to-noise ratio. However, the applications of current MRI contrast agents 
are hampered by their uncontrolled blood circulation time, low relaxivity, and low specificity. 
To address such need, I have developed a series of analitical methods to determine and evalu-
ate the strong metal binding affinity and metal selectivity of developed protein-based contrast 
agents (ProCAs). In addition, we have successed designed contrast agents ProCA3 series based 
on key determinats for metal binding sites and relaxivity. We have dementrated that one of the 
ProCA3 variants, ProCA32, has a high Gd3+ affinity less than 10-21 M and high metal selectivity 
with relxivity of more than 30 mM-1s-1 per Gd and 60 mM-1s-1 per particle. Moreover, we have 
demonstrated that ProCA3 variants have proper blood circulation time, high relaxivity, high 
metal selectivity and low toxicity, which facilitate MR imaging of multiple organs, such as liver, 
kidney, and blood vessels, as well as tumors. ProCA32 is also able to image liver metastases a 
tumor size less than 0.25 mm, which is more than fourty times more sensitive than that of clini-
cal diagnostics of liver metastases using MRI and our developed methodology.  We have further 
created ProCA3 variants with targeting peptide moieties such as ProCA3.bomb or ProCA3.affi to 
against cancer biomarkers such as GRPR and HER2 with capability to imaging tumor biomarker 
expressions in vivo at molecular level. We have shown that ProCA3 has an excellent safety pro-
file and pharmacokinetics for MRI in animals. With our additional effect in protein expression, 
modification, and scale up production of these developed protein contrast agents, ProCA3 is 
expected to be a promising MRI contrast for the diagnostics for disease, such as metastatic tu-
mor and blood vessel abnormalities, and tumor biomarkers.  
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1 INTRODUCTION 
1.1 MRI and MRI contrast agents  
1.1.1 Magnetic resonance imaging  
Magnetic resonance imaging (MRI) is a promising imaging technique, which provides 
three dimensional images of living subjects by exploiting the magnetic properties of water 
hydrogens and their interactions with an external magnetic field. In addition, MRI is a non-
invasive technique and does not require the use of radioactive probes, which significantly 
reduces the potential of side-effects due to radioactive exposure. In addition to its superior soft 
tissue contrast, MRI also has high resolution, especially compared to positron emission 
tomography (PET) and to single-photon emission computed tomography (SPECT). The 
resolution of preclinical scanner can reach 10 µM or even less.  Owing to these advantages, MRI 
has become one of the most prevalent imaging modalities in clinical and preclinical tests.1-3 It 
has wide applicability in diagnosing and following the treatment of different types of cancers 
and other human diseases including various cardiovascular diseases and disorders of the central 
nervous system.4-8 
1.1.2 MRI contrast agents 
Compared to PET and SPECT, however, MRI has relatively low sensitivity. To enhance 
the contrast and sensitivity of imaging, 35% of clinical MRI scans requires the injection of MRI 
contrast agents.9 Current MRI contrast agents are based on paramagnetic, ferromagnetic or su-
per paramagnetic metal ions. All MRI contrast agents can decrease both longitudinal (T1) and 
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transverse (T2) relaxation times of water protons. MRI contrast agents that can decrease the 
same level of T1 and T2 relaxation times of water protons are called T1-weighted MRI contrast 
agents. Contrast agents that cause much shorter T2 than T1 are called T2-weighted contrast 
agents.10 T1-weighted contrast agents are preferred due to their capability of generating bright-
er contrast. Gadolinium (Gd3+), a lanthanide metal with seven unpaired electrons, long electron 
spin relaxation time, and high magnetic moment, is one of the most widely used ions in T1-
weighted MRI contrast agents.11  
1.1.3 Clinical MRI contrast agents 
MRI contrast agents increase the difference in contrast between tissues by changing the 
tissue relaxation time. Since the first MRI contrast agent, gadopentetate dimeglumine, ap-
proved in 1987, MRI contrast agents have been successfully applied in the MR imaging of dif-
ferent type of tissue. They have also been successfully applied in diagnostics and characteriza-
tion of tumors and other diseased tissue where the permeability of the blood vessel is changed, 
such as infrared, strock, liver fibrosis, neoruon degenerative diseases and so on. These clinical 
contrast agents are applied to probe abnormal function organs such as liver, kidney, and gall 
bladder. 
In general, currently clinically approved Gd3+-based MRI contrast agents are all formed 
by one Gd3+ encapsulated by organic chelators, such as DTPA or DOTA (Table 1-1). Total 8 nitro-
gen and oxygen from chelator function as Gd3+ binding ligands. In addition, Gd3+ in clinical MRI 
contrast agent has one coordination water molecule, and water molecules robustly interact 
with Gd3+ through the Gd-O interactions. Based on the charge and structures of chelators, cur-
rent clinically approved Gd3+ MRI contrast agents can be divided into four groups: ionic linear 
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contrast agents (Magnevist, Multihance, Abalavar and Eovist), non-ionic linear contrast agents 
(Ominiscan and Optimark), ionic cyclic contrast agents (ProHance and Gadovist) and non-ionic 
cyclic contrast agents (Dotarem).  Except Multihance and Eovist, most of the clinical MRI con-
trast agents function as extracellular contrast agents, are excreted from kidney. These are ap-
plied to image the whole body, blood vesculature and central nervous system with great suc-
cess. Eovist and multihance can be uptaken by the hepatocyte with 50 % and 5 % billiary excre-
tion, respecitvely. These two contrast agents are widely applied for the imaging of liver and 
billiary diseases, such as hepatocellular carcinoma, PEComa, liver metastases, and liver 
fibrosis.12, 13  
With the application of MRI contrast agents, contrast enhanced MRI became one of the 
best imaging technique for the disease diagnosis. Take the diagnosis of liver metastases as an 
example. The diagnosis of the liver metastases mainly relies on imaging techinques, such as 
MRI, CT, untrasound and PET. MRI is the best diagnostic approach for the liver metastases. 
With the administration of the contrast agents, MRI can detect all of the liver metastases with a 
size of 2 cm or larger and most of those are 1 -2 cm in size. Although intraceaoprative ultra-
sound may detect leisions down to 2 mm, such technique requires surgery and can only detect 
tumors on the surface of the liver.14 Besides disease diagnosis, clinical MRI contrast agents play 
critical roles in MRI guilded biopsy and MRI guilded intervention therapy for many types of 
dieseases, such as prostate cancer and liver cancer.15 
While having many advantages, current clinical contrast agents have a short half-life 
time (half-life of approximately 0.5 - 3 minutes in the blood vessels of mice and elimination half 
life of about 1.5 hours in patients16, 17) because of their small molecular mass. If the properties 
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of MRI contrast agents are optimized, this would lengthen the time window for MRI data collec-
tion and eliminate repeated dose injections. Moreover, the number of potential biological tar-
gets for molecular imaging could be significantly increased if the detection limits of the contrast 
agents were improved (~30 µM in mouse skeletal muscle for the contrast agent [Gd(HP-
DO3A)(H2O)]18). All of these factors have driven the need to develop contrast agents with sig-
nificantly improved relaxivity, optimal retention time, and increased potential targeting capabil-
ities. In my Ph. D. reasearch, we developed a new class of the protein-based MRI contrast 
agents (ProCAs). I will introduce my research regarding the improvement of relaxivity, blood 
retention, and molecular imaging with biomarker targeted ProCAs in Chapters 4, 7 and 8. 
The toxicity and pharmacokinetics of clinical MRI contrast agents have been well charac-
terized since 1980. A high safety profile has been found in all of these studies.  They were also 
proven to be safer than iodinated contrast agents for CT and x-ray radiography. However, clini-
cal MRI contrast agents require an injection dosage of 0.1 - 0.3 mmol/kg and a local concentra-
tion of 100 μM of contrast agent to clearly see contrast differences in tissues. The injection 
dosage and concentration could be theoretically lower if the longitudinal relaxivity (r1) of the 
contrast agents were optimal. Concerns have been raised in renal toxicity caused by release of 
free Gd3+ from the most commonly used contrast agent, gadolinium-diethylene-triamine-
pentaacetic acid (Gd-DTPA), with increased reports of nephrogenic systemic fibrosis (NSF), a 
complication found in patients with end stage renal failure (GRF < 30 ml min-1). 19, 20,21-24   
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Table 1-1. Clinical Gd3+-based MRI contrast agent. 25-29 
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1.1.4 Criteria for the design of Gd3+ MRI contrast agents 
Several factors must be considered for a ideal contrast agent. First, negligible or low 
toxicity is a prerequisite. The contrast agents should be thermodynamically and kinetically 
stable, with high binding affinity and metal selectivity to minimize the release of free Gd3+. A 
high metal selectivity for paramagnetic metal ions against physiological metal ions such as Zn2+ 
and Ca2+ is required.30, 31 Second, high relaxivity, especially for longitudinal relaxivity, is 
preferred in order to obtain images with high dose efficiency and high contrast-to-noise ratio 
(CNR). Third, an ideal contrast agent should have proper vascular retention time allowing for 
imaging of tissue enhancement, gauging tissue blood perfusion, and evaluating changes in 
capillary integrity. Different strategies have been applied to increase the contrast capability of 
small chelator based MRI contrast agents. For example, the non-covalent binding of small 
chelators to plasma proteins, such as albumin (MS-325), greatly increases the relaxivity and 
blood retention time. On the other hand, the applications of those contrast agents are currently 
limited to magnetic resonance angiography.32, 33 A contrast agent with proper excretion time 
from the body is desired for optimal imaging and reduced toxicity. Molecules that are greater 
than 7 nm (~ 60 kDa) in diameter are able to pass through the glomeruli. The circulation half-life 
of the aforementioned molecules, compared to molecules with a hydrodynamic diameter of 
less than 5 nm, dramatically increases to over 78 minutes in mice, as the molecular weight is 
larger than 60 kDa.34-37 Finally, targeting specific molecular entities is greatly desired for 
increasing the specificity of MRI contrast agents as powerful diagnostic and prognostic tools 
with the advantage of high spatial resolution. Due to limited expression of biomarkers in the 
disease region, developing contrast agents with high dose efficiency, low toxicity, optimal 
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pharmacokinetics, and capability of targeting and permeability are required for robust 
molecular imaging. A thorough understanding of the relaxivity theory will be beneficial for the 
development of MRI contrast agents with optimized relaxivity. 
1.1.5 Relaxivity theory 
Proton relaxivity ri (in units of mM
-1s-1) represents the efficiency of a paramagnetic 
contrast agent to enhance the relaxation rate of water protons. The relaxivity can be defined in 
Equation (1-1), 
]/[)
T
1
is
T
1
(=ir
3
 Gd
ib
 i = 1, 2        (1-1) 
where ri is the relaxivity, Tis is the relaxation time of water protons in the presence of 
contrast agent with a certain concentration, Tib is the relaxation time of water protons without 
contrast agent, and [Gd3+] is the concentration of Gd3+. The ri is composed of the contributions 
from inner sphere ri
IS, second coordination sphere ri
2nd, and outer sphere ri
OS (Equation 1-2). 
The r1
IS and r1
2nd can each be defined by varying parameters q, T1m, and τm in Equation (1-3),  
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ii r+ r+ r = r    i =1, 2           (1-2)                                                   
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where PM is the mole fraction of metal ion per solvent molecule, q is the number of wa-
ter molecules bound per metal, T1m is the relaxation time of bound water, and τm is the resi-
dence time of the bound water (the reciprocal of the water exchange rate, kex) (Fig. 1-1). 
The factors which influence T1m are described by the Solomon-Bloembergen Equation
38-
40 (Equations 1-4 to 1-7).   
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where T1
DD is the relaxation time of bonded water generated by dipole-dipole (DD) 
mechanism, T1
SC is the relaxation time of bonded water generated by scalar or contact (SC) 
mechanism, γI is the nuclear gyromagnetic ratio, g is the electron g-factor, μB is Bohr magneton, 
μ0 is permeability of vacuum, S is the spin quantum number of the metal ion, rGdH is the dis-
tance between Gd3+ and a proton, τc is the correlation time, A/ћ is the electron-nuclear hyper-
fine coupling constant, ωI is the proton nuclear spin, and ωs is the electron spin resonance fre-
quency (rad s-1), which is 658-fold of ωI. Since the contribution of T1
DD is much more pro-
nounced than T1
SC in Gd3+-based MRI contrast agents, the effects of scalar or contact mecha-
nism can be neglected.41  
To optimize T1m for the design of novel contrast agents, τc should be carefully 
considered. τc is a time constant that refers to local magnetic fluctuations. These local magnetic 
fluctuations are characterized by electronic relaxation time of metal ion (Tie), rotational 
correlation time of metal water complex (τR), and residence time of the bound water (τm).  
T iemci R
1111


  i=1,2              (1-7)                                                                                                     
9 
For metal ions with S >1/2, the collision between ions and solvent molecules induces the 
zero field splitting (ZFS) of the electron spin level. Tie is related to ZFS, which is characterized by 
the modulation of zero-field-splitting interaction (τv) and the mean-square zero-field-splitting 
energy (Δ2). As described by Bloembergen, Morgan42 and McLachlan43 in Equations (1-8) -(1-
10), Tie is governed by the magnetic field, the spin quantum number, τv, and Δ
2.  
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Tie is largely determined by the environment of metal ion, which is largely determined 
by τv, and Δ
2. The Tie value in low field (B < 0.1T) is small, and dominates τc. For gadolinium 
based contrast agents, as field strength increases, the electron spin relaxation time increases. τR 
becomes the dominant factor. T1e (electronic longitudinal relaxation time) is about 10 ns and 
T2e (electronic transverse relaxation time) is 1 ns at 50 MHz in water.
17 Based on our simulation 
by Equations (1-8)-(1-10) using τv =10 ps and Δ
2 = 5 × 1019 s-2, the strong magnetic moment of 
Gd3+ gives a T1e value of about  0.5, 2.8, 10.5, 64, and 114 ns at 20, 60, 120, 200, 300, and 400 
MHz, respectively.  
  
10 
 
Figure 1-1. Relaxivity theory of Gd3+-based MRI contrast agents. 
A. Schematic representation of a Gd3+ chelate surrounded by bulk water with one inner sphere 
and two second sphere water molecules; τR refers to the rotational correlation time of the mol-
ecule and kex to the water/proton exchange rate or the reciprocal of residence lifetime of the 
coordinated water τm. Modified after Toth et al.
38 B. Simulated magnetic field-dependent 
relaxivity r1 of clinical MRI contrast agents based on the given τR, τm, τv, and Δ
2 and Equations (1-
3 to 1-10) using combinations of τR (100 ps), τm (0.1, 1, 10, and 100 ns), τv (10 ps), and Δ
2 (5×1019 
s-2) under a magnetic field strength from 0.01 MHz to 1000 MHz. Clinical MRI contrast agents 
such as DPTA and other small molecules have τR at 100 ps level. Their relaxivity values are 
shown at the level of 5 mM-1 s-1. C. Simulated magnetic field-dependent relaxivity r1 of macro-
molecular MRI contrast agents based on the given τR, τm, τv, and Δ
2 and Equations (1-3 to 1-10) 
using combinations of τR (10 ns), τm (0.1, 1, 10, and 100 ns), τv (10 ps), and Δ
2 (5×1019 s-2) under 
a magnetic field strength from 0.01 MHz to 1000 MHz. Our protein-based MRI contrast agents 
have a τR at 10 ns level, and their relaxivities can be increased to be more than 10- to 20- fold 
greater than that of clinical MRI contrast agents at the clinical field strengths. This simulation 
was performed using Solomon-Bloembergen-Morgan (SBM) Equations (Equations 1-3 to 1-10) 
based on different τR (100 ps, and 10 ns), τm (0.1, 1, 10, and 100 ns), τv (10 ps), and Δ
2 (5×1019 s-
2).38-40, 42, 44  
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Figs. 1-1B and C show our simulations of the relaxivity as a function of resonance 
frequency changes based on equations (1-3) through (1-10). Here, we only consider the 
contribution from the dipole-dipole mechanism. For Gd3+-based MRI contrast agents, the 
contribution from the scalar or contact mechanism is too small to be considered.41 For small 
molecules (Fig. 1-1B), a short τR is the major reason for the low relaxivity seen in these contrast 
agents. Contrast agents based on small chelators such as DTPA have a τR of approximately 54 ps 
at 37 ˚C.28  This value is much smaller than Tie (T1e is about 2.8 ns at 60 MHz based on 
simulation) and τm (143 ns).
28, 29 According to Equation (1-7), the reciprocal of correlation time, 
1/τc, is described by the three time constants Tie, τR, and τm. The smallest value of these time 
constants governs the value of τc.
10 Therefore, τR determines the value of τc, which 
subsequently determines T1m and thus restricts the relaxivity to values less than 10 mM
-1s-1, 
regardless of the adjustment of the other parameters. In order to generate an effective image, 
a contrast agent concentration of 0.1 mM is needed.10, 45, 46  
Since τR is the limiting factor for r1 at clinical magnetic field strengths, optimizing τR can 
effectively increase relaxivity. As shown in Figs. 1B and C, when τR increases from 100 ps to 10 
ns, r1 increases from 3.7 to 46.1 mmol
-1 s-1 at 60 MHz (τm = 10 ns). The theoretical calculation by 
the Solomon-Bloembergen-Morgan (SBM) Equation shows that the maximum relaxivity, r1, can 
be achieved is up to 100 mM-1s-1 for Gd3+ contrast agents with q=1 and optimized τR (around 10 
ns) and τm. Maximum relaxivity is calculated in a magnetic field strength ranging from 0.5 T to 
1.5 T. Outside of this range, the relaxivity is dramatically reduced. With increased application of 
MRI in higher magnetic field, there is a strong need to develop MRI contrast agents with 
improved relaxivity in higher magnetic field. Caravan and colleagues41 show that contrast 
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agents with τR values ranging from 0.5 to 4.6 ns exhibit excellent relaxivity at high magnetic 
field. Furthermore, according to Helm’s44 simulation, the optimized τR decreased to about 1 ns 
at 3 T and further decreased to less than 1 ns at 9.4 T. Accordingly, the optimized τm decreases 
from about 20 ns at 1.4 T to less than 10 ns at 9.4 T. Increasing the molecular weight of contrast 
agents by covalently or noncovalently linking Gd3+ chelates to large molecules can slow the 
overall τR of the molecule, but this approach does not necessarily increase the local τR of the 
Gd3+-1H vector, and the relaxivity of this class of contrast agents is usually much lower than the 
expected relaxivity due to internal flexibility and uncontrolled local motion.10  
Relaxivity can also be enhanced by optimizing τm. When τm is too small, relaxivity 
decreases because the coordination water in the complex does not have enough time to be 
relaxed. On the other hand, if τm is too large, the relaxation effects will not be transferred to the 
solvent effectively.10 τm influences the relaxivity in two ways. In addition to being a component 
of 1/T1 as described by Equation (1-3), τm also indirectly contributes to the relaxivity by 
changing τc as described by Equations (1-3 to 1-7). If τm is smaller than τR and Tie, T1m is governed 
by τm (Equation 1-7). τm can be measured by recording the transverse relaxation rate as a 
function of temperature using O17-NMR or by fitting into the nuclear magnetic resonance 
dispersion (NMRD) profile. 
For macromolecules with a τR of around 10 ns, modifying τm will significantly change the 
relaxivity.  As shown in Fig. 1-1C at 20 MHz, relaxivity can be increased from < 5 mM-1 s-1 at a τm 
of 100 ps to ~ 25 mM-1 s-1 at τm of 1 ns, to a maximum of 46 mM
-1 s-1 at τm of 10 ns, and then 
decreased to 39 mM-1 s-1 at τm of 100 ns. According to the simulation by Doble and coworkers, 
the optimal value of τm is 30 and 15 ns in 20 and 60 MHz, respectively.
47 Replacing the 
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oxygen/nitrogen donors of the aminocarboxylates by oxygen ligands from hydroxypyridinone 
complex increases the water exchange rate by decreasing the energy differences between 
eight- and nine- coordinate states, which in turn enhances the relaxivity of the MRI contrast 
agents.47-49 The relaxivity of these classes of contrast agents is further increased upon binding 
to human serum albumin via benzyl derivatives or PEG.47, 49 A pH responsive contrast agent 
(GdDOTA-4AmP5-) was developed based on  τm values that vary in response to pH changes, from 
a slower inner sphere water exchange (τm = 26 µs) at high pH to a faster exchange at low pH 
due to the protonation of four phosphate groups at the Gd3+ binding sites.50  
The relaxivity enhancement is also associated with rGdH. As shown in Equations (1-4) and 
(1-5), T1m is also affected significantly by the distance between Gd
3+ and its coordination water 
proton (rGdH). 1/T1m is a function of 1/rGdH
6. The reported distance between Gd3+ and water 
proton in the inner sphere of the contrast agent varies between 2.7 to 3.3 Å.10 However, most 
of reported rGdH are obtained by fitting NMRD profile in different magnetic fields.
10 Electron-
nuclear double resonance (EnDOR) spectroscopy studies demonstrate that rGdH is approximately 
3.1 Å for 8- and 9-coordinated Gd3+ complex, and rGdH is independent of the ligand type or the 
total charge.33, 51, 52  
For small molecules, contributions from the second sphere to the overall relaxivity are 
usually not significant due to the lack of interface for interactions with water, fast water 
diffusion, fast molecular tumbling, and longer proton Gd3+-proton distance. However, such 
contributions cannot be neglected when calculating a macromolecule complex with an 
optimized τc and large interface for water molecule interactions. The Equations to describe the 
second sphere relaxivity are the same as Equations (3) to (5); the only differences are replacing 
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water number, correlation time and Gd3+-water distance (rGdH
2nd) with values corresponding to 
the second sphere. According to the simulation at 20 and 60 MHz with rGdH
2nd = 5 Å, τR = 10 ns, 
τm = 10 ns, and q = 4, the second sphere relaxivity in a protein metal complex could potentially 
increase to 3.3 and 8.8 mM-1 s-1, respectively. A class of small molecules with q = 0 exhibit 
considerable relaxivity.53 Such relaxivity can be further enhanced upon binding to albumin.10, 33 
In this case, the second and outer sphere water of this class of molecules were proposed to be 
influenced by Gd3+.  
Although the SBM Equation is widely used to characterize relaxation phenomena, the 
application of the SBM Equation is subject to several limitations. First, SBM is invalid in low 
magnetic fields. Electronic spin Hamiltonian is contributed by time dependent Zeeman energy 
and time independent ZFS energy. The perturbation theory assumption (redfield limit) to the 
SBM is valid at high field strength, where Zeeman energy is much larger than ZFS energy.10,44,54, 
55 Second, Tie is field dependent and the Equations (1-8) and (1-9) are only valid as 
monoexponential processes occurring in a very narrow magnetic field range (ωs
2τv
2 << 1). Out-
side of this extreme field condition, the electronic relaxation becomes multiexponential.41, 54, 55 
Third, to apply the SBM Equation to macromolecules such as dendrimers and nanoparticles, the 
overall τR can not be equal the τR of Gd
3+ -1H vector. This is because the rotation of Gd3+-1H vec-
tor is much more flexible than the macromolecule itself and the relaxivity increase is limited by 
uncontrolled local motion.29 Fourth, the relaxivity of Gd3+ chelators conjugated to large mole-
cules such as proteins could decrease, since donors present in proteins near the Gd3+ location 
interact with Gd3+ to decrease the water number.56, 57  
As shown from Equation (1-2), the overall relaxivity of contrast agents is composed of 
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the inner sphere, 2nd sphere and outer sphere relaxivity. In the outer sphere, the interaction 
between Gd3+ and water is only governed by translational diffusion. In principle, 
macromolecules have a greater potential to tune outer sphere relaxivity because their 
environments have different solvent accessibility and hydration surface as opposed to small 
chelators. The contribution of the outer sphere relaxivity to the overall relaxivity is described by 
the diffusion coefficient of water and the distance to Gd3+ using the hard-sphere model 
(Equation 1-11 to 1-13).58-60 
        
 (1-11) 
i=1, 2      (1-12)
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Where NA is Avogadro’s number, ħ is the Dirac constant, [M] is the concentration of the 
metal ion, a is the distance of closet approach between water and Gd complex, D is the sum of 
the diffusion constant of solvent proton and Gd-complex. τD is the diffusion correlation time, 
j(ω) is the spectral density function, Re stands for “the real part of”.  
Due to the contribution of outer sphere relaxivity, some contrast agents with no inner-
sphere water molecules also have high relaxivity. Gd(C11-DOTP)
5- is a Gd-DOPT5- derivative  with 
q = 0. Gd(C11-DOTP)
5- has an overall r1 relaxivity about 4.6 mM
-1 s-1 at 20 MHz at 25 ˚C, which 
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dramatically increase to 23 mM-1 s-1 when it binds to albumin. The NMRD of this contrast agent 
fits well with outer-sphere relaxivity theory for q = 0 complex with rapid outer sphere water 
exchange, indicating that the outer-sphere water plays a critical role on the relaxivity of Gd(C11-
DOTP)5- and albumin-Gd(C11-DOTP)
5- complex.61  
1.2 Current progress in development of Gd3+ MRI contrast agents with improved relaxivity 
1.2.1 Application of Gd3+ labeled protein as MRI contrast agents 
The relaxivity of clinical contrast agents, such as Gd-DTPA, is not optimized, which 
requires high injection dosage. Gd3+ is labeled to proteins with improved imaging capabilities. 
Two strategies were used to label proteins with Gd3+: (1) covalent or noncovalent conjugation 
of Gd3+-chelates to proteins; (2) directly designing Gd3+ binding pockets on the protein (the 
protein itself serves as a chelator). The first strategy has been extensively studied to develop 
MRI contrast agents. Some Gd3+ chelates were designed to noncovalently interact with 
proteins, which dramatically changes the relaxivity and distribution of Gd3+ chelates.32, 33 In 
addition, proteins, such as albumin, were directly reacted with DTPA-dianhydride and the 
DTPA-proterin complex and then loaded with Gd3+.62  Gd3+-labeled albumin has been applied to 
many preclinical studies, such as evaluating tumor permeability and angiogenesis by dynamic 
contrast enhanced MR imaging of cancer tissue, and monitoring the changes of tumor 
vasculature.63, 64  Dr. Meade and colleagues developed a class of biodegradable contrast agents 
based on conjugation of evenly distributed lysine residues on protein polymers to Gd-chelates. 
By optimizing the polymer length and lysine distribution, an r1 of 14 mM
-1 s-1 per Gd3+ and 461 
mM-1 s-1 per particle (60 MHz and 37 ˚C) was achieved. Interestingly, these contrast agents can 
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be degraded by plasmin, which facilitates fast excretion in vivo.65  
Since it is not an easy task to build a Gd3+ binding site on a protein with high Gd3+ 
binding affinity, only a few groups use strategy (2) to label Gd3+ to proteins. In this strategy, 
protein functions as chelater to interact Gd3+ and the key parameters that govern relaxivity can 
be optimized by protein design. The design and application of this class of contrast agents will 
be introduced in section 1.3 and 1.4. 
1.2.2 Current progress to improve the relaxivity of the contrast agents 
Since relaxivity is a key determinant for dose efficiency of MRI contrast agents, several 
strategies have been applied to improve the relaxivity. One of the most used strategies 
currently is to increase τR, since the τR of small contrast agents is on the order of 100 ps, which 
is the limiting factor to increasing the relaxivity (Fig. 1-1B and C). Meade and coworkers have 
conjugated three to seven DOTA-Gd-alkyne complexes to azide to form a triazole ring with 
constrained local rotation of the Gd3+ complex. They found that the relaxivity of DOTA-Gd-
alkyne increases along with molecular size and restricted rotation of Gd(III) chelates. Gd-DOTA-
alkyne derivative with one Gd3+ has a relaxivity of 3.2 mmol-1 s-1 (at 60 MHz 37 ˚C). The per Gd3+ 
relaxivity with seven Gd-DOTA complex increases up to 12.2 mM-1 s-1 at 60 MHz 37 ˚C.66  
Since τR increases with expanding molecular weight, macromolecular-based contrast 
agents have been generated either by covalent binding of small monomeric agents or by non-
covalent binding to macromolecules such as proteins (e.g. serum albumin) and polylysine with 
an observed increase in relaxivity (Table 1-2).67-73 Nanosized candidates, such as dendrimers, 
micelles, liposomes, nanoparticle emulsion, lipid nanoparticles, viral capsid, and nanotubes (Ta-
ble 1-2), have been conjugated with chelators such as DTPA or DOTA. Due to the increase in 
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molecular size, the per Gd3+ relaxivities of these contrast agents are increased several folds 
compared with current clinical contrast agents. Although the relaxivity values are much lower 
than the theoretical upper limit, the per particle relaxivity can be extremely high due to high 
amount of Gd3+ conjugation. For example, the per Gd3+ relaxivity of emulsion is 10.8 mM-1 s-1 at 
60 MHz, which is approximately three-fold higher than that of Gd-DTPA. Raymond’s group con-
jugates gadolinium chelates to the interior and exterior surfaces of MS2 viral capsids which 
leads to a peak relaxivity of 41.6 mM-1 s-1 at 30 MHz74. 
 Unfortunately, it is not an easy task to optimize τR and τm for macromolecular-based 
contrast agents, as the macromolecular contrast agents face several limitations. First, the local 
motion of the Gd3+-1H vector is hard to optimize due to the flexible spacer between the carrier 
and the contrast agent. In addition, since r1 decreases when ω
2τc
2 > 1 (Equations 1-3 to 1-7), 
macromolecular contrast agents, such as nanoparticles that have a large τR, may exhibit a sharp 
drop in relaxivity at high magnetic field. Moreover, as our simulation shows in Fig. 1-1C, when 
macromolecules have optimized τR value (in range of 10 ns) in clinical magnetic fields, τm often 
becomes the limiting factor to significantly increasing the relaxivity. Macromolecule contrast 
agents face an additional size limitation because increased size results in low permeability in in 
vivo applications. Furthermore, the size and charge differences in these high payload MRI con-
trast agents could influence blood distribution, which could potentially lower the efficient de-
livery of the contrast agents to the desired targeting site.  
Tight noncovalent aggregation between small Gd3+ contrast agents with protein deriva-
tives can yield significantly higher relaxivity due to decreased local motion and increased τR.
33  
Binding to albumin, a 65 kDa protein in the serum, increases τR of MS-325, and consequently 
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increases the relaxivity of MS-325 from 6.9 to 42 mM-1 s-1 at 20 MHz 37 ˚C.75 Binding to albumin 
also increases the blood circulation of MS-325. Recently, several responsive contrast agents 
have been developed based on τR values that vary with a change in relaxivity due to either me-
tabolite76 or zinc-triggered binding of small chelators  to albumin.77 Proton relaxivity can also be 
increased by decreasing the internal motion of the contrast agents through multilocus 
binding.78  Caravan points out that targeting contrast agents to other proteins could potentially 
increase relaxivity by decreasing τR. For example, the relaxivity of EP-2104R, a fibrin-specific 
contrast agent with four Gd-DOTA molecules conjugated to a fibrin targeting peptide, increases 
from 10.1 mM-1 s1 at 60 MHz 37 ˚C in TBS buffer to 17.8 mM-1 s-1 in clotted plasma at 60 MHz 
37˚C.79 Similarly, collagen targeted contrast agent, EP-353380, exhibits a comparable r1 increase 
in the presence of plasma.  
According to Equation 1-3, increasing q should significantly shorten the relaxation time 
of water protons and result in a higher relaxivity. However, increasing q for small chelators may 
decrease the stability of the metal chelator complex because of the risk of free Gd3+ release. 
Tweedle suggests that Gd3+ deposit in bones is correlated with instability of gadolinium contrast 
agents.21, 81, 82 In addition, when q increases from 1 to 2, Gd3+ has greater solvent accessibility 
and is able to interact with anions56, 57 which decreases the relaxivity. Therefore, most of the 
clinically approved contrast agents, except for ProHance with q = 1.3,81 have an inner sphere q 
value equal to 1.  
Recently, Raymond’s group designed a series of contrast agents using 
hydroxypyridinone class compounds with increased q values. When q is equal to 2, r1 is 
increased to approximately 9 mM-1 s-1 at 20 MHz 25 ˚C.45, 47-49, 83, 84 When q is equal to 3, the 
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relaxivity is further increased up to 13.1 mM-1 s-1 at 20 MHz 25 ˚C. Interestingly, their primary 
stability constant pGd value is 18.7, which is similar to the stability constant of clinical contrast 
agents.85 However, the design of Gd3+ binding proteins with desired change of water 
coordination number is not reported. I will introduce my research on the optimization of 
relaxivity and metal stability of ProCA3 variants by manupulating of water number at the 
coordination shell (Chapter 4). 
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Table 1-2. The relaxivity of typical Gd3+- based MRI contrast agents. 61, 62, 72, 77, 78, 84-102 
 
 CA class Compounds r1 (mM
-1 s-1) r2 (mM
-1 s-1) B0 (T) 
Designed proteins CA1 117 129 1.5 
Small compound Gd-DTPA 5.4 8 1.5 
Pyridine-N-oxide Analogues 4.54  0.47 
HOPO derivatives Gd-TREN-1,2-HOPO 10.5  0.47 
Gd-TACN-3,2-HOPO 13.1  0.47 
Cell-permeable CAs Gd3+-DTPA-Arg8 7.8  1.5 
Linear polymer Gd4(H2O) 4.5  9.4 
Dendrimers Gadomer-17 13  1.5 
Protein carriers Albumin 11.5 12.4 0.25 
Poly-lysine 13 15 0.47 
protein polymer contrast 
agents 
14  1.5 
High-density lipoprotein 41 55 0.47 
Multimeric CAs  12.2  1.5  
Targeting peptide 
conguated CAs 
EP-2104 24.9  0.47 
17.8 27.7 1.5 
EP-3533 27.9  0.47 
15.6 32.5 1.5 
EP-1084 27.7  0.47 
Liposome ACPL 12 11 1.5 
porous polymersomes porous polymersomes 7.2  1.5 
Nanoglobular MRI CAs G3 nanoglobular MRI CA 10.0  3 
Nanoparticle emulsion Gd-perfluorocarbon 
nanoparticles 
34 50 1.5 
Ca2+-protein α-lactalbumin 4.2 5 3 
Nanoassembled Capsules NACs 24  0.54 
Gold Nanoparticles Au@DTDTPA-Gdx 4.1  7 
Y-DtNP ~60  0.7 
Lipid Nanoparticles GdDOTA(GAC12)2 40  0.47 
Hydroxypyridonate Viral 
capsid conjugates 
Gd-TREN-bis-HOPO-TAM-CO2H 41.6  0.7 
Dendrimer Nanoclusters dendrimer nanoclusters 12.3  1.5 
Trimetallic Nitride 
Metallofullerene CA 
Gd3N@C80[DiPEG(OH)x] 79  2.4 
Nanodiamond Nanodiamond 58.82  1.5 
Paramagnetic 
nanoparticles 
Gd@C82(OH)22±2 61.1  4.7 
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1.3 DESIGN OF PROTEIN-BASED MRI CONTRAST AGENTS WITH HIGH RELAXIVITY 
1.3.1 Choice of protein as a scaffold for designing MRI contrast agents 
We have developed a class of novel MRI contrast agents with high relaxivity using 
proteins as a scaffold. Our design of protein-based contrast agents (ProCAs) is based on several 
considerations in addition to the above discussion about relaxivity theory. First, proteins are 
biocompatible materials that are advantageous for in vivo applications. There are many protein 
drugs such as insulin that have been successfully applied against human diseases.86 Second, 
some well-folded proteins have a proper size which allows for good circulation time and tissue 
penetration. A well-packed globular protein with molecular weight of 10 - 14 kDa has a size of 2 
- 3 nm that can be easily excreted from the kidneys. Third, through numerous efforts, we have 
developed computational and protein engineering strategies to design metal binding sites in 
proteins with high coordination and strong metal binding properties. Fourth, the structural and 
dynamic properties of some proteins have been well studied by various methods, especially 
high resolution NMR. These properties are essential for designing Gd3+-MRI contrast agents 
with desired metal binding and relaxation properties. Fifth, once the high relaxivity and metal 
binding affinity have been achieved, it is relatively simple and straightforward to extend the 
applications to targeted contrast agents with the addition of targeting moieties for various 
disease biomarkers by protein modification. Sixth, current advances in biotechnology and 
pharmacology facilities make it feasible to produce a large number of protein agents for 
preclinical and clinic needs. 
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1.3.2  Design of MRI contrast agents using CD2 as a scaffold 
Based on our hypothesis that an MRI contrast agent with high relaxivity, high dose 
efficiency and strong metal binding affinity can be achieved by designing Gd3+ binding sites into 
a scaffold protein with desired metal binding properties and relaxation parameters such as q, τm 
and τR, we have chosen domain 1 of the cell adhesion protein, CD2, as a scaffold protein to host 
Gd3+-binding sites. Domain 1 of CD2 is a small (99 amino acid) well packed beta-sheet protein 
with a popular Ig fold. It has a rotational correlation time value of ~ 10 - 30 ns87 which matches 
the optimal relaxivity for the current clinically allowed magnetic field strength. It has a size of 
about 2.5 nm with good circulation and tissue penetration.88 In addition, we have successfully 
designed several calcium binding sites with similar coordination properties to Gd3+ using our 
developed computational methods and established structural parameters describing the 
common properties of Ca2+ and Ln3+ binding sites.89-97 Further, we have determined the NMR 
structure of one of the CD2 variants and demonstrated that it has the desired metal binding 
geometric properties. These unique factors make CD2 one of the best candidates for the design 
of protein-based MRI contrast agents.  
The design of Gd3+ binding sites is based on our analysis of metal binding sites in over 
500 small chelators and metal proteins. Gd3+, Tb3+ and Ln3+ have coordination similar to Ca2+ 
with a strong preference for oxygen ligands. Although small molecules such as DTPA use both 
oxygen and nitrogen as ligands, proteins almost always use oxygen as a ligand with an average 
number of 7.2 for Ln3+.98 For example, oxygen ligands from the side chain oxygens of Glu15, 
Glu56, Asp 58, Asp62 and Asp64 are used at different stretches of the protein sequence. One 
position of metal geometry is left open to allow fast water exchange between solvent and 
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metal (Fig. 1-2). We reasoned that an embedded metal binding site without internal flexibility is 
the key to achieving high relaxivity. As a comparison, we have also created a metal binding site 
with high flexibility by inserting a Gd3+ binding loop between positions 52 and 53 with flexible 
linkers between them, named CA9.CD2.  
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Figure 1-2. A carton demonstration of ProCA1 with PEG modifications.  
Oxygen ligands from the side chain of Glu15, Glu56, Asp 58, Asp62 and Asp64 are used at dif-
ferent stretches of the protein sequence. One position of metal geometry is left open to allow 
fast water exchange between solvent and metal. Adapted with permission from referernce99.   
26 
The relaxivity values of the designed contrast agents are determined at 1.5, 3 and 9.4 T. 
As shown in Table 1-2, the designed contrast agent ProCA1, previously named CD2.CA1, 
exhibits per Gd3+ r1 relaxivity up to 117 mM
-1 s-1 at 1.5 T 25 ˚C, a more than 20-fold increase 
compared to that of Gd-DTPA. This is very important since it allows a significantly lower local 
concentration of Gd3+ (~ 0.69 μM) for high resolution imaging.  
1.3.3 Factors contributing to high relaxivity in ProCAs 
Several factors such as correlation time and inner, second, and outer sphere water 
number contribute to the significantly increased relaxivity in ProCAs compared to small 
molecular-based contrast agents.  
Optimized correlation time is one of the major reasons for the significantly increased 
relaxivity of ProCAs. As shown in Equations (3)-(10) and Fig. 1-1C, a protein contrast agent with 
τR of ~ 10 ns has near optimal relaxivity value at clinically relevant magnetic field strength (1.4 
T). We have applied high resolution NMR to probe the dynamic properties of our designed 
protein contrast agents.87, 100 Consistent with other proteins of similar size, the τc of protein MRI 
contrast agents is 9.08 ns in the presence of metal and 9.20 ns in the absence of metal. The 
dynamic NMR experiments suggest that the metal binding pocket of the protein contrast agents 
rotates along with the scaffold protein as a rigid complex. In contrast, the relaxivity of CA9.CD2  
is much lower than ProCA1(r1 = 3.5 mM
-1 s-1 at 3 T 25 °C), in which the Gd3+ binding site is linked 
by flexible linkers and the estimated τc of  the flexible metal binding site is 3.04 ns.  
Water number is also optimized in the protein-based MRI contrast agents. As shown in 
Equation (3), the relaxivity of the contrast agents is directly related to q. The relaxivity of the 
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contrast agent can be increased when more water molecules can interact with Gd3+ at the same 
time. An enzyme responsive contrast agent, Egad, inhibits water access to Gd3+ (q = 0) by 
appending a galactopyranose moiety to a Gd-DO3A chelate. In response to galactosidase 
activation, galactopyranose sugar is cleaved from Gd3+, and the Gd3+ is exposed to water 
proton. After enzyme cleavage, q increased from 0.7 to 1.2101 and the r1 increased from 0.903 
mM-1 s-1 to 2.72 mM-1 s-1 accordingly.102 Using the luminescence lifetime of Tb3+, we have 
shown that the water number of protein contrast agent ProCA1 is 2.1.103 An increase of the 
water number q will increase the relaxivity (Equation 3). In addition,  proteins with large 
molecular surfaces may have additional contributions from 2nd sphere relaxivity that could 
reach 3.3 and 8.8 mM-1 s-1 at 20 and 60 MHz, respectively (τR = 10 ns, τm = 10 ns, q = 4, rGdH = 5 
Å).  Taken together, it is likely that coordination water from the inner, second, and outer 
spheres of ProCA1 may all contribute to the dramatic increase of relaxivity of ProCA1.  
The success in the design of the first generation ProCA, named ProCA1 opens a new 
avenue to significantly increase relaxivity. However, clinical application of contrast agents also 
requires strong metal binding stability and high payload if possible.  In this dissertation, we will 
report our design of a new generation of the ProCAs, named ProCA3 variants. This new 
generation of the ProCAs has multiple Gd3+ binding sites in one scaffold protein with improved 
stablitity, solubility, and pharmacokinetics. The design of the ProCA3 variants will be discussed 
in Chapter 3.  
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1.4 IN VITRO AND IN VIVO PROPERTIES OF PROTEIN-BASED MRI CONTRAST AGENTS  
1.4.1 Thermodynamic and conditional stability of MRI contrast agents 
Long term toxicity of the contrast agents is caused mainly by the toxic systemic effects 
of Gd3+  and free chelators (the LD50 of Gd
3+ is 0.2-0.3 mmol/kg and the LD50 of Na3Ca-DTPA  is 5 
mmol/kg).104 Gd3+ has an ionic radius of 0.99 Å, which is very similar to the ionic radius of Ca2+. 
Therefore, free Gd3+ is likely to compete with Ca2+ in the biological system and cause further 
interference with the Ca2+ signaling pathway by interacting with calcium binding proteins such 
as calcium sensing receptor,105 Ca-ATPase,106 and voltage-gated calcium channels.107 
The metal stability of contrast agents to Gd3+ often is characterized by the 
thermodynamic stability, the conditional stability, and the kinetic stability. Since Gd3+-based 
contrast agents are used in medical diagnosis, it is extremely important that Gd3+ and chelators 
remain in complex in vivo, and that they exhibit high metal binding stability and selectivity. 
Thermodynamic stability can be described by Equations (1-14) and (1-15),  
GdLLGd          (1-14) 
][][
][
LGd
GdL
KML

          (1-15)
 
 
where KML is thermodynamic stability constant, [GdL] is the concentration of metal 
ligand complex and [Gd] and [L] are the concentrations of free Gd3+ and ligand in the solvent. 
Clinical MRI contrast agents have thermodynamic stability constants ranging from 16.6-25.8 
(log KML) (Table 1). ProCA3, a new generation of contrast agents with two Gd
3+ binding sites, has 
a thermodynamic stability constant of 21.6, which is greater than Gd-DTPA-BMA (log KML= 16.6)  
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(Xue et al., unpublished data). The conditional stability constant characterizes the stability of 
the metal-chelator complex at physiological pH, which considers protonation of the chelator at 
pH 7.4.81 To assess the metal binding affinity and selectivity of ProCAs, we have applied several 
spectroscopic methods such as dye competition and Tb3+-sensitized energy transfer. ProCA1 
has a metal selectivity for Gd3+ over physiological metal ions (log (KGd/KCa) > 9.84, log (KGd/KMg) > 
10.06, log (KGd/KZn) = 5.34). Although the Gd
3+ binding constant (log Ka) for ProCA1 is weaker 
than DTPA, the metal selectivities of ProCA1 for Gd3+ over Zn2+ and Mg2+ are 2.4 fold and 1.3 
fold greater than Gd-DTPA (log (KGd/KMg) = 4.25, log (KGd/KZn) = 4.17). The ProCA1 metal 
selectivity values of Gd3+ over Ca2+ are comparable to Gd-DTPA (log (KGd/KCa) = 11.70).
103  We 
further assessed the stability of Gd3+ binding under conditions mimicking the extracellular 
environment and the effect of other biological metal ions on the relaxivities of ProCAs. The 
relaxivities (r1 and r2) of ProCAs were not significantly affected in the presence of up to 10 mM 
excess Ca2+, supporting the strong stability and metal selectivity for the Gd3+-protein 
complex.103 
It is worth pointing out that achieving unprecedentedly strong metal stability and 
selectivity of our designed Gd3+-protein, significantly greater than those of a few reported 
peptides or designed protein-based complexes, is not a trivial achievement because of in vivo 
applications. For example, a peptide fragment encompassing an EF-hand calcium binding loop 
and a DNA-HTH motif was designed with a thermodynamic stability constant of 5.2 and r1 
relaxivity of 21.2 mM-1 s-1 at 60 MHz 37 ˚C.108 A thermodynamic stability constant of 7.1 was 
reported for metal binding to a genetically engineered subunit of cowpea chlorotic mottle virus 
(CCMV) capsid with r1 relaxivity of up to 210 mM
-1 s-1 per particle at 61 MHz 23˚C.109 Clearly, 
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significant improvement of Gd3+ binding affinity is a prerequisite for in vivo application.  
Due to the unique nature of proteins, traditional methods such as pH titration110 can not 
be applied to determine metal stability of protein contrast agents.  To address such need, I have 
developed a series of analitical methods to determine and evaluate the metal binding affinity 
and metal selectivity of developed protein contrast agents. In addition, we dementrate that one 
of the ProCA3 variants, ProCA32, has a high Gd3+ affinity less than 10-21 M and high metal 
selectivity. This part of work will be discussed in Chapter 4.  
1.4.2 The kinetic stability and metal selectivity of MRI contrast agents 
Metalloproteins plays essential roles in the biological system. Ca2+ binding proteins play 
varity roles on cell proliferation, migration, protein-protein interaction, protease activation, 
signal transduction, immunoresponses et al.,.111-124 Metaloproteins such as Ca2+- and Zn2+- 
binding proteins could potentially interact with free Gd3+ released from contrast agents in vivo. 
Blood plasma and interstitial fluid contain multiple ions such as Ca2+ and Zn2+ that can 
potentially compete with Gd3+ in the contrast agent to release free Gd3+. High concentrations of 
phosphate (0.6 M) and bicarbonate (0.36 M) in the biological system form a precipitant with 
free Gd3+, which in turn further drives the disassociation of Gd3+ from the metal contrast agent 
complex. The rate of this dissociation process is determined by the kinetic stability properties of 
the contrast agents; contrast agents with high kinetic stability will release less Gd3+ per unit 
time.125 To evaluate the kinetic stability, the dissociation rate of the Gd3+ from the complex is 
usually measured at pH=1, at which the dissociation rate of a contrast agent is significantly 
increased compared with physiological pH. Generally, linear contrast agents have higher 
dissociation rates or lower kinetic stability than cyclic contrast agents. Among these approved 
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contrast agents, Gd-DTPA-BMA has the lowest kinetic stability, while Gd-DOTA has highest 
kinetic stability. Wedeking et al.,126 show that the dissociation rate of the Gd-chelator complex 
correlates well with the Gd3+ retention in mice 14 days after injection of these Gd3+ chelates.  
1.4.3 Transmetallation studies of MRI contrast agents 
The transmetallation of Gd3+ chelates by physiological ions such as Fe3+, Cu2+, and Zn2+ 
must also be considered in the development of the contrast agents. Laurent et al., applied the 
relaxometric protocols to compare the transmetallation of the approved contrast agents (2.5 
mM) in the presence of 2.5 mM Zn2+ in the phosphate buffer. Highest kinetic stability was 
observed for Gd-DOTA.127 Frenzel et al.,128 further tested the kinetic profile of Gd3+ dissociation 
of Gd3+-based MRI contrast agents in serum for up to 15 days using coupled HPLC-ICP-MS. 
Nonionic linear contrast agents, such as Gd-DTPA-BMA, show 10 times higher Gd3+ release than 
that of ionic linear contrast agents, such as Gd-DTPA. In contrast, no free Gd3+ release is 
detected from macrocyclic contrast agents, such as Gd-DOTA.128 All this data indicates cyclic 
contrast agents have increased kinetic stability compared to linear contrast agents.  
1.4.4 Acute and chronic toxicity study on MRI contrast agents 
The physiological deposit sites of Gd3+ are in bone, lung, and liver. Gd3+ retention in 
bone correlates directly with the dissociation rate of the contrast agents. Tweedle et al., 
compared the Gd3+ retention in mice 14 days post injection of Gd3+ chelates with different 
dissociation rate. Mice injected with Gd-DTPA-BMA or Gd-NP-DO3A showed much higher Gd3+ 
accumulation in the whole body, especially in bone and liver, than that of the mice injected 
with Gd-DOTA or Gd-HP-DO3A.126 Gibby et al., analyzed Gd3+ concentration in the bones of hip 
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replacement patients after injection of 0.1 mmol/kg Gd-HP-DO3A or 0.1 mmol/kg Gd-DTPA-
BMA. Their findings indicated that Gd3+ retention was 1.77 μg Gd/g bone for Gd-DTPA-BMA and 
0.447 μg Gd/g bone for Gd-HP-DO3A, revealed by ICP-AES.82 The dissociation of the contrast 
agents, especially in patients with preexisting kidney conditions, is proposed to trigger NSF. 
Recent biopsies of NSF patients found insoluble Gd3+-phosphate deposits in the skin.129 The 
long term fate of internalized paramagnetic liposomes is well characterized by Kok et al., The 
distribution and relaxivity of the contrast agents were tracked for five days after internalization. 
Both r1 and r2 of the contrast agents were much lower than the starting r1 and r2, due to the 
gradual dissociation of Gd3+ from the contrast agents and interaction with intracellular anions 
such as phosphate and Zn2+ to form precipitates.130      
The acute toxicity of contrast agents was studied in our laboratory with cytotoxicity and 
blood enzyme tests. The cytotoxicity of designed proteins was examined with cell lines SW620, 
SW480 and HEK293, using the MTT assay.131, 132 A slight decrease in viability was observed in 
HEK293 cells treated with CD2 and ProCA1 protein. No cytotoxicity was observed in all tested 
cells treated with designed proteins and concentrations up to 50 µM. In addition, the acute 
toxicity, measured with liver enzymes (ALT, ALP, AST, LDH), urea nitrogen, bilirubin, and total 
protein from CD1 mice 48 hours post tail veil injection of 4 µmol/kg ProCA1, was found to be 
negligible compared to control subjects (CD-1 mice). 103 
  Long term toxicity can also be caused by immunogenicity towards contrast agents. To 
test the immune response to ProCA1 and PEGylated ProCA1, they were injected into a rabbit 
and ProCA1 was found to illicit a weak antibody production shown with rabbit antiserum, 
magnified with the addition of adjuvant. Injection of PEGylated ProCA1 with adjuvant produced 
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an even weaker antibody production compared with ProCA1 without adjuvant, as shown by 
ELISA. No significant immuno-responses were observed without using adjuvant. The results 
suggest that the protein MRI contrast agents do not generate strong immune-responses in 
rabbits.99  
The serum stability test is useful for screen unstable compounds in vitro. To test the 
resistance to enzymatic cleavage, we have analyzed the serum stability of designed proteins by 
incubating the designed proteins in complex with an equal concentration of GdCl3 in human 
serum at 37 ˚C. The degradation of the protein was analyzed by both SDS-PAGE and MALDI 
mass spectrometry. The results showed that the protein remained intact for at least 48 hours in 
the absence of serum as well as in the presence of 70% human serum following the 48 hour 
incubation.103 Although great achievement has been made in the design of protein based MRI 
contrast agents with good acute toxicity safety profile, the long term Gd3+ retention and 
pharmacokinetics of ProCAs have not been well studied in detail. In Chapter 7, I will introduce 
my researches on the biodistribution, pharmacokinetics and toxicity study of ProCAs variants. 
1.5  In vivo MR image enhancement by the developed protein contrast agents  
After tail vein injection of 2.4 μmol Gd3+/kg ProCA1, which is about 40-fold lower than 
the dosage of Gd-DTPA used in diagnostic imaging, we observed the MRI contrast enhancement 
in several organs of CD-1 mice at 3 T, 4.7 T and 9.4 T. The T1 contrast enhancement in the kidney 
cortex diminished substantially 18 h after the administration of Gd3+-CA1.CD2.103 To further 
increase the contrast capability, protein-based MRI contrast agents with four and two Gd3+ 
binding sites in a single protein, were engineered, expressed and characterized (denoted as 
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ProCA2 and ProCA3, respectively). Fig. 1-3 shows that tail vein injection of 0.02 mmol/kg 
ProCA3 (~10-fold lower dosage (0.02 mmol/kg) than that of Gd-DTPA (0.2 mmol/kg)) resulted in 
an enhancement of blood, liver and kidney 50 minutes post-injection at 4.7 T. The blood 
circulation time was much longer than small molecule contrast agents, which indicates that 
ProCA3 could be potentially used as a blood pool contrast agent. The enhancement of liver and 
kidney completely disappeared two days after injection.103  
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Figure 1-3. Mouse MR imaging before (left) and after injection of modified ProCA3 for 50 min 
(right). 
0.02 mmol/kg of ProCA3 was injected into the anaesthetized CD1 mouse via tail vein. The 
mouse was scanned before injection (left) and 44 min post injection (right). MR imaging were 
generated under 4.7 T magnetic fields with TR =40 ms and TE=2.9 ms. After inject with ProCA3, 
the liver, blood vessel and kidney show high contrast enhancement. 
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Using inductively-coupled plasma mass spectrometry (ICP-MS), we analyzed the 
biodistribution of Gd-ProCA1 in different mice organs one hour after injection compared to Gd-
DTPA and GdCl3. Gd-ProCA1 was predominantly located in the kidney of injected mice.  Almost 
no increasing signal was detected using Gd-DTPA and GdCl3 was detected mainly in the liver.
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These biodistribution results were further confirmed using immunohistochemical staining and 
ELISA assay by monitoring protein in different tissues.103 In Chapter 7, I will further report our 
research of the biodistritbuion of ProCAs analyzed by various techniques. 
1.6 MOLECULAR IMAGING BY MRI AND BY PROTEIN-BASED MRI CONTRAST AGENTS 
1.6.1 Molecular imaging by MRI 
Current assessments of disease biomarkers in patients using invasive methods such as biopsy 
coupled with immunostaining are prone to errors. For example, one out of five HER2/Neu clini-
cal tests for breast cancer provides incorrect results, which severely affects the selection of ap-
propriate patients for personalized treatment using targeted therapies.134, 135 With its capability 
to provide repetitive and non-invasive assessment of biological/disease processes of the same 
organs at various time points, molecular imaging of disease biomarkers by MRI can potentially 
be an ideal method to enhance our understanding of the disease, to monitor disease progres-
sion and to monitor the effect of drug activity during preclinical and clinical drug treatment. Use 
of MRI for molecular imaging is likely to significantly reduce the cost and number of animals 
required for preclinical studies. However, the application of MRI to assess specific disease 
markers for diagnosis and drug effect monitoring has been severely hampered by the lack of 
contrast agents that combine high relaxivity, targeting capability, and tissue permeability.  
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In principle, molecular imaging of diseases via receptor-mediated recognition depends 
on several factors including the number of receptors on the cell surfaces, the binding affinity of 
the target peptide to the receptor, the diffusion capability, circulation time, and kinetic 
stability. The majority of receptors or biomarkers have an expression level of < 106 per cell. 
Unfortunately, about 5×106 Gd3+/cell are required to obtain a clear contrast enhanced image 
using currently approved contrast agents based on small chelators (e.g. DTPA) because of the 
low relaxivity of 5 mM-1s-1.136 Although endocytosis of contrast agents in tissue is considered a 
beneficial process for accumulation of a contrast agent in a local area, recent studies show that 
the relaxation enhancement is “quenched” and reaches a plateau when the local concentration 
of Gd is higher than 1010 Gd3+/cell.137-139 The decline of the relaxivity in this case is probably 
caused by insufficient water exchange across the plasma membrane. 
To achieve molecular imaging by MRI, many studies have been devoted to developing 
targeted MRI contrast agents.80, 140-155 Most reported molecules are targeted to biomarkers ex-
pressed on the surface of blood vessels and it is difficult to target the biomarkers outside of the 
blood vessels. In order to improve the dose efficiency, antibodies and peptide fragments with 
high affinity to receptors are extensively used in conjugation with high payload MRI contrast 
agents, or contrast agents with high dose efficiency. Demitri et al. developed two-component 
Gd3+-based MRI contrast agents by the binding of avidin-Gd3+ complexes to tumor cells 
prelabeled with a biotinlyated antibody in two steps.156, 157 Unfortunately, the practical applica-
tion of these contrast agents to target tumors in vivo is limited by slow diffusion. We and others 
have shown that an antibody exhibits improper distribution and mainly clusters around the tu-
mor blood vessel even 24 hours-post injection in mice.155 Due to their relatively small size com-
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pared to the antibodies, peptide fragments have excellent tissue penetration.149, 158-160 Howev-
er, molecular imaging by peptide targeting requires further improvement in targeting capability 
and resistance to protease cleavage. To date, very limited success has been reported in spite of 
significant research conducted to improve molecular imaging with MRI. Therefore, there is a 
critical need for the development of MRI contrast agents with significantly improved relaxivity 
and improved targeting capability to image the expression level and spatial distributions of bi-
omarkers by MRI. 
1.6.2 Molecular maging gastric-releasing peptide receptor by ProCA1.GRP 
GRPR is a cancer biomarker with a high expression level in many cancer cells and a low 
expression level in normal cells.161-164 Its natural ligand, gastrin-releasing peptide (GRP), can 
tightly bind to GRPR with a dissociation constant of about 2 nM.165 
We have further developed protein-based MRI contrast agent with targeting capability 
for molecular imaging of cancer biomarkers such as gastric-releasing peptide receptor (GRPR). 
We hypothesize that insertion of GRP to ProCA1 (denoted as ProCA1.GRP) provides a strong 
targeting capability for the molecular imaging of prostate cancer using MRI via the specific 
interaction between GRPR and ProCA1.GRP. GRP is grafted between residues 52 and 53 of 
ProCA1 (denoted as ProCA1.GRP(52)) (Fig. 1-4) or linked to the C-terminal of ProCA1 (denoted 
as ProCA1.GRPC). The targeting capability of the developed GRP-targeting contrast agent has 
been examined using various binding assays. ProCA1.GRP(52) showed higher binding capability 
with GRPR positive cancer cells compared to ProCA1.GRPC. 
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Figure 1-4. Model structure of ProCA1.GRP(52). 
Model structure of ProCA1.GRP(52) predicted by I-TASSER.166-168 The tumor targeting peptide, 
GRP, is grafted in ProCA1 with flexible linkers.  
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We then tested whether ProCA1.GRP can be applied to the targeted imaging by 
scanning the cancer cells using MRI. Cancer cells with different GRPR expression levels were 
incubated with ProCA1.GRP. The cells with high GRPR expression, PC3 and DU145, showed 
enhanced signals in the presence of our targeted MRI contrast agents as demonstrated by T1-
weighted imaging. In contrast, no changes were observed in H441 cells, which have a low 
expression level of GRPR. We also evaluated the targeting capabilities of ProCA.GRP in the living 
animals with a prostate tumor model. Fig. 1-5 shows that PC3 tumor in xenograft mice can be 
imaged by intratumoral injection of Gd-ProCA1.GRP(52),164 which indicate that Gd-
ProCA1.GRP(52) is promising for the MR imaging of expression level of GRPR.  
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Figure 1-5. T1-weighted MR imaging of PC3 (circled) xenograft mice pre and post intratumoral 
injection of Pro-CA1.GRP(52). 
T1-weighted MR imaging of PC3 (circled) xenograft mice pre and post intratumoral injection of 
ProCA1.GRP(52). A. Pre-injection; B. 10 min post injection; C. 30 min post injection; D. 24 h post 
injection; E. 48 h post injection. F. MRI signal intensity changes from PC3 tumor before and af-
ter injection of ProCA1.GRP(52). Modified after Wei et al.164 
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1.6.3 Molecular imaging of Her-2 expression by ProCA1.affi 
Breast cancer is the second most common cancer in women. According to national 
cancer institute, it is estimated that 39,510 women will be diagnosed to have breast cancer and 
39,510 women will die for this disease. HER-2 is a major prognosis biomarker expressed in 30% 
breast cancer and 60 - 70% of DCIS tissue. Monitoring the spatial and temporal changes of 
several molecular biomarkers such as HER2/EGFR sharing the same signaling pathway during 
cancer progression and treatment is the key for understanding the molecular basis of cancers, 
for early and accurate diagnosis, and for developing effective drugs with synergistic effects to 
treat this deadly disease. Biomarkers such as the epidermal growth factor receptors EGFR and 
HER2/Neu are highly expressed in various diseases such as breast and ovarian cancers and play 
important roles in disease progression and survival. They are also major drug targets for 
targeted therapy. Since the clinical application of targeted therapy is largely limited because 
current methods for assessment of these cancer biomarkers involve invasive methods, such as 
biopsy. The effectiveness of the target therapy largely depends on the pre-selection of patients 
over-expressing these biomarkers. To date, one of five HER2/Neu clinical tests, including biopsy 
and immunohistochemistry (IHC), provides incorrect results, leading to improper selection of 
appropriate patients for personalized treatment using biomarker targeted therapies.134, 135 
There is an urgent need to develop non-invasive and accurate methods for diagnosis and 
selection of patients and to monitor biomarker levels/distribution and their changes upon 
treatment by targeted drugs.  
Due to the high relaxivity and tumor penetration, we use ProCA1.Affi to carry the 
molecular imaging of HER-2, instead of using HER-2 antibody for molecular imaging. We linked 
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HER-2 affibody at the C-terminal of ProCA1. The fusion protein, named ProCA1.affi, has a 
molecular weight of 15 kDa. HERE-2 affibody strongly and selectively binds to HER-2 with a Kd of 
22 pM, which is comparable with the binding affinity of antibody.  
Since ProCA1.affi has high relaxivity, high tumor penetration, and high binding affinity to 
HER-2, ProCA1.affi could be used as a prognosis tool to evaluate HER-2 expression level in 
tumor. We implant tumors in mouse. SKOV-3 has high HER-2 expression level (106 
receptors/cell), whereas MDA-MB-231 tumor has low HER-2 expression level (104 
receptors/cell). As show from Fig. 1-6, after tail vain injection of contrast agents, ProCA1.affi 
can specifically enhance MR images of SKOV-3 tumor which has high expression level of HER-2. 
These results indicate that ProCA1.affi can be used to evaluate the expression level of HER-2 
biomarkers by the molecular imaging of MRI. It could be further applied to quantitatively 
evaluate tumor biomarker expression using MRI. 
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Figure 1-6. Molecular imaging of HER-2 by ProCA1.affi. 
(a) Model structure of ProCA1.Affi. (b) Magnetic resonance imaging (MRI) of HER-2 xenograft 
tumor (SKOV-3 and MDA-MB-231) before and after injection of 0.02 mmol/kg ProCA1.affi. (c) 
Tumor intensity changes over time postinjection of ProCA1.affi. SKOV-3 has much higher HER-2 
expression and SOKV-3 has more MRI signal enhancement than that of MDA-MB-231. The MRI 
signal intensities of SKOV-3 or MDA-MB-231 tumor regions from six adjacent slides were 
quantified by Image J software. The average signal intensities and the standard derivation were 
then calculated from these six adjacent slides. (d) MRI of the mouse SKOV3 tumor pre-blocked 
by affibody ZHER2:342 (bottom) and without blocking (top). Adapted with permission from 
referernce.155, 169  
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Mainly due to the large size and low permeability, antibody is not an ideal targeting 
moiety for molecular imaging. To test the penetration of contrast agents to tumor, we linked 
the HER-2 targeting moiety, affibody, to ProCA (named ProCA1.affi) and then compared the 
tumor penetration of antibody (MW about 150 kDa) and ProCA. Affi (MW about 15 kDa) at 
different time point. We I. V. inject either HER-2 antibody or ProCA.affi into the SKOV-3 tumor 
bearing mice. ProCA.affibody can be stained in the tumor after 4 hours post injection. On the 
contrary, no antibody in tumor can be stained by IHC at the same time point. ProCA.affi are 
evenly distributed in tumor with high concentration 24 hours post injection, whereas the 
antibody only localized in the region near the blood vessel with much lower accumulation (Fig. 
1-7). These results indicate that ProCA.affi has a proper size for tumor penetration and 
targeting.99, 103, 155, 164, 169 In Chapter 7, I will report our studies to develop biomarker targeted 
contrast agents based on ProCA3 variants with signficantly imporved stability and shorter blood 
rentention time than ProCA1 vairants for molecular imaging of cancers. 
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Figure 1-7. Immunofluoresence imaging of ProCA1.affi (left) or HER-2 antibody (right) in 
SKOV-3 xenograft tumors in mice after IV injection. 
ProCA1.affi and HER-2 antibody are stained with red color. Blood vessel is stained with green 
color. ProCA1.affi is evenly distributed in tumor 24-h post injection, whereas HER-2 antibody 
only accumulated in near the blood vessel. Adapted with permission from references.155 
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1.7 Development of MRI contrast agents for both T1-weighted and T2-weighted MRI. 
The relaxation decay of water can be characterized into two processes: spin-lettice 
relaxiation time (T1) and spin-spin relaxiaition time (T2). As show in Fig. 1-8, once put a proton 
into a constant magnetic field, the net magnetisation will be face z axis. After giving a RF pulse, 
the net magnetisation will be forced in to different directions. After this radio frequency is fin-
ished, the protons will return to the orgininal state. Such process can be characterized by ob-
serving the signal increase on the z-axis (T1 relaxiation time) or the signal loss on the xy-plane 
(T2 relaxiation time).   
 The signal differences of tissue in MRI are determines by the T1 and T2 relaxation time 
differences in these tissue and such differences can be visilized by MRI using different repeti-
tion time (TR) and echo time (TE). Based on the different TR and TE, the basic MRI scnascan be 
devided in devided three major groups: T1-weighted MRI, T2 (or T2*)-weighted MRI, proton 
density MRI. T1-weighted MRI usually have a short TR (at around 300 – 500 ms) and shor TE, T2 
(or T2*)-weighted MRI have a long TR (usually more than 3 s) and long TE (at around 40 – 100 
ms), while proton density imaging have long TR (more than 3 s) and shor TE (at around 10 ms). 
By utilizing different TR and TE parameters, MRI is able to show the differences of T1 or T2 (or 
T2*) of the tissue, or both of them.
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Gadolinium-based MRI contrast agents are most frequently used as T1 contrast agents 
due to its ability to short the T1 time of the water and tissue, while the ion oxide nanoparticles 
are widely used as T2 weighted MRI contrast agents because of their high efficiency or shorten-
ing T2 of the tissue. Most of the MRI contrast agents can be used to either increase MRI signal in 
T1 weighted sequence or decrease MRI signal in T2 weighted MRI, but these contrast agents 
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cannot be applied to both T1-weighted MRI and T2-weighted MRI with the same contrast agents 
because of their intrinsic properties. In addition, clinical Gd3+-based MRI contrast agents has 
very low relaxivity and sensitivity which further limits their application in T1-weighted MRI. 
In princle, if a MRI contrast agent has both high r1 and r2, such contrast agent can be 
used to increase signal in T1-weighted MRI and to decrease the signal in T2-weighted MRI. In 
addition, the MRI signals changes induced by these contrast agents can be further boosted by 
deviding the MRI signal from T2-weighted MRI to T1-weighted MRI. We name this approach as 
T2/T1 ratiometic imaing. As show from Fig. 1-8 and Equation 1-1 and 1-2, the T2/T1 ratiometric 
imaging can futher increase the signal to noise ratio and decrease unwanted signal generated 
by the proton density differences, inhomogenecity of magnetic field and motion artifacts. 
Xiaoyuan Chen and colleagues use iron oxide nanoparticles with T2-weighted contrast agent 
mixed with Gd-DTPA, a T1-weighted MRI contrast agents, with effert to improve the in vivo con-
trast capabilities.171 However, the dramatically different PK/PD limits the effect of both T1 and 
T2 proterties.  To data, such concept has not been widely reported in the literature due to the 
limited relaxivity of small contrst agents. This question will be addressed in Chapter 5. 
1.8 Motivation of this dissertation and questions to be addressed 
In the past three decades, Contrast- enhanced MRI has heen widely successfully applied 
the disgnosis of different type of disease, such as cancer and cardiovascular diseases. Althroguh 
great achievement has been made, the current application of the contrast agent in MRI still 
have some major limitations need to be improved, such as transmetalation, low relaxivity and 
unble to apply for molecular imaging. In the past 10 years, our lab developed a novel class of 
MRI contrast agents using protein as Gd3+ chelator. The protein-based MRI contrast agents 
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(ProCAs) have more than 10 times higher r1 and r2 relaxivity than that of clinical MRI contrast 
agents. Such high relaxivity improves the dose efficiency in vivo. In addition, because of the high 
relaxivity and longer blood rention time, the targeted ProCA1 variants can be applied for mo-
lecular imaging of biomarker using MRI for the cancer diagnosis. However, the metal stability, 
metal selectivity, protein production of first generation of ProCA needs to be improved. In addi-
tion, the application of ProCAs for the diagnosis has not been fully explored. To further extend 
the application of ProCAs in disease diagnosis, we ask the following questions: 
1). Can we develp a new generation of MRI contrast agents with multiple Gd3+ binding 
sites? 2). Can we improve the metal stablity and metal selectivity of ProCA so that we can pre-
vent the Gd3+ resease in vivo? 3). Can we tune the relaxivities of ProCAs by protein design? 4). 
Can we design MRI contrast agents for liver imaging? 5). How early the metastatic tumor can be 
detected by MRI? 6). What is the smallest size of tumors can be detected? 7). Can we improve 
accuracy and specificity of tumor detection by taking advantage of both r1 and r2 values of 
ProCAs?  
1.9 Overview of this desertation 
To address the pressing needs for better MRI contrast agents and questions discussed 
above, in this Ph.D. dissertation, I have developed a novel class of MRI contrast agents, ProCA3 
series, by protein engineering in collaboration with collabrators and team members.  
Chapter 2 details experimental methods and protocols that we are used for the disserta-
tion. 
Chapter 3 describes our rationales for design a novel class of protein contrast agents 
(ProCA3 series) and our hypotheses about increasing metal selectivity and relaxivity by protein 
50 
engineering.  Our effort in cloning, bacterial expression, purification and conformational charac-
terization of   ProCA3 variants will be reported.  
Chapter 4 reports the development of novel methods for determination of strong metal 
binding affinity and selectivity of metalloprotiens. The metal binding affinity and selectivity of 
ProCAs are detailed.  Their relaxivity at different field strenghths are also carefully studied to 
verify our hypotheses proposed in Chapter 3. 
Chapter 5 reports our characterization of in vitro detection limits and mouse detection 
dose required for the in vivo MRI application. In addition, a new method taking advantage of 
high R1 and R2 values of the unique properties of ProCAs has developed. The application of 
ProCA32 in vivo detection of liver metastasis and transplanted liver cancer will be reported. 
Chapter 6 reports our intial studies about the application of ProCA3s to dynamic con-
trast enhanced MRI. 
Chapter 7 reports the detailed studies for the safety profile and pharmacokinetics of this 
novel class of MRI contrast agents (ProCA3 variants) for in vivo MRI imaging. 
Chapter 8 reports our attempt in extending the application of ProCA3 variants for the 
molecular imaging of tumor biomarkers  
Chapter 9 reports our additional studies for protein modification by Pegylation, humani-
zation of ProCAs variants, and  our effort on overcoming the barrier of the large scale produc-
tion of ProCA3 variants by establish a GMP-like protocol for the expression and purification of 
ProCA3 variants.  
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In Appendix, I will also include our other studies in prediction and identification of the 
Ca2+ and calmodulin binding sites in VP1 and VP7 of rotavirus, and neuron proteins such as dicer, 
clc7 and exportin 5. 
  
52 
 
 
Figure 1-8. The basic principle of T2/T1 ratiometric MRI imaging for the detection of small 
tumors in the liver. 
Without injection of the MRI contrast agents, the tumor and liver have the same MRI signal in-
tensity in both T1-weighted and T2-weighted MRI because of the similar T1 and T2 relaxiation 
time between tumor and liver. After IV injection of the ProCA within 1 hour, ProCA will accumu-
late in the liver tissue rather than tumor. Because ProCA has both high r1 and r2, both T1 and T2 
in liver tissue decreased and the T1 and T2 in tumor remain unchanged. As a results, liver shows 
hyper-intnsity in T2-weighted MRI and tumor shows hypo-intensity in the T1-weighted MRI. By 
the ratio of the MRI intensity of T2-weighted MRI over T1-weighted MRI, the signal differences 
between liver and tumor dramatically boosted. As shown in Equation 1-1 and 1-2, the MRI sig-
nal is in both T1-weigthed and T2-weighted MRI are determined by the instrumental setings (k), 
proton density (ρ), T1 and T2 of the tissue, and different setings of TR and TE. By the ratio of MRI 
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signal of T2-weighted MRI over T1-weighted MRI, some parameters such as k and ρ are canceled 
out, the signal intensity of the tissue of ratio metric imaging is mainly determined by the T1 and 
T2 of the tissue, TE values in T2-weighted MRI and TR values in the T1-weighted MRI.  
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Table 1-3. Summary list of the Protein-based MRI contrast agents 
 
  
Name of ProCA Discription 
ProCA1 The first generation of ProCAs with one Gd3+ binding site in a scaffold 
protein. 
ProCA2 The second generation of ProCAs with 2- 4 Gd3+ binding sites in a scaf-
fold protein. 
ProCA3 The third generation of ProCAs with two Gd3+ binding sites in a scaf-
fold protein. 
ProCA30 Wild type protein of ProCA3 with no mutations. 
ProCA31 ProCA3 variants with F103W mutation to introduce fluorescence 
probe to ProCA3 
ProCA32 ProCA3 variants with S56D and F103W mutations. This ProCA3 viriants 
has the highest stability and metal selectivity.  
ProCA33 ProCA3 variants with E60D and F103W mutations. 
ProCA34 ProCA3 variants with G99D and F103W mutations. 
ProCA35 ProCA3 variants with S56D, E60D and F103W mutations.This ProCA3 
variants has the highest r1 and r2 relaxivities among all the ProCA3 var-
iants. 
ProCA36 ProCA3 variants with S56D, E60D, G99D and F103W mutations. 
ProCA32M PEGlyated ProCA32 by PEG-40-NHS-ester. 
ProCA32-P40 PEGlyated ProCA32 by PEG-40-NHS-ester, same as ProCA32M. 
ProCA3.bomb ProCA32 linked with GRPR targeting peptide in the C-terminal through 
GGG linker 
ProCA3.Affi ProCA32 linked with HER-2 affibody in the C-terminal through GGG 
linker. 
ProCA3.RGD ProCA32 linked with GRDGRDGRDGRD in the C-terminal by GGG link-
er. 
ProCA32Cys ProCA32 with additional cystein at the C-terminal. This cystein residue 
can be used for site specific PEGlytion and labling. 
ProCA32.selectin ProCA32 linked with selectin-targeting peptide in the C-terminal by 
GGG linker. 
hProCA32 Humanlized ProCA32 
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2     EXPERIMENTal Methods 
2.1 Simulation of the relaxivity over a broad magnetic field 
The relaxivity of the clinical MRI contrast agents and ProCAs were simulated based on 
Solomon-Bloembergen-Morgan Equations36-38, 40, 42 according to Equations 1-2 to 1-9. The de-
tailed Equations for this simulation are show in Chapter 1. The simulation were done in Mi-
crosoft Excel software using the given values of different τR (100 ps for clinical MRI contrast 
agents and 10 ns for ProCA), τm (0.1, 1, 10, and 100 ns), τv (10 ps), and Δ
2 (5×1019 s-2). q is as-
sumed to be 1 and the agent concentration (C) is 0.001 M. The following values are used in the 
calculation: the gyro-magnetic constant for proton γI = 2.675 × 10
8 T-1s-1; g = 2.0; μB = 9.274 × 
10-24 J T-1; S = 7/2; μ0 = 1.257 × 10
-6 N A-2; rGdH = 3.0 × 10
-10 m. A relaxivity simulator (Appendix 3) 
were generated by Microsoft Excel and different relaxivity in a broad range of magnetic field 
can be generated by changing τR, τm, τv, Δ
2, q, rGd-H and other parameters.  
2.2 Molecular Cloning, Site-direct mutagenesis 
2.2.1 Constract parvalbumin expression vector  
Rat α-parvalbumin (PV) in pcDNA3.1 vector is a gift from Dr. Emmy Lee at Emory Univer-
sity. PV was double digested by restriction enzyme: nde I and xho I (New England Biolabs) and 
then transferred in to bacteria expression vectors such pET-22b, pET-20b and pRSETb vector. 
The successfully cloning of PV in these vectors were confirmed by DNA sequencing at GSU core 
facility. 
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2.2.2 Site directed mutagenesis and DNA insertion 
The general procedures for site directed mutagenesis and DNA insertion are shown in 
Fig. 2-1. Mutations on S56D, E60D, G99D and F102W and peptide insertions of PV are achieved 
by site directed mutagenesis using the primer listed in Table 2-1. Polymerase chain reaction was 
applied under following condition: 95 ˚C denatured for 10 min, then 94 ˚C for 30 seconds, 58 ˚C 
for 45 seconds and 72 ˚C for 10 min with 30 cycles. The products were finally elongated at 72 ˚C 
for 15 min. The PCR products were analyzed by agarose gel electrophoresis and the DNA with 
correct size were phosphorylated by PNK (New England Biolabs), ligated by T4-ligase (New Eng-
land Biolabs) and the successful ligations were amplified by by E coli. DH5α strains. The correct-
ed plasmid constructs were finally confirmed by DNA sequencing at GSU core facility or 
Genewiz Company. 
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Figure 2-1. General procedures for site direct metagenesis and DNA insertion for PV.  
Primers were first phosphorylated before performing PCR. Then, the linear DNA obtained from 
PCR was linked to circulcualr plasmid by T4-ligase. Then, the DNA was transorformed to E. coli 
after ligation. The E. coli harbored corrected plasmid were growned on LB solid medium. The 
plasmids were extracted from these E. coli and send for DNA sequencing. If the desired muta-
tions or insertions are confirmed via DNA sequencing analysis, the new plasmids could be fur-
ther used for protein expression and purification. Subsequently, the purified protein can be 
used for various in vitro and in vivo experiments. Modified from 112.  
58 
Table 2-1. Primer design for ProCA construction. 
Primer name Sequence Mutation/insertion in PV 
PVE60D_for TTCATTGACGAGGATGAGCTGGG E60D 
PVE60D_Rev GCCGTCTTTGTCTTTGTCCAGAAT E60D 
   
PV99103_for AAGATTGACGTTGAAGAATGGTCCACT G99DF103W 
PV99103_Rev GCCGTCCCCGTCCTTGTCTC G99DF103W 
   
F103W_for GAA GAA TGG TCC ACT CTG GTG GC F013W 
F103W_Rev AAC CCC AAT CTT GCC GTC CCC F013W 
   
F103WG99D_for GAA GAA TGG TCC ACT CTG GTG GC G99DF103W 
F103WG99D_Rev AAC GTC AAT CTT GCC GTC CCC GTC G99DF103W 
   
PVE60D56D_fov TTCATTGACGAGGATGAGCTGGG S56DE60D 
PVE60D56D_Rev GTC TTT GTC TTT GTC CAG AAT GTG GAA S56DE60D 
   
PV52E_For ATTCTGGAGAAAGACAAAGACGGCTT  D52E 
PV52E_Rev GTGGAACACCTTCTTCACATCATC D52E 
   
PV111C_inser_For TGTTAAGGATCCACTAGTCCAGTGTG  111C insertion 
PV111C_inser_Rev   GCTTTCGGCCACCAGAGTGGA  111C insertion 
   
PV99E103W_f GAGGTTGAAGAATGGTCCACTC G99EF103W 
59 
PV99E103W_r AATCTTGCCGTCCCCGTCCTT G99EF103W 
   
D99E1_F GTTGAAGAATGGTCCACTCTGGT G99EF103W 
D99E1_R TTCAATCTTGCCGTCCCCGTCC G99EF103W 
   
D99E2_F TGGTCCACTCTGGTGGCCGAA G99EF103W 
D99E2_R TTCTTCAACCTCAATCTTGCCGTCC G99EF103W 
   
Selectin_CD2_for GGGATCAACTTTGGGATCTTATGAAGGGCG
GAGGTGGAGCATTTGAGATCGACGCAAA 
Selectin targeting pep-
tide intertion 
Selectin_CD2_rev AAGTAATATCTCCATCATACTTGCCTCCGCC
CGATTTCAAAAAAGGCTTCATCTTC 
Selectin targeting pep-
tide intertion 
   
RGD_CD2_for GATGGCGGAGGTGGAGCATTTGAGATCGA
CGCAAA 
Integrin targeting pep-
tide insetion 
RGD_CD2_rev ACCTCTATCACCTCTATCACCTCTGCCTCCGC
CCGATTTCAAAAAAGGCTTCATCTTC 
Integrin targeting pep-
tide insetion 
Primer name Sequence Mutation/insertion in PV 
collegan_CD2_for TTATTTTCCTCATCATTATTGTGTTTATGGAG
GTGGAGCATTTGAGATCGACGCAAA 
Collegan targeting pep-
tide insertion 
RGD_CD2_rev GTATAACAATGCCACTTCTTGCCTCCGCCCG
ATTTCAAAAAAGGCTTCATCTTC 
Collegan targeting pep-
tide insertion 
   
56103aff1_for GCAAAGAAGTTGAACGATGCTCAAGCACCT Her-2 affibody insertion 
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AAGTAAGGATCCACTAGTCCAGTGTG part 1 
56103aff1_rev ATTGAACTTGTTGTCGACGCCGCCGCTGCC
GCCGCTTTCGGCCACCAGAGTGGA 
Her-2 affibody insertion 
part 1 
   
56103aff2_for GACCCTTCTCAATCAGCTAATTTACTTGCAG
AGGCAAAGAAGTTGAACGATGCTCAA 
Her-2 affibody insertion 
part 2 
56103aff2_rev TAACGCGATTTCCCAGTACGCATTACGCATT
TCTTTATTGAACTTGTTGTCGACGCCG 
Her-2 affibody insertion 
part 2 
   
56103aff3_for TTTATCCGTTCATTGTACGATGACCCTTCTC
AATCAGCTAATTTA 
Her-2 affibody insertion 
part 3 
56103aff3_rev GGCACGCTTTTGCTGATTGTTCAAGTTGGG
CAATAACGCGATTTCCCAGTACGCAT 
Her-2 affibody insertion 
part 3 
   
Bomb_for TGGGCAGTAGGCCACCTAATGTAAGGATCC
ACTAGTCCAGTGTG 
GRPR targeting peptide 
insetion 
Bomb_rev TTGGGCTCCTCCTCCGCTTTCGGCCACCAGA
GTGGA 
GRPR targeting peptide 
insetion 
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2.3 Protein Expression, purification and PEGlytion 
ProCA varients were purified following Dr. M. Henzl’s method with some modifications.172 
ProCAs were expressed in E. coli BL-21DE3 or Tuner cell strains. ProCA expression was induced 
by IPTG after OD500 reached 0.6. After IPTG induction overnight, the bacterial culture was 
sonicated in 10 mM Tris/ HCl buffer, pH 7.2, 100 µM PMSF and benzonuclease and followed by 
passing through a French pressure cell. The supernatant of cell lysate was incubated at 85 ˚C for 
10 min, cooled at 4 ˚C in an ice-water bath, and centrifuged (17000 rpm, 20 min, 4˚C). The su-
pernatant was collected for further purification. DNA was then precipitated by supplementation 
of 3% strepmyosin sulfate. After dialysis for 24 h at 4 ˚C against 10 mM Tris/HCl at pH 8.5, the 
protein mixture was further purified by the HiTrap Q column. After removing unbound proteins 
with 3 bed volumn of 10 mM Tris at pH 8.5, the column was eluted with a 0–1 M NaCl gradient 
in 10 mM Tis/HCl at pH 8.5. The protein and DNA separations were monitored by the SDS-PAGE 
and agarose gel, respectively. The purified ProCA32 was dialyzed against 10 mM Tris, pH8.5. 
Metals in ProCAs are removed by chelex-100 and metal content in ProCAs is analyzed by ICP-
OES. 
ProCAs were PEGlyted by the following steps: 1). ProCAs were dialyzed against 10 mM 
HEPES at pH 7.0-7.2 to remove all possible Tris. 2). ProCAs were mixed with PEG-NHS ester with 
a molar ratio of 1:3 and then incubated at room temperature for 4 hours or 4 ˚C overnight. 3). 
Unreacted free PEG-NHS were quenched by adding 100 mM Tris/HCl with a final concentration 
of 10 mM. 4) PEGlyated ProCAs were further purified by HP Q column. After removing unbound 
proteins with 3 bed volumn of 10 mM HEPES at pH 8.0, the column was eluted with a 0–1 M 
62 
NaCl gradient in 10 mM HEPES at pH 8.0. The PEGlyation procedures were monitored by SDS-
PAGE with protein staining by coomassie brilliant blue and PEG staining by I2.  
2.4 Large scale protein expression and purification 
2.4.1 Large scale expression of ProCA by fermentation  
The plasmid for ProCA3 was first transferred in BL21-DE3-plysS bacteria cultured on agar 
plate supplemented with ECAM media. 1 ml of a glycerol stock of ProCA32 expressing bacteria 
were innoculated in 100 ml ECAM and left to shake at 150 rpm and 37 ˚C over night. Then, 10 
ml of the bacteria was transferred to 250 ml ECAM medium and incubate at 37 ˚C and 200 rpm 
for 6 hours. 120 ml of these bacteria were used as an inoculum for the bioreactor.  
The bioreactor were setup as follows: Initial glucose concentration 21g/L; Batch media 
contained 50ug/ml carbenicillin; Vessel was inoculated to give 1.5x10-2 cells; oxygen 
conenctration was set  to 30% and maintained with stirrer (min= 160 rpm, max = 450 rpm) and 
Gas Mix; Air flow was constant at 10 LPM. Bacteria were harvested by continous centrifuge. 
 
2.4.2 Exploring different methods for large scale purification of ProCA3 obtained from bio-
reactor 
The bacteria cell pellets were suspended by 10 mM HEPES, pH 7.0 and then broken by 
cell discruptor. After concentrigation at 6000 rpm for 30- 60 min, the supernatant of bacteria 
lysate were collected for further protein purification. In order to separate ProCA3 from other 
proteins or bio-moleculars, such as DNA, different concentrations of PEG-8000 were added to 
the supernatant of the cell lysate. Due to the differences of the solubility and molecular weight, 
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different proteins can be precipated at different concentration of PEG-8000. The concentration 
range of PEG-8000 for ProCA32 precipitation was determined by SDS-PAGE. The detailed results 
and discussions will be shown in Chapter 7. 
To further purifiy ProCA3, ProCA3 precipitate by PEG-8000 was dissolved in HEPES buff-
er at pH 7.0. These protein solution were load to FPLC equipped with Hi-trap Q column. After 
binding to the column, the unbounded component was first washed out with 7 column volume 
(CV) of buffer A (10 mM HEPES buffer at pH 8.0). Then, buffer B (10 mM HEPES buffer, 1 M NaCl 
at pH 8.0) concentration were increase to 25 % within 7 CV. We further wash the column with 
25% of buffer B for 2 CV and then increase to 100 % of buffer B of 1 CV to wash out every com-
ponent bounded to the column. The fractions containing purified ProCA32 were determined by 
UV abs and SDS-PAGE.  
At last, since ProCA32 is very stable at 90 ˚C, we further incubate the purified ProCA32 
at 90 ˚C for 20 min and followed by a centrifugation at 6000 rpm for 30 min to remove residue 
uwanted protein.  
2.5 Gd3+, Tb3+ Ca2+, Mg2+ and Zn2+-Binding Affinity Determination  
Fluorescence spectra were recorded using a QM1 fluorescence spectrophotometer (PTI) 
with a xenon short arc lamp at ambient temperature. Tryptophan fluorescence was monitored 
using excitation at 280 nm and emission between 290 and 370 nm with 2 - 4 nm slit width and 
phenylalanine signal was monitored by excitation at 259 nm and emission between 270 and 
350 nm. Tb3+ luminescence resounance energy transfer (LRET) experiments were acquired by 
excitation of phenylalanine and tryptophan at 259 nm and 280 nm and emission from 500 to 
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650 nm. Fluozin-1 emission spectra were obtained at excitation 495 nm and emission between 
500-600 nm. 
For the equilibrium method, 10 µM ProCA32 were added in to the calcium-buffer sys-
tem containing 50 mM HEPES, 100 mM NaCl, 5 mM EGTA, pH7.2. Subsequently, different calci-
um chloride concentrations were titrated into the buffer system. Thus, free calcium concentra-
tion was calculated based on tsein’s method (Kd of EGTA is 1.51×10
-7 M 173) using Equation (2-
1). 
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          (2-2) 
where [CA2+]free is the free Ca
2+ concentration in each titration point, KdCa,EGTA is the dis-
sociation constant of GGTA to Ca2+, [Ca-EGTA] is the concentration of total Ca-EGTA complex in 
each titration point, and [EGTA]free is the concentration of EGTA in each titration point.  
Tb3+ binding affinity of ProCA were obtained by Tb3+ LRET-competition methods or Tb3+-
DTPA buffer system. For Tb3+ LRET-competition method, 10 µM of ProCA and 20 µM Tb3+ were 
incubated with different concentration of NTA or DTPA at room temperature over night. 
ProCA3 are exitated at 260 nm for phenylalanine ro at 280 nm for tryptophan. The Tb3+ LRET 
signal changes were measured by the emission at 545 nm. The apparent Kd (Kapp) was obtained 
by one to one binding Equation (Equation (2-3)) and the dissociation constants of ProCA were 
fitted by Equation (2-3).  The dissociation constants of Tb3+ to NTA (10-13 M) and EGTA (10-18 M) 
is obtained from NIST.  
  
                                    
 
          
     
       (2-3) 
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          (2-4) 
where f is the fractional change, Kdapp is the apparent dissociation constant for Tb
3+ and 
[P]T, [M]T are the total concentrations of the protein and Tb
3+, KdTb,ProCA is the dissociation con-
stant of ProCA to Tb3+, KdTb,NTA is the dissociations constant of NTA to Tb
3+. 
For Tb3+-DTPA buffer system, 30 μM of ProCA were added into Tb3+-DTPA buffer system, 
which contains 5 mM DTPA, 50 mM HEPES, 100 mM NaCl at pH7.2. Then, TbCl3 was titrated in-
to the buffer and free Tb3+ concentration is calculated by Equation (2-5). ProCA3 is exciated at 
280 nm and Tb3+-LRET signal is observed in the emission wavelength between 500-650 nm. The 
KdTb,DTPA is calculated by Hill Equation (2-6) 
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          (2-6) 
where [Tb3+]free is the free Tb
3+ concentration calculated from buffer system, KdTb,DTPA is 
the dissociation constant between Tb3+ and DTPA, [Tb-DTPA] is the concentration of Tb-DTPA 
complex, [DTPA]free is the free DTPA concentration in the buffer, f is the fractional change, 
KdTb,ProCA is the dissociation constant between Tb
3+ and ProCA. 
LRET competition method was applied to measure the Gd3+ binding affinity to ProCA. 10 
µM of ProCA and 20 µM Tb3+ were incubated with 0 to 1000 µM of GdCl3 at room temperature 
over night. The Tb3+ FRET changes were measured by the emission at 545 nm. The apparent Kd 
were fitted by 1 to 1 binding Equation (Equation 2-3) and Kd of Gd3+ were calculated by Equa-
tion (2-7), 
                 
         
                 
        (2-7) 
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where KdGd,ProCA is the dissociation constant between Gd
3+ and ProCA, Kdapp is the ap-
parent Kd for Gd3+, ProCA between and ProCA obtained from Equation (2-6) and KdTb,ProCA is the 
dissociation constant between Tb3+ and ProCA calculated from Equation (2-4) and [Tb3+]T is the 
total concentration of Tb3+ in the competition experiments. 
Fluozin-1 competition experiments were applied to calculate the Zn2+ binding affinity of 
ProCA according to Yang’s method with some modifications.103 Briefly, 2 μM of Zn2+ and 1 μM 
of Fluozin-1 were added in 50 mM HEPES, 100 mM NaCl, pH 7.2. Then, 0-100 μM of ProCA were 
titrated in to the solution. The fluoresence signal changes were recorded in an equilibrium state 
after each titration point. Dissociation constant between ProCA and Zn2+ were calculated by the 
following Equations (2-8 and 2-9) 
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where KdZn,ProCA is the dissociation constant between Zn
2+ and ProCA, Kdapp is the appar-
ent Kd calculated by Equation (2-8), KdTb,fluozin is the dissociation constant between Tb
3+ and 
Fluozin-1 . KdTb,fluozin is measured by yang’s methods
103.  
2.6 Determination of r1 and r2 Relaxivity Values  
The relaxation times (T1 and T2) were measured by Bruker relaxometer (1.47 T). The con-
trast agents with different concentration were prepared in 50 mM HEPES, 100 mM NaCl, pH 
7.4. The relaxivity were calculated by the Equation (2-10 and 2-11).113 
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          i= 1, 2         (2-10) 
67 
where ri is the per Gd
3+ relaxivity, Tisample is the relaxation time of water after adding 
ProCA, Tibuffer is the relaxation time of water without adding contrast agents and [Gd
3+]T is the 
total Gd3+ concentration in the tested solution. 
2.7 Measurement of Water coordination number by Terbium Lifetime Luminescence. 
The number of water ligands coordinated to Gd3+-ProCA complex was determined by 
measuring Tb3+ luminescence decay in H2O or D2O using the previously published methods with 
some modifications.174, 175  Tb3+ was excited at 265 nm with a Xenon Flash lamp and the 
Tb3+ emission was collected at 545 nm at a series of time in both H2O and D2O solutions. Lumi-
nescence decay lifetime of Tb3+ or Tb3+-chelator complex in H2O and D2O solution were ob-
tained by fitting monoexpernantial decay equation. A standard curve of water number (q) over 
ΔKobs (the difference of the decay constant between H2O and D2O) were established using Tb-
NTA (q=5), Tb-EDTA (q=3), Tb-DTPA (q=1) and Tb3+ in aqueous solution (q=9). The water num-
ber of ProCA was calculated based on the standard curve. 
2.8 Serum stability 
Gd3+-ProCA32 (400 µM) was mixed with mice serum with 1:1 ratio, and then incubated 
at 37 ˚C for different time point. SDS-PAGE and mass spectrum were applied to detect the re-
maining Gd3+-ProCA32 after incubating in the serum for each time point. The protein separated 
by SDS-PAGE is stained by coomassie brilliant blue or west blot. Homemade rabbit ProCA32P40 
antibody is used as primary antibody with 1:3000 dilutions. For western blot detection, AP-
conjugated Goat anti rabbit antibody (Bio-Rad) is used as secondary antibody with 1: 3000 dilu-
tions. 
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2.9 Immunoblot and tissue homogenizes 
Mouse tissue with and without ProCA32 injection were homogenized in RIPA buffer sup-
plemented with 1 mM PMSF and 10 ul protease inhibitor cock tale. Each 300 mg tissue was 
homogenized in 500 µl buffer. Homogenized tissues were then mixed with 2× SDS sample buff-
er and loaded into SDS gel. The electrophoresis was done at 120V voltage for 1 hour. 7.5% and 
15% resolving gel were used for the GRPR and ProCA, respectively. Electron transformation was 
done at 20 mV at 4 ˚C overnight. As primary antibody, homemade rabbit against ProCA32-P40 
antibody was diluted 3000 times. Rabbits against GRPR antibody are diluted 500 times.  The 
membranes are blocked with 0.2% non-fat milk, 4 ˚C overnight incubation with primary anti-
body. After washing three times with TBST buffer, AP-conjugated Goat anti Rabbit antibody are 
diluted 3000 times and incubated at room temperature for 1 hour. The western blots were vir-
tualized by Bio-Rad kit with the exposure time of around 30 seconds to 3 minutes. 
2.10 Immunofluorescence image 
The cryoslice of tumor and normal tissue were cut with a thickness of 10 μm. The tissue 
were fixed with acetone for 10 min at -20 ˚C and then washed with TBST for three times. Tis-
sues were then blocked at room temperature for 1 hour by 1% BSA in TBST, and incubated with 
primary antibody for 1 and half hour. Homemade ProCA32-P40 anitbody with 1:100 dilution 
and Rabbit anti GRPR from ABCAM were used as primary antibody in the separated slides. After 
washing for three times, the slides were incubated with Alaxa fluo (red) goat anti rabbit anti-
body (Invitrogen) as secondary antibody. The fluorescence images were obtained from Leica 
imaging system for 400 × amplification.  
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2.11 NIR labeling and NIR imaging 
Protein and Cy5.5 were mixed with 5 to 1 ratio, and incubated at room temperature for 4 
hours. Unreacted Cy5.5 was quenched by adding 5 times access amount of Tris at pH 7.0. For 
the animal injection, the final sample was dialysised against 10 mM HEPES three times and con-
centrated to a ProCA concentration of 5 mM. The mice cy5.5 imaging was perfomed every day 
after ProCA32-bombsin injection under Xengen imaging system with excitation wavelength of 
640 nm and Cy5.5 filter. After finishing a continuous three-day MRI experiments, the mice are 
scarified, and tumor, liver, kidney, muscle, spleen and heart were taken out and imaged under 
NIR imaging system. Along with these NIR images, bright field are also taken each time. 
2.12 Mice MRI image 
CD-1 mice or tumor baring nude mice of about 20-30 g were selected for the MR imaging. 
MR angiography of mice after injection of ProCA3M was collected by Varian MR scanner (4.7 T) 
at Emory University. 0.03 mol/kg MRI ProCA32M were injected into the mice and scanned with 
3D gradient echo sequence (TR = 40 ms, TE = 2.9 ms). The field view was 8 cm × 4 cm × 6.4 cm 
with matrix of 384 × 192 × 64 MR images were obtained before ProCA injection and 0.7, 3, 44 
and 54 h post injection of contrast agents. The images were analyzed by Image J and MRI croN. 
The intensities of blood, liver and kidney were plotted over time. T1-weighted 2D MRI of mice 
or phantom were collected before and after injection of contrast agents using spin echo se-
quence with TR = 400 ms, TE = 11 ms, FOV = 4 × 4 cm, matrix =512 × 512, thickness = 1 mm. T2-
wegithed 2D MRI of mice or phantom were collected before and after injection of MRI contrast 
agents using fast spin echo with TR = 5 s, effective TE = 28 ms FOV = 4 × 4 cm, matrix =512 × 
512, thickness = 1 mm. The ratiometric imaging MRI were then calculated by the ratio of MRI 
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signal intensity of T2-weighted fast spin echo and T1-weighted spin echo sequence. A threshhold 
was setup to further eliminate extremely low intensity from background (air). 
Bi-brililant MRI were collected by T2-weighted inversion recovery sequence with long TE 
by fast spin echo sequence (TR = 5 s, effective TE = 28 ms, FOV = 4 × 4 cm, matrix =512 × 512, 
thickness = 1 mm) and spin echo sequences (TR = 5 s, TE = 11 ms, FOV = 4 × 4 cm, matrix =512 × 
512, thickness = 1 mm). After the injection of ProCA, inversion time to null liver signal was de-
termined by a series of inversion recovery sequence with different inverstion time. We then 
applied bi-brilinat MRI with this inversion time to collect the MR imaging from live animal and 
liver tissue using both fast spin echo sequence (TR = 5s, effective TE = 28 ms, FOV = 4 × 4 cm, 
matrix =512 × 512, thickness = 1 mm) and spin echo sequences (TR = 5s, TE = 11 ms, FOV = 4 × 4 
cm, matrix =512 × 512, thickness = 1 mm). 
MR images of GRPR in tumor were collected by Varian MR scanner (7 T) at the University 
of Georgia. H441 and PC3 cells were implanted in the flank of nude mice in the animal facility of 
Georgia State University. MR image were collected after the tumor size reached to 1 cm3. MR 
images were collected with spin echo sequence (TR = 500 ms, TE = 14.52 ms). The field view 
was 3.5 cm × 3.5 cm with matix of 128 × 128 and slice of 1 mm in thickness. One of MR images 
were collected before ProCA3 injection followed by 0.02 mol/kg ProCA32.bomb into the nude 
mice through the tail vain. Tumor MR Images were acquired at the following time points: 30 
min, 2 hr, 1 day, 2 days. MR images were analyzed by Image J and MRI croN. 
Dynamic contrast enhanced-MRI (DEC-MRI) data were acquired using Varian 7 T MR 
scanner. A 26 G catheter was implanted into the tail vein of the mice before the scanning. Two 
group of mice were used for the DCE‐MRI experiments at UGA. Each mouse was acquired three 
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slices in kidney with proton density map, T1 map and DCE‐MRI sequence. T1 map of 3 slices of 
mice kidney were acquired before contrast agents injection by saturation recovery FSEMS se-
quence with different length of TR (mice injected with Gd-DTPA: TR=350, 500, 700, 900, 1200, 
2000, 3000, 5000; Mice injected with ProCA32: TR=350, 500, 700, 900, 1000, 2000, 3000, 5000) 
matrix: 256 x 256, fov=4 cm × 4 cm and thickness=2 mm. Then, DCE‐MRI was applied with 
FLASH sequence with 150 repeated scanning. 20 scans were acquired before contrast agent in-
jection as baseline. For Gd-DTPA group, DCE‐MRI are acquired with following parameters 
TR=18.80 ms, TE=2.95 ms, Flap Angel=25 °, average=1; gain=20. Data were acquired every 2.3 
second. 0.2 mmol/kg Gd‐DTPA (100 μl) was quickly injected after 20 scan followed with the 
quick injection of 150 μl Saline. For ProCA32 group, DCE‐MRI were acquired with following pa-
rameters TR=18.80 ms, TE=2.95 ms, Flap Angel=25 °, average=3; gain=25. Data was acquired 
every 7 second. 0.015 mmol/kg ProCA3 (100 μl) was quickly injected after 20 scan followed 
with the injection of 150 μl Saline. 20 round of scannings were acquired as baseline before the 
injection of contrast agents, and then a total volume of 100 μl of DTPA (0.2 mmol/kg) or ProCA3 
(0.015 mmol/kg) were injected in to the mice during scanning with an injection rate of 10 μl per 
second. Total 150 rounds of scannings were finally acquired with a 2.3 s for Gd-DTPA and 7 s for 
ProCA in each round. MRI were acquired by FLASH sequence with TR= 18.80, TE=2.95 ms, flip 
angel 25 ˚. The field view was kept to be 4 cm ×4 cm with matrix of 128×128 and slice of 1 mm 
thickness. 
2.13 Detection limits study 
PCR tubes filled with buffer or different concentration of the contrast agents were 
scanned in 7 T Varian scanner. MR images were collected with spin echo sequence (TR = 300, 
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500, 600, 700 and TE=13.82). The field of view was 10 cm × 8 cm with matrix of 128 × 128 and 
thickness of 1 mm. 
T1 maps were acquired with inversion recovery FSEMS sequence with TR = 7000 ms, ef-
fective TE= 48 m (esp = 12 ms, etl = 8, kzron = 4, average = 2), Ti = 0.01, 0.05, 0.1, 0.3, 0.5, 0.7, 
0.9, 1, 2, 3, 4 s. The field of view was 10 cm × 8 cm with matrix of 128 × 128 and thickness of 1 
mm. 
CD1 mice of about 20-30 g were injected with different concentration of contrast 
agents. MR imaging were acquired under 7 T Varian MRI scanner by two different sequences. 
The kidney enhancements were collected with spin echo sequence with TR = 300 - 700 ms and 
minimum TE. The field view was 4cm × 4cm with matrix of 128 × 128 and thickness of 1 mm. 3 
D image of the mice were collected by gradient echo sequence (TR = 40 ms, TE = 2.48 ms). The 
field view was 8 cm × 4 cm × 4 cm with matrix of 128 × 128 × 64. 
2.14 Blood retention, tissue distribution and toxicity 
2.14.1 Short term and long term Gd3+ distribution and toxicity study by ICP-OES 
Mice with a body weight of 20-25 g were injected with 0.2 mmol/kg of Gd-DTPA, 0.0016 
mmol/kg of GdCl3 or 0.0008 mmol/kg of ProCA3 variants, respectively. Blood were collected 
from saphenous vein at different time point from 10 min to 14 days. Tissues from mice were 
collected after the mice were euthanized at 10 min or 14 days after injection of Gd-DTPA, GdCl3 
or ProCA3 variants.  
To determine Gd3+ concentration in tissues, the collected tissue and blood samples were 
digested with 70% HNO3 at 130 ˚C overnight. The HNO3 with tissue digestions were collected 
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the next day and diluted with 2% HNO3 to 10 ml. The sample was analyzed by ICP-OES  (Varian 
720-ES) at Gadolinium wavelength of 342.76 nm. ICP-OES was running at the following condi-
tions: Pwr for 1.2 kW, PlasFlow at 15 L/min, AuxFlow at 1.50 L/min, NebFlow at 0.90 L/min, 
Replicate Time for 10 s, Stable Time for 15 s, Sample Uptake for 30 s, Rinse Time for 10 s, Pump 
Rate at 15 rpm. A standard curve with different concentration of Gd3+ was generated to calcu-
late the Gd3+ concentration in testing samples. 2 ppm of YCl3 was used as internal reference. 
For pharmacokinetics and biodistribution study, different tissues from at least 5 mice in each 
group were analyzed.  
2.14.2 Clinical chemistry study of ProCA variants 
Mices with a body weighted of 25 – 30 g were I. V. injected with 0.03 mmol/kg of ProCA 
variants. The bloods of the mice were collected two days post injection using heparin-coated 
capillary. The sera of the blood were obtained by centrifuge at 3000 rpm at 4 ˚C for 10 min. 
About 300 µl of mice serum were collected for clinical chemistry study in IDEXX Laboratories. 
The clinical chemistry evulate the liver, kidney, heart functions based on the levels of enzyme, 
proteins, glucose and ions in the serum.  
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3         DESIGN, EXPRESSION, PURIFICATION OF PROTEIN-BASED MRI CONTRAST AGENTS 
3.1 Introduction  
As discussed in Chapter 1, there is a strong need to develop MRI contrast agents for pa-
tient diagnosis and diseaseprognosis. In order to design protein contrast agents with superior in 
vivo applications, protein based MRI contrast agents must have several key features. 1). Pro-
tein-based MRI contrast agents must be stable, which means engineered proteins resistances to 
protease cleavage to prevent degradation in vivo, and Gd3+-must bind to protein tightly to avoid 
competition by physiological cations and inions. Free Gd3+ is toxic, with LD50 = 0.2 mmol/kg,
104 
thus, Gd3+ must binds with protein contrast agents and avoid free Gd3+ release before excreted 
out. 2). Protein-based MRI should have high relaxivity to increase the dose efficiency. In this 
way, total injection dosage of Gd3+ can be decreased to reduce to the toxicity caused by free 
Gd3+ release. High relaxivity also improve the sensitivity for the molecular imaging to bi-
omarkers with limited expression level. 3). Protein contrast agents must have a proper size for 
optimized organ/tissue distribution and blood retention time. Good contrast agents must have 
fast accumulation in the organ/tissue of interests and should be quickly excreted to reduce the 
toxicity. 4). As  protein imaging reagents, the immunogenicity must be decreased. Thus, 
PEGlytion of ProCA is very important. 5). Protein contrast agents are preferred to incorporate 
with targeting moieties to improve the imaging specificity and enable quantitatively imaging 
tumor biomarkers. Previous members in our lab have shown that by designing a Gd binding site 
into a scaffold protein CD2 is able to increase of relaxivity by tuning τc and other factors, such as 
secondary coordination shell contributors.169 However, further increase of metal binding affini-
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ty, stability as well as additional metal binding sites to increase payload is challenging.99, 155, 164, 
169  
In order to design protein contrast agents with high binding affinity, we carefully ana-
lyzed the metal binding sites in protein and small contrast agents. Like other lanthanide such as 
Tb3+ and Eu3+, Gd3+ use oxygen and nitrogen as metal binding ligands and oxygen ligand is the 
most preferred ligand in protein to interact with Gd3+ with an average coordination number of 
7.2. EF-hand motif in Ca2+ binding proteins is one of the most promising candidates for the de-
sign Gd3+ binding pocket due to highly similarity of ligand type and ionic radius between Ca2+ 
and lanthanide. For example, Tb3+ and Eu3+ are usually applied as a fluorescent probe for Ca2+ 
binding. Native Ca2+ binding pockets in proteins are usually form penta-bipyramid structure 
with oxygen ligands, which provide good candidate for the design Gd3+ binding proteins. Lan-
thanide usually binds to EF-hand with ambient binding affinity. The dissociation constant (Kd) 
for Tb3+ binding affinity to grafted calcium binding loop in CD2 protein is always less than 1 µM. 
The design CCMV particles with CaM EF hand motif only have Gd3+ Kd around 3 nM.
109 Carnavan 
construct Helix-loop-helix contrast agents, while the Gd3+ affinity is still not strong enough for in 
vivo applications. To date, there are no successful applications using EF-hand to design MRI 
contrast agents due to the undesired low Gd3+ binding affinity.108 All of these initial attempts 
have a Gd3+ binding constant far weaker than the estimated stability constant 1.8 x 10-21 M of 
Gd-DTPA with requires in vivo applications.  Additional challenges for developing protein based 
contrast agents are arised from the lack of accurate methods for determing metal bining 
afifnity and selectivity with in vivo application. This question will be addressed in Chapter 4.  
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Our central hypothesis: We hypothesize that a Gd3+ binding protein with high relaxivity, metal 
stability can be achieved by modifying natural metal binding proteins based on key determi-
nants for metal selectivity and relaxivity and our knowledge in protein design and modifications.  
In this chapter, I will first introduce our stretegies for design a novel class of ProCAs, 
named ProCA3. Then, we will show our results on the cloning, expression, purification and 
modification of ProCA3 variants. Next, I will introduce our studies on structural characterization 
of this novel class of MRI contrast agents. The other properties, such as metal stability and 
relaxivity, will be shown in Chapter 4. Further modification of our protein contrast agents by 
pegylation and large scale production of these developed reagents will be discussed in Chapter 
9.  
3.2 Results 
3.2.1 Design of ProCA3 variants with high metal binding affinities and relaxivities 
Based on these requirements for ideal contrast agents, we carefully designed a novel 
protein-based MRI contrast agents based on a new scarfold protein, PV. Fig. 3-1 shows the 
modeled structure of designed protein contrast agent (ProCA) ProCA3 based on following ra-
tionales. First, to achieve maximal value of r1 relaxivity of Gd contrast agent at medical field 
strength, a correlation time of the Gd binding around 10 ns is needed. This can be achieved by 
embedding a Gd3+ binding site in a fixed protein frame with a size between 10 - 20 kDa. Based 
on our simulation in Chapter 1, protein environment has the addition of secondary water shell 
that also contributes to the increase of relaxivity. We also achieve high r2 relaxivity by improv-
ing the three key factors of τc, q, and outer coordinate shell contributions. PV is a small globular 
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protein with a molecular weight of about 11 kDa with a rigid structure.  The τR of Ca
2+ binding 
site is similar to the overall τR of PV, which provide a great advantage to decrease the τR of Gd
3+-
vector when the Ca2+ binding site is engineered as Gd3+ binding sites.Second, the engineered 
metal binding sites should have strong metal binding affinity for Gd and metal selectivity for Gd 
over physiological metal ions such as Ca2+, Mg2+ and Zn2+. Ideally metal binding affinity con-
stants especially for metal selectivity (or kinetic selectivity) should be comparable or stronger 
than clinical approved ones to overcome NSF effect associated with the Gd toxicity. To design a 
MRI contrast agent from protein with high thermodynamic stability, we carefully selected PV as 
the scaffold protein. This protein is very stable at high temperature, resistance to protease 
cleavage, and has strong Ca2+ binding affinities.  This protein is a Ca2+ buffer protein with Kd for 
calcium about nM and its metal binding affinity can be modified. 176 PV is distributed in the cy-
tosol of neuronal and muscle cells without any interactions with other proteins.177  PV also has 
high thermostability, high solubility, high resistance to the enzyme cleavage, and high tolerate 
mutations. Based on extensive analysis of structural parameters such as the ligand types, coor-
dination numbers, water numbers,  bond angles and lengths of different classes of metal bind-
ing sites in proteins 98, 178 and small chelators and key determinants for metal binding affinity, 
selectivity, conformational change, and dynamic properties of metalloproteins87, 100, 103, 179-182, 
we proposes that addition of one more negatively charged ligand at S56D at position 5 in EF-
hand motif 1 of PV is able to  convert this calcium binding site to Gd3+ binding site with desired 
Gd relaxation properties. A F103W was introduced to allow the determination of metal binding 
affinity by Tb-FRET.  Third, modifying protein surface by PEGylation allows to increase blood re-
tention time and to increase liver preference based on previous studies by us and others.  
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PV has two EF-hand Ca2+ binding sites. EF-hand I in wild type PV has four carboxyl lig-
ands (D52, D54, E60 and E63). EF-hand II of PV WT are formed by the four carboxyl group (D91, 
D93, D95, E102) and one water ligand (G99) to bind Ca2+.   One noncharged oxygen liagnd (S56) 
directly interact with Ca2+.  X-ray structure (Fig. 3-1 and Fig. 3-2) and other technique shows 
that position 9 in EF-hand I (E60) of PV directly use side chain carboxyl group as oxygen ligand 
to interact with Ca2+, however, most other EF-hand protein use water as oxygen ligand to inter-
act with Ca2+. X-ray structure of Ca2+ indicates that this mutation use one water ligand to bind 
Ca2+, while carboxyl side chain in this position moved away. Earlier studies from Yang lab and 
others have show that the metal selectivity for Ln3+/ Ca2+ can be achived by increasing numbers 
of charged residues in the metal coordination shell.87, 100, 103, 180 To further verify our hypothesis 
for tuning metal selectivity by charged residues, we further studied the effects of 
pentacarboxylate EF-hand on Gd3+ binding affinity. We created two S56D variant with a modi-
fied Gd3+ binding site by E60D mutation in both WT and S56D mutant. By this way, total carbox-
yl group for metal binding in EF-hand I is expected to be decreased. G99D mutants are generat-
ed to study the charge effects on the metal selectivity of EF-hand II. Table 3-1 summarizes 6 
variants with mutations at the metal binding sites we designed to use to create protein contrast 
agents with   additional modifictions such as and complex formation and Pegylation (Chapter 9).  
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Figure 3-1. The design of Gd3+ binding protein based on PV. 
Two Gd3+ binding pockets were generated on the wild type PV by mutations at S56D, E60D, 
and/or G99D.  
  
 
1S3P 
Site 1  
S56D 
E56D 
Site 2  
G99D 
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Table 3-1. Design of PV-based contrast agents.  
Mutations in EF-hand motifs are labeled with grey background. 
 
Contrast agent Site 1 (52-63) Site 2 (91-102) Tryptophan mutation 
PV (ProCA30) DKDKSGFIEEDE DKDGDGKIGVEE N/A 
PV (ProCA31) DKDKSGFIEEDE DKDGDGKIGVEE F103W 
PV (ProCA32) DKDKDGFIEEDE DKDGDGKIGVEE F103W 
PV (ProCA33) DKDKSGFIDEDE DKDGDGKIGVEE F103W 
PV (ProCA34) DKDKSGFIEEDE DKDGDGKIDVEE F103W 
PV (ProCA35) DKDKDGFIDEDE DKDGDGKIGVEE F103W 
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Figure 3-2. Schematic representation of designed Gd3+ binding protein. 
Two Gd3+ binding pockets were generated on the CD and EF-loop of helix-loop-helix structure in 
wild type PV by mutations at S56D, E60D, and/or G99D. Organ dots stand for Gd3+ ion, blue 
dots stand for charged oxygen ligand for Gd3+ from carboxyl group, black dots stand for oxygen 
ligand for Gd3+ from protein main chain, green dots stand for non-charged oxygen ligand for 
Gd3+ from Ser, and red dots stand for oxygen ligand for Gd3+ from brighted water molecule. P1, 
P3, P5, P7, P9 and P12 are the residue postions in EF-hand.   
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3.2.2 Constructing ProCA3 expression vector 
The general procedures for constructing ProCA3 are shown in Fig. 3-3. The Rat a-PV in 
pcDNA 3.1(+) vector was a generally gift from Dr. Amy Lee at Emory University. In order to con-
struct bacteria expression vector for PV, the plasmid were first inserted the Nde I cleavage se-
quence (CATATG) by DNA insertion methods shown in Chapter 2 and then the new plasmid was 
double digested by Nde I and Xho I (New England Biolab). The plasmids of pET20b-7E15, 
pET22b-A7 and pRSETb were also digested with Nde I and Xho I. As show from Fig. 3-3 b, 
pcDNA3.1-PV, pET-20b-7E15, pET-22b-A7 and pRSETb vector were successfully digested by the-
se two enzymes. Then, the double digested PV was subcloned into these vectors by T4-ligase. 
After insertion, we sequenced the plasmids to make sure that full length of PV was inserted into 
the corrected location of the plasmids. As shown from Fig. 3-4 a, PV was successfully inserted in 
to the pET22b plasmids (named pET22b_PV). We next translated the DNA sequence into pro-
tein sequence. Sequence alignment (Fig. 3-4 b) shown that protein sequence translated from 
pET22b-PV is identical with rat PV sequence in the protein data base. These results indicate that 
PV is successfully inserted into the pET-22b vector. Using similar procedure, we also successfully 
inserted PV into pET20b and pRSETb vector (data not shown). 
  
83 
 
 
 
Figure 3-3. Construction of expression vector of PV. 
pRESTb, pET20b, pET22b vector and pcDNA3.1 (+)-PV DNA were double digested by NdeI and 
xhoI restriction enzyme. The digestion products were further separated by electrophoresis (bot-
tom). PV and vectors were further linked by T4 ligase.
Construction of pET22Tb-PV
Insert NdeI site into the 
pcDNA(+)-PV
Double digestion the pcDNA(+)-
NdeI-PV with NdeI and XhoI 
Double digestion of pET22b, pRSETb
and pET20b vector with NdeI and XhoI
Ligation, transformation and sequencing
PV        pET20b-7E15      pET22b-A7                           PV                   pET20b-7E15 pRSETb
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Figure 3-4. DNA and protein sequence of PV.  
DNA and protein sequence of PV in pET-22b vector were analyzed by vector NTI (top). The pro-
tein sequence of PV in pET22b vector (pET22b_PV) shows 100% identity as rat PV sequence in 
the PubMed (Bottom). 
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3.2.3 Protein expression and purification  
3.2.3.1 Protein expression 
We next test the expression conditions of PV in pET22b and pRSETb vectors. PV in two 
different vectors (pRETb-PV and pET22b-PV) were expressed in LB medium (Fig. 3-5). When the 
OD500 reached to 0.8, the bacteria were induced with 0.1 mM, 0.5 mM or 1 mM IPTG. As shown 
in Fig. 3-5, the protein greatly expressed after 3 hours induction and same level of expression 
were observed after IPTG induction overnight. For pRSETb-PV vector, the best IPTG concentra-
tion for PV expresion is 0.5 mM and the protein expression level decreased when IPTG concen-
tration increase to 1 mM. However, the best concentration of IPTG for the expression PV in 
pET22b vector is different from that in pRSETb vector. As shown in Fig. 3-5, 1 mM IPTG can in-
duce the highest level of PV expression in pET22b vector. Compared with the expression levels 
of PV with different IPTG concentration and in two vectors, we found that the best PV expres-
sion condition is pET22b vector and induced at 1 mM IPTG for 3 hr or overnight.  
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Figure 3-5. The expression of PV by E. coli. 
pRESTb-PV (left top) and pET22b-PV (left bottom) plasmids were transferred into bacteria BL21-
DC3-plysS strain and were further expressed in LB-medium with IPTG induction.   
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3.2.3.2 Early procedure for PV purification (Protocol 1)  
Fig. 3.6 shows the early procedure for PV purification. BL21 plysS bacteria with pET22b-
PV transformation were expressed in 2 liter LB medium. When the optical density (OD) reached 
to 0.8, the bacteria were induced with either 1 mM IPTG. The protein greatly expressed after 3 
hours induction. High amount of proteins were expressed in pET22b vectors after cultured at 37 
˚C overnight. After that, the proteins were purified followed by Henzl’s 172 protocol with modifi-
cations. SDS-PAGE and DNA agarose gel were used to monitor the PV purification. To purify this 
protein, the bacteria with PV expresion were lysated by French press or sonication. As shown 
from the SDS-PAGE in Fig. 3-7, PV mainly exists in the supernatant after spinning down at 13000 
rpm for 10 min. The purification of PV took the advantage of high thermal stabilities of this pro-
tein. The supernatant of bacterial lysate were incubated at 85 ˚C for 5-20 min. After heating and 
centrifugation, most of the PV was in the supernatant while other proteins were denatured and 
precipitated by high temperature (Fig. 3-7 A). We then ran two set of FPLC equipped with Hi-
Trap Q column to further purify PV. The PV in the first round of FPLC were eluted by 10 mM 
Tris/HCl, pH7.6, 3 mM EGTA and 1 M NaCl. As shown in the SDS-PAGE in Fig. 3-7 B, the fractions 
12 and 13 contains PV with 95% purity. However, DNA agarose gel indicates that fractions 12 
and 13 contains DNA and RNA (Fig. 3-7 B), although major DNA peak is shown in fraction 15 and 
16. To further purify PV, we collected fraction 12 and 13, added 6 mM CaCl2 and then injected 
into FPLC. As shown from Fig. 3-7, fraction 4-8 contains PV with high purity. After purified by 
second round of FPLC, PV with more than 99 % purities were obtained (Fig. 3-7).  
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Figure 3-6. Schematic representation of initial strategies for PV purification (Protocol 1). 
PV is expressed in E. coli after IPTG induction. Then, the bacteria were breaked by sonication 
and/or French press. The supernatant of bacteria lysate were incubated in a water bath at 85 ˚C 
for 5-20 min. The bacteria were further purified by two round of FPLC with different elution 
buffer. For the first round of FPLC, buffer A contains 3 mM EGTA in HEPES buffer at pH 7.2, 
buffer B contains 3 mM EGTA, 1 M NaCl in HEPES buffer at pH7.2. All the fractions of PV were 
further purified with second round of FPLC with 3 mM CaCl2 instead of EGTA in both buffer A 
and buffer B.  
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Figure 3-7. Purification of PV with two round of FPLC. 
The purification of PV using stretegies shown in Figure 3-6 monitored by SDS-PAGE (A, C and B 
(top)) and agarose gel (B (bottem)). A. Expresion of PV induced by IPTG and purification of PV 
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by frech press and heat incubation. B. Different fractions from first round FPLC purification with 
HP Q colume, monitored by SDS-PAGE (top) and DNA agarose gel (bottem); C. Different frac-
tions from second run FPLC purification equated with Q HP column. 
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3.2.3.3 Structural characterization of purified PV variants 
We next scan the UV absorbance spectra of PV and it mutants. Since pavalbumin wild 
type doesn’t have trptophan and tyrosine, the UV absorbance peak is mainly from Phe at 259 
nm. As shown from Fig. 3-8 A, PV wild type has the maximum peak at 259 nm, which is con-
sistent with literature reported carp PV absorbance spectrum.183 PV variants with tryptophan 
showed the UV absorbance peak at 280 nm and a sharp peak at 285-290 nm (Fig. 3-8B, C, D), 
which is also consistent with literature reported absorbance spectrum of PV with F103W muta-
tion184. UV absorbance spectrum also indicates that purified PV variants do not have DNA or 
RNA contamination. 
We further perform MALDI-mass analysis to verify our purified PV (Fig. 3-9). The mo-
lecular weight of the purified protein is 11776.8 kDa, which is consistent with the calculated 
value of PV (11776 kDa). 
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Figure 3-8. UV spectra of PV. 
UV spectra of PV wild type (A) and its variants: PVF103W (ProCA31) (B), PVS56DF103W 
(ProCA32) (C), and PVS60DF103W (ProCA33) (D). 
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Figure 3-9. Mass spectra of PV. 
The expected MW of PV is 11776 kDa. The MALDI measured molecular weighte of PV is 11776.8 
kDa. 
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3.2.3.4 Further optimization and simplification of for PV purification (Protocol 2) 
Previously, we are able to obtain the recombinant PV and its variants using heating 
combined with two round of FPLC in the present or absent of Ca2+ (Fig. 3-6). Using this method, 
we are able to obtain PV with 99% purity. However, lots of proteins were lost during these two 
sets of FPLC. In order to improve the yield of PV, remove DNA contamination more efficiently 
and simplify the purification procedure, six major modifications were made based on previous 
purification protocol (Fig. 3-6). 1). We added additional step before FPLC for DNA precipitation. 
We added 3 % streptomycin sulfate and incubated at 4  C overnight. After spin down at 13000 
rpm for 10 min the supernatant were incubated at 85  C for 5 min.  After spin down, the super-
natant was dialysis against 10 mM Tris/HCl at pH 8.0 before injecting into FPLC column. 2). We 
increased the buffer pH 7.5 to 8.0. Since the Q column is anion exchange column, increasing the 
pH of buffer improves the binding of PV to the column. 3). We found that our protein can be 
eluted out from Q column at 200 mM NaCl, therefore, we decrease the percentage of buffer B 
(containing 1 mM NaCl) during elution from 70% to 25% of buffer B. 4). The flow rate of FPLC 
was decreased from 5 ml/min to 2 ml/min to improve the binding of the pavalbumin to Q col-
umn. 6). We use 9 column volumes to let buffer B slowly increase from 0% to 25% (Fig. 3-10). 
The very slow increase of salt gradient further facilitates the separation between PV and DNA. 
After FPLC remaining small fragment of DNA can be further removed by concentrating protein 
using through 3 kDa membrane.  
The FPLC prufication curve is shown in Fig. 3-11A. The UV absorbance at 280 nm from 
FPLC detector shows four peaks during buffer B elution. Each peak were collected and then 
tested by UV spectroscopy, SDS PAGE and agarose gel. As show from Fig. 3-11A, the third frac-
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tion (28-30) has a single band at 11 kDa, which is consistent with the molecular weight of PV. 
UV spectrum of this frection is the same as the PV F103W mutants in the old methods in 
3.2.3.2. The first and second peaks do not have any protein and the last peak contains protein 
with a molecular of 30 kDa. DNA and UV absorbance data show that the peak 1 and peak 4 has 
a lot of DNA/RNA because these frections have high obsorbance at 260 nm. The final yield of 
this protein is about 50-70 mg per liter bacteria expression in LB medium. Taken together, this 
new method simplified PV purification procedure with much higher yield compared with the 
early purification methods described in section 3.2.3.2. 
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Figure 3-10. The FPLC program for ProCA3 variants purification. 
After binding to the column, the unbounded component were first washed with 7 column vol-
ume (CV) of buffer A (10 mM HEPES buffer at pH 8.0). Then, buffer B (10 mM HEPES buffer, 1 M 
NaCl at pH 8.0) concentration was increase to 25 % within 7 CV. We further wash the column 
with 25% of buffer B for 2 CV and then increase to 100 % of buffer B of 1 CV to wash out every 
component bounded to the column. At last, the column was requilibriated with 100% buffer A 
for 5 CV.  
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Figure 3-11. FPLC fractions, SDS-PAGE and UV absorbance spectrum analysis of ProCA3 purifi-
cation with improved protocol. 
Only one round of FPLC are required in this new purification method. There are four major 
peaks during FPLC purification (A). SDS-PAGE results (B) show that the fractions 28-32 contain 
ProCA3 with more than 99% purity. UV spectrum of fraction 28-32 (C) shows the typical spec-
trum of ProCA3, which has the maximum absorbance at 280 nm and a shoulder peak at 285 nm. 
The UV absorbance at 260 nm is lower than that at 280, indicating the DNA concentration in 
these fractions are very low. 
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Figure 3-12. Conformational analysis of ProCA3 variants in the presence Ca2+ or EGTA by CD. 
The ProCA3 variants shows typical helix structure in CD and the secondary structures of proCA3 
variants do not change in the presence Ca2+ or EGTA at 10 mM Tris buffer at pH 7.2. 
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3.3 Discussion  
3.3.1 Selection of scaffold protein 
The selection of scaffold protein is essential for the design of protein based MRI contrast 
agents. The scaffold protein must have above unique features: 1). The scaffold must stable and 
resistant to the enzyme cleavage; 2). The scaffold protein should have very good solubility; 3). 
To engineer metal binding pocket, scaffold protein must tolerate to mutations; 4). The scaffold 
should have no interference of its nature function such as interacting with cell membrane re-
ceptors to trigger signaling pathway; 5). The scaffold should have a molecular size between 10 
kDa and 20 kDa to have good tumor penetration and proper blood retention time.  
Due to above requirement, we choose PV as our scaffold protein to develop new gener-
ation of protein-based MRI contrast agents. PV is a small calcium buffer protein abundant in the 
central neuron system and muscle cells. The main biological role of this protein is to serve as a 
buffer to modulate cytosolic Ca2+ concentration. There is no reported interaction between PV 
and any other protein. This protein also doesn’t have extracellular cellular functions. PV is very 
stable, and it does not precipitated even in boiling water. This protein is also resistant to en-
zyme cleavage.  
3.3.2 Design Gd3+ binding pocket in PV 
We next design Gd3+ binding sites into PV. We named these PV variant as ProCA3. PV 
has two Ca2+ binding sites with high binding affinity. Unlike other calcium binding proteins, Ca2+ 
binding to PV do not induce large conformational changes. Henzl et al.,185 report that the Ca2+ 
binding affinity of some PV variants is higher than EGTA. Since lanthanide usually bind to pro-
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tein much stronger than Ca2+, we hypothesis the PV also has higher Gd3+ binding affinity than 
that of Ca2+. We use two strategies to design optimized Gd3+ binding affinity: 1) introducing 
more negative charge in the metal binding pocket (S56D, G99D); 2) change the ligand types 
(S56D, E60D). Henzl et al.,185-187 reported that mutating key residues in EF-hand can alter the 
Ca2+ binding affinity. Double mutation S56DE60 in PV dramatically increase Ca2+ binding affinity 
(K1 = 1.65 × 10
9 M-1 K2 = 3.0 × 10
8 M-1 for S56DE60D mutant, and K1 = 1.2 × 10
8 M-1 K2 = 1.2 × 10
8 
M-1 for WT PV). Therefore, we want to further study the effects of these mutations on Gd3+ 
binding affinity.  
In addition, we want to study the relaxivity of PV with different Gd3+ binding ligands. 
Mutations on EF hand could also change the water coordination number. The position 9 in EF-
hand usually interacts with Ca2+ through one bridged water molecular.112, 115, 188 The EF-hand I 
of PV, however, use side chain of Glu to bind to Ca2+. We designed E60D mutant to introduce 
more water ligand into the Gd3+ binding pocket. 
The metal binding affinity, relaxivity and water number of designed ProCA3 variants will 
be tested in Chapter 4 since these experiments reqires methodology development.  
3.3.3 ProCA3 expression, purification and PEGlytion 
After obtaining the ProCA3 variants mutants, we established the protein expression and 
purification protocol. Since ProCA3 is very stable at high temperature, it is very easy to separate 
this protein from other proteins by incubating at 85   C for 5-20 minutes. However, we face a big 
problem to separate ProCA3 from DNA/RNA, since DNA/RNA is also soluble at high tempera-
ture. We use two round of FPLC to completely separate between ProCA3 and DNA/RNA.  
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Since two rounds FPLC in Protocol 1 is time consuming and decrease the yield of ProCA3, 
we further simplified the purification procedure for ProCA3 in Protocol 2. Since streptomycin 
sulfate precipitates DNA, we add 3% streptomycin sulfate to precipitate DNA. Our results indi-
cate that streptomycin indicate precipitate large amount of DNA. By adding this step, we great-
ly reduced the DNA concentration before injection to the FPLC. Since DNA concentration is de-
creased, we only need one round of FPLC to separate ProCA3 and DNA. As shown from Fig. 3.10, 
we successfully purified ProCA3 with one round of FPLC. Optimization of ProCA3 purification 
greatly increases the yield and decreases the time and efforts for the ProCA3 purification.  
3.3.4 Standard protocol for PV purification 
After explore different methods for PV purification, we established the standard proto-
col for PV puri ca on. This protocol contains several steps: lyate the bacteria, 85   C incubation, 
DNA precipitation and FPLC separation. 
 Since this protein is a super dissolving and super stable protein (shown later), the pro-
tein is always in the supernatant even heat at 85   C for 5-20 min. However, DNA is also very sta-
ble at 85 ˚C and it is very hard to separate the DNA from PV. We added 3% of streptomycin sul-
fate to precipitate DNA. After try different conditions of FPLC, we found that Q column is the 
most efficient column to separate DNA and PV. The SDS-PAGE shows that the fractions 28 to 32 
are the major peak for PV, although the small peak around fraction 20 also contains our pro-
teins. The last peak (47-50) are DNA/RNA and some protein peak, which can be detected by 
agarose gel with EB staining or SDS-PAGE with Commassie brilliant blue staining (data not 
shown). According the UV absorbance and ε280 = 7200 M
−1cm−1, the highest yield of ProCA32 we 
can get from 1 liter LB medium is 50-70 mg. 
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3.3.5 Secondary and teriary strucure analysis of PV mutants 
Far-UV CD spectra of PV variants were detected in the present or absent of Ca2+. As 
show in Fig. 3-12, these mutants share the same alpha-helical structure, characterized by the 
low CD signal peak at 208 nm and 225 nm. We also compared with the secondary conforma-
tional changes in the present or absent of calcium. The CD signal of F102W, S55DF102W and 
E60DF103W do not have significant conformational changes, which is consistent with the re-
ported NMR and X-ray structure of apo- and holo-PV variants.187, 189, 190  
3.4 Summary 
To design novel protein-based MRI contrast agents (ProCA3), we carefully selected PV as 
our scaffold protein based on our criteria for an ideal contrast agent. This protein is well packed, 
highly stable, highly soluble, tolerant to mutations, have a rigid structure and metal binding 
sites. There is also no reported interaction between PV and other proteins.  
We have designed 7 variants with mutations on the metal binding sites to improve Gd3+ 
binding affinity, metal selectivity by tuning charged numbers in the coorinaton shell and 
relaxivity of ProCA3 by altering water number q associated to ligand total numbers. We have 
constructed vectors for the bacteria expression. 
We have optimized the bacterial expression and tag-less purification procedures of 
ProCA3 by selecting expression straints and removal of DNA contaimnations.  
After obtaining purified ProCA3, we are able to test the metal selectivity, relativity, met-
al coordination ligands, and serum stabiltiy of ProCA3. We are also able to purify and PEGylate 
ProCA3 variants (also refer to Chapter 9) for in vivo study, such as MR imaging, molecular imag-
ing, biodistribution and toxicity.  
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4 STABILITY, METAL SELECTIVITY AND RELAXIVITY OF PROTEIN-BASED MRI CONTRAST 
AGENTS 
4.1 Introduction 
As discuessed in Chapter 1, to develop contrast agents with superior safety profile, the 
contrast agents must have high Gd3+ stability, high metal selectivity and relaxivity. Long term 
toxicity of the contrast agents generally coming from the free Gd3+ release due to the competi-
tion of other physiological cations and ionons, such as Zn2+, Mg2+ and PO4
3+. Gd3+ has ionic radi-
us of 0.93 Å, which is similar to the ionic radius of Ca2+. Thus, Gd3+ can bind to the physiological 
Ca2+ binding sites. Such binding disrupt the dynamic function of calcium binding proteins. Be-
sides, long term accumulation of Gd3+ could cause NSF (Nephrogenic systemic fibrosis), a lethal 
disease in the renal impaired patients.125 A safe MRI contrast agent with high metal stability 
and Gd3+ selectivity is highly needed to reduce the toxicitiy caused by MRI contrast agent injec-
tion. 
 Tradditionally, pH titration methods were used to determine the meal binding affinities 
for the small chelators (refs). Small chlators, such as DTPA, has a Gd3+ binding affinity of 1.8 x 
10-21 M. Due to multiple protonations of residues in proteins, traditional methods such as pH 
titration can not be applied to determine the Kd between ProCA and Gd
3+ or other metals. Tb3+- 
or Eu3+- FERT methods are used to measure protein-metal binding affinity measurement. How-
ever, these methods are only sensitive to determine a Kd of around 1 µM or above. Due to this 
limitation, the metal binding affinity for Tb3+ for ProCA1 we previously reported as around 10-7 
M. To date, while several other methods such as the Ca45 flow dialysis, equilibrium dialysis, flo-
rescence dye titration and NMR were been applied to determine metal binding afifnities for 
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calcium binding proteins 185, 191,  the Gd3+ binding affinity of EF-hand binding proteins are not 
accurately reported. The Ca2+ binding affinity of all EF-hand proteins such as PV can reach to 10-
9 M.  Thus, a method to accurately mesure Gd3+ binding affinity in the range between 10-22 and 
10-18 M should be developed to study the Gd3+ affinity to ProCA variants. 
Relaxivity is another key parameter for MRI contrast agents as discussed in Chapter 1. 
The MRI signals are generated based on the different relaxation properties of protons. Howev-
er, such differences are very small among organs in vivo. The contrast and sensitivity of MRI can 
be improved by administrate the contrast agents. MRI contrast agent works as “catalyst” to 
catalyze the relaxation properties of each water molecule. By differential distribution in vivo, 
MRI contrast agents make the relaxation properties difference in each organ. The relaxivity of 
clinical MRI contrast agent is around 5 mM-1 s-1. The therotical maxium relaxivity, however, is 
about 100 mM-1 s-1. There is a strong need to develop MRI contrast with high relaxivity.  
In this chapter, we first report our efforts in developing a sensitive new  method to 
evaluate metal binding affinity and selectivity of metalloporteins. We then report our studies 
on determining Gd3+ binding affinity and selectivity of our developed protein contrast agents 
ProCA3 series designed in Chapter 3 based on determinants for metal binding.  We further 
measured the water number of these contrast agents to test the hypothesis of tuning relaxivity 
by tuning water number without trading off metal binding affinity. 
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4.2 Results 
4.2.1 Thermodynamic stability study and metal selectivity of protein based MRI contrast 
agents. 
We developed metal-chelator buffer system to control of the free metal ion in solution. 
In this way, we can successfully obtain the accurate Kd between ProCA3 variants and metal ions 
such as Ca2+, Mg2+ and Tb3+. 
4.2.1.1 Determine Ca2+ binding affinity of ProCA variants using Ca2+-EGTA buffer system. 
Some of the ProCA3 variants has been reported to have strong Kd around 10
-9 M to 
Ca2+,191 which is even stronger than EGTA. We hypothesis that our ProCA3 variants also has sim-
ilar Ca2+ binding affinity compared with these reported ProCA3 variants. However, such strong 
Kd cannot be accurately measured by the regular fluorescent titration methods due to the limi-
tation of background free metal in solutionand the sensitivity of this methods. In principle, an 
accurate method for Kd determination requires the use of protein and metal concentration 
close to the Kd. However, Tb
3+ and other durect method requires protein and metal concentra-
tion to be nM or above. To overcome these limitations, we developed metal chelator buffer 
system to control the free Ca2+ concentration between 10-13 M to 10-8 M, and then we can use 
the fluorescence change of Phe or Trp to probe the Ca2+ binding affinity at extremely low con-
centration of free Ca2+.  
Fig. 4-1 shows our experimental procedure of Ca2+-EGTA buffer system. This buffer sys-
tem contains 5 mM EGTA, 100 mM KCl, 50 mM HEPES at pH 7.2. ProCA3 variants were added 
into this system to a final concentration of 5 μM before the experiments. As we can see, this 
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system contains 1000-times high concentration of EGTA than ProCA3. Therefore, majority of 
ProCA3 variants should maintain app-form. We then titrated different concentration of Ca2+. 
We can calculate free Ca2+ concentration according to Equation (2-1). Ca2+ binding to ProCA3 
variants cause the fluorescent intensity changes, therefore, we are able to derive the fraction of 
the Ca2+ bonded ProCA3 variants based on the fluorescent signal changes in each titration point 
(Fig. 4-1 B). We then fit the titration points (Fig. 4-1 C) using Hill Equation (Equation (2-2)).  
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Figure 4-1. Determine Ca2+ binding affinity to ProCA variants by metal chelator buffer. 
This buffer system contains 2-20 µM of ProCA variants, 5 mM EGTA, 100 mM KCl, 50 mM HEPES 
at pH 7. This system contains 1000-times high concentration of EGTA than ProCA3. Due to 
strong Kd of EGTA to Ca
2+ and high concentration of EGTA, the majority of ProCA3 variants 
should maintain apo-form. When we titrated different concentration of Ca2+ in this system, the 
majority of Ca2+ binds to EGTA. Due to dynamic equlibium, low concentration of Ca2+ will be 
stay as free form. These “free” Ca2+ can bind to ProCA variants. We can calculate free Ca2+ con-
centration according to Equation (2-1). Ca2+ binding to ProCA3 variants cause the fluorescent 
intensity changes, therefore, we are able to know the fraction of the Ca2+ bonded ProCA3 vari-
ants based on the fluorescent signal changes in each titration points (B). We then fit the titra-
tion points using Hill Equation (B, Equation (2-2)).   
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Fig. 4-2 shows how we calculate the free Ca2+ concentration based on total concentra-
tion of Ca2+ in the Ca2+-EGTA buffer system. The total Ca2+ of the buffer system contains three 
major sources: (1) residue Ca2+ in the buffer, even after dialysis with Chelex-100 bag to deprive 
Ca2+; (2) Ca2+ which originally binds to ProCA3 variants were introduced to the system when 
adding ProCA variants before titration; (3) Ca2+ titrated in to the system. The total residue Ca2+ 
concentration, [Ca2+]Residue were measured by Fura-2 dye, which is around 10
-7 - 10-6 M after 
chelex-100 treatment. According to Equation (2-1), [Ca2+]residue contributes 10
-12 - 10-11 M of free 
Ca2+ when total EGTA concentration is 5 mM. We add 5 μM ProCA3 variants in experiments. If 
KdProCA to Ca is 10
-9 M, then we introduced 10 µM of total Ca2+ into the system, which further con-
tribute 7.37 × 10-10 M of free Ca2+ in the system. The total Ca2+ concentration in each titration 
point is tightly controlled, and we know the exact total Ca2+ concentration have been titrated 
into the system. For example, if we titratated 100 µM of total Ca2+ in the system, it generates 
7.51 × 10-9 M free Ca2+ in the system according to Equation (2-1). 
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Figure 4-2. Schematic demonstration of free Ca2+ calculation in Ca-EGTA buffer system. 
Ca2+ in our system is contributed from three major sources: residue calcium in the buffer, calci-
um introduced by adding ProCA variants and calcium added during titration. According our cal-
culation by Equation 2-1, residue calcium in the buffer contribute 10-12-10-11 M free calcium to 
the Ca-EGTA buffer system. Since ProCA3 variants has a Kd to Ca
2+ around 10-8 M, adding calci-
um bounded ProCA3 variants also introduce free Ca2+ in the system. For example, 10 µM Ca2+ in 
ProCA introduce 7.37 × 10-10 M free calcium in the buffer system. The total calcium tritrated in 
the system is know and well controlled during titration, we can then calculate free Ca2+ concen-
tration in the system during titration. For example, adding 100 µM total Ca2+ will generate 7.5 × 
10-9 M free Ca2+ in the system.  
[Ca2+] Total
[Ca2+] titration point[Ca
2+] protein[Ca
2+]Residue
Known 
(e.g. 100 μM )
Depend on the 
Kd of protein
10-7 ~10-6 M
7.37X10-10 M
(10 μM Ca2+ in ProCA)
10-12 ~10-11 M
Known 
(e.g.7.51X10-09 M)
[Ca] total
[Ca] free
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Fig. 4-3 shows Ca2+ titration results of ProCA3 variants using Ca2+-EGTA buffer system as 
described above. ProCA30 has 10 Phe residues and do not have Trp and Tyr. Therefore, we ex-
cite the Phe fluorescence at 260 nm and collect emission fluorescence spectrum between 270- 
320 nm. As we can see from Fig. 4-3 A, the fluorescence signal decreases during the titration 
and finally reaches the plateau. ProCA31, ProCA32, ProCA33 has one Trp residue of each. Thus, 
we exite the Trp fluorescence at 280 nm and collect emission spectrum between 290-370 nm 
(or 300-340 nm). The fluorescent signalsincrease during the titration and finally reach the plat-
eau (Fig. 4-3 B,C,D).  
Table 4-1 shorws the Ca2+ binding affinity of ProCA3 variants. Wild type PV (ProCA30) 
has a Ca2+ binding affinity of 8.35 × 10-9 M. F103W mutation (ProCA31) increase Ca2+ binding 
about 2 folds. Introducing one more negative charged ligand (S56DF103W) in EF-hand I does 
not change Ca2+ binding affinity, while replacing Glu ligand to water ligand (E60DF103W) de-
creases calcium binding affinity when compared with F103W mutant. 
4.2.1.2 Determine Mg2+ binding affinity of ProCA variants using Mg2+-EGTA buffer system. 
Similar to Ca2+-EGTA buffer system, we use Mg2+-EGTA buffer system to determine the 
Mg2+ binding affinity to ProCA3 variants (Fig. 4-4). ProCA30 and ProCA31 has similar Kd to Mg
2+ 
about 2 × 10-5 M. Interestingly, ProCA32 has 10 times stronger Kd to Mg
2+ than ProCA31 and 
ProCA32. Such dramatic increase of Kd to Mg
2+ of ProCA32 may caused by one more negative 
charged residue in EF-hand I of ProCA32. 
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Figure 4-3. Determine Kd of Ca
2+ to ProCA3 variants. 
Kd of Ca
2+ to ProCA3 variants were determined by Phe (A)/ Trp (B, C) fluorescence titration us-
ing Ca-EGTA buffer system in 50 mM HEPES 100 mM NaCl at pH 7.2. Phe fluorescence decrease 
(A, D) in wild type ProCA3 or Trp fluorescence increase in ProCA3 mutant (B,E: ProCA31; C,F: 
ProCA32, G: ProCA33) were observed when increase total Ca2+ concentration in the system. 
Free Ca2+concentration were calculated according to the method described by Fig. 4-1 and 4-2. 
The Kd of Ca
2+ to ProCA3 variants were calculated by Hill equation (Equation 2-2).    
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K d K a lg K a n
P roC A 30 8.35E -09 1.20E +08 8.08 2.1
P roC A 31 3.32E -09 3.01E +08 8.48 1.9
P roC A 32 3.07E -09 3.26E +08 8.51 1.5
P roC A 33 8.83E -09 1.13E +08 8.05 1.2
Table 4-1. The Ca2+ binding affinity of ProCA3 variants. 
 
 
 
The binding affinities of ProCA3 variants were determine at in 50 mM HEPES 100 mM NaCl at 
pH 7.2.  
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Figure 4-4. Determine Kd of Mg2+ to ProCA3 varants. 
Kd of Mg
2+ to ProCA3 variants were determined by Phe (A, excitation at 260 nm)/ Trp (B, C, exci-
tation at 280 nm) fluorescence titration using Mg-EGTA buffer system in 50 mM HEPES 100 mM 
NaCl at pH 7.2. Phe fluorescence decrease (A, D) in wild type ProCA3 or Trp fluorescence in-
crease in ProCA3 mutant (B, E: ProCA31; C,F: ProCA32) were observed when increase total Mg2+ 
concentration in the system. Free Mg2+concentration were calculated according to the method 
described by Fig. 4-1 and 4-2. The Kd of Mg
2+ to ProCA3 variants were calculated by Hill equa-
tion (equation 2-2).    
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4.2.1.3 Determine Tb3+ and Gd3+ binding affinity of ProCA3 variants using Tb3+-chelator buffer 
system and competition methds. 
Next we applied metal-chelator buffer system to measure the ProCA3 variants to lan-
thanide metals. Lanthnide usually binds to EF-hand calcium binding proteins with a Kd between 
10-11 - 10-9 M. Our first generation of ProCAs, ProCA1 has a Kd to Gd
3+ around 10-12 M. 
Nitrilotriacetic acid (NTA) has a Kd of 5.62 × 10
-12 M to lanthanide, and NTA-lanthanide buffer 
system can maintain the free lanthanide concentration between 10-13 - 10-10 M, which is the 
proper range of free lanthanide concentration for titration. We use Tb3+ luminescence energy 
transfer methods to probe the binding between ProCA3 variants and Tb3+.  We excited Trp resi-
due in ProCA3 variants at 280 nm, it usually has the fluorescence emission at 315 nm. However, 
if Tb3+ binds to ProCA3, Tb3+ will be excited by Trp emission fluorescence signal and have an 
emission peak at 545 nm (Fig. 4-5). After obtaining the Kd between ProCA3 variants, we can cal-
culate the Kd between Gd
3+ and ProCA3 variants by competition methods.  
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Figure 4-5. Trp-Tb3+ LRET assay. 
Carton demonstration of Trp-Tb3+ LRET assay to characterize the interaction between ProCA3 
variants and metal ions such as Ca2+, Tb3+ and Gd3+. ProCA3 varients (except wild type) all have 
one Trp mutation (F103W). ProCA3 variants have an emission peak at 315 nm, when they were 
excited at 280 nm. If Tb3+ binds to these metal binding sites, the emission from Trp are trans-
ferred to Tb3+ and have a fluorescence/luminescence emission at 545 nm. In the competition 
assay,10 µM Tb3+ was pre-loaded into 5 µM ProCA3 variants. We added Gd3+ in the system. 
Since Gd3+ and Tb3+ binds to ProCA3 variants in the same site, Gd3+ competes Tb3+ out of the 
metal binding pockets. Since there is no energy transfer between Gd3+ and Trp, the emission at 
545 nm decrease and emission at 315 nm increases.  
116 
Fig. 4-6 shows the Tb3+ LERT fluorescence spectrum changes by changing the free Tb3+ 
concentration in the presence and absence of ProCA31. The buffer initially contains 1 mM Tb3+, 
1 mM NTA, 50 mM HEPES, 100 mM KCl and 30 µM ProCA31. We then titrated different concen-
trations of NTA to decrease the free Tb3+ concentration in the system. As we can see from Fig. 
4-6, the fluorescence decrease to a plateau when adding NTA, which indicate that Tb3+ is disso-
ciated from ProCA31 then the free Tb3+ concentration decrease (adding NTA decrease free Tb3+ 
concentration). On the contrary, the system without ProCA31 has very low fluorescence and 
such low fluorescence does not have obvious intensity changes. We then calculate the free Tb3+ 
concentration using Equation (2-5) and then calculate Kd between ProCA31 and Tb
3+ by Hill 
Equation. Similarly, we also use this method to obtained the Kd between ProCA33 and Tb3+ (5-
9). ProCA31 and ProCA33 have KdTb3+ of 4.3 × 10
-12 and 1.55 × 10-12 M. 
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Figure 4-6. Determine Kd of ProCA31 to Tb3+ by Tb-NTA buffer system. 
The Tb-NTA system contains 50 mM HEPES at pH 7.2, 100 mM KCl, 1 mM Tb3+ and 1 mM NTA 
and 30 µM ProCA31. Due to the strong binding between ProCA31 and Tb3+, the metal binding 
pockets in ProCA31 were occupied by Tb3+. After titrating NTA in the buffer system, Tb3+ will 
release from ProCA31 due to the free concentration of Tb3+ decrease (B). In a control experi-
ments without, no significant fluorescen change after adding NTA (A). In the control experi-
ments without ProCA3, the fluorescence signal doesn’t change due to the lack of FRET (A). The 
Kd of ProCA31 to Tb
3+ was calculated by Hill Equation based on the relative fluorescence intensi-
ty vs. free Tb3+ concentration plot (C).
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Figure 4-7. Determine Kd of ProCA33 to Tb3+ by Tb-NTA buffer system. 
The Tb-NTA system contains 50 mM HEPES, 100 mM KCl, 1 mM Tb3+ and 1 mM NTA and 30 µM 
ProCA33. Due to the strong binding between ProCA33 and Tb3+, the metal binding pockets in 
ProCA33 were occupied by Tb3+. After titrating NTA, Tb3+ will release from ProCA31 due to the 
concentration of free Tb3+ decreases (B). In the control experiments without ProCA33, the fluo-
rescence signal doesn’t change since there is no LRET phanamana occured in the control exper-
iments (A). The Kd of ProCA33 to Tb
3+ was calculated by Hill Equation based on the relative fluo-
rescence intensity vs. free Tb3+ concentration plot. 
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To our surprise, we failed to observe the fluorescence decrease in the NTA-Tb3+ buffer 
system when applied to ProCA32 and after adding NTA. We reasoned that ProCA32 has much 
stronger affinity for Tb3+ than other ProCA3 variants and ProCA32 is always saturated by Tb3+ 
when the free Tb3+ concentration is between 10-13 M to 10-11 M. To test our hypothesis, we did 
dye competition experiments to explore the Kd of ProCA32 to lanthanide. Table 4-2 shows the 
Gd3+ binding affinity of fluoresce dyes determined by our previous lab members Dr. Jin Zou and 
Dr. Jie Jiang. Fura-2 has the strongest Gd3+ binding affinity (Kd = 1.5 × 10
-14 M) among these 
dyes. We then test if ProCA32 is able to compete Gd3+ out of the Fura-2. 18 µM GdCl3 and 20 
µM Fura-2 were added in 10 mM Tirs/HCl, pH 7.4. Then, ProCA32 or CaM was titrated in to the 
cell with different concentration. The fluorescence spectra were obtained with λex 250-450 nm 
and λem 510 nm.  As shown from Fig. 4-8, the fura-2 fluorescence peak shift from 380 nm to 340 
nm after adding 18 μM Gd3+, which indicates that Fura-2 binds to Gd3+. Then, different concen-
tration of ProCA32 or CaM were titrated into the system. As shown in Fig. 4-8, The fura-2 fluo-
rescence dramatically decreases after adding ProCA32, and the fluorescence peak shift to 380 
nm with the same intensity of apo-fura-2 when titrated 10 μM ProCA32 (20 μM of total Gd3+ at 
two binding sites). Thus, 10 μM ProCA32 is able to completely compete Gd3+ out of fura-2, 
which indicate that ProCA32 has a much greater Gd3+ binding affinity than Fura-2 ((Kdfura-2,Gd = 
1.5 × 10-14 M)). As a control experiment, we also titrate calmodulin in a parallel experiment, 
CaM cannot compete Gd3+ out of fura-2 even at much higher concentration (20 μM of 
Calmodulin or 80 μM of Gd3+ binding pocket). 
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Table 4-2. Excitation, emission and Gd3+ binding affinities of fluorescent dyes determined by 
Gd-chelator buffer system. * 
Fluoresence Dye Excitation  
(nm) 
Emission  
(nm) 
Gd3+ binding affinity  
(Kd, M) 
Fura-2 340/380 510 1.5 х 10-14 
Fura-6F 340/380 510 8.4 х 10-12 
Fluo-5N 488 520 3.8 х 10-12 
Mag-Fura-2 340/380 510 2.4 х 10-9 
Rhod-5N 550 580 2.5 х 10-9 
 
* Experimental data from Dr. Jin Zou and Dr. Jie Jiang.
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Figure 4-8. Evaluation of Gd3+ binding affinity to ProCA32 and calmodulin by fura-2 competi-
tion assay.   
20 µM of fura-2 were added into 50 mM HEPES, 100 mM NaCl at pH 7.0. Fluorescence changes 
were collected after adding 18 µM Gd3+, and different concentration of ProCA32 or CaM by ex-
citation between 250 – 450 nm, and emission at 510 nm using PTI.  
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18 µM GdCl3 and 20 µM Fura-2 were loaded in 10 mM Tirs/HCl, pH 7.4. Then CA32 
or CaM were titrated in to the cell with different concentration. The fluorescence 
spectra were obtained with λex 250-450 nm and λem 510 nm.
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To determine the exact lanthanide binding affinity of ProCA32, we developed Tb3+-DTPA 
buffer system. This system contains 5 mM DTPA, 30 µM ProCA32, 0.06 µM Rhod-5N, 5 mM 
HEPES, and 100 mM NaCl, pH7.2. DTPA has a Kd to Tb
3+ of 9.55 × 10-22 M.  Tb-DTPA is able to 
generate a buffer range between 10-24 and 10-18 M of free Tb3+. As a low-affinity-metal indica-
tor, the fluorescene of Rhod-5N can increase when free [Tb3+] is higher than 10-6 M. We added 
Rhod-5N as an internal standard and make sure that that DTPA is not saturated by Tb3+. Fig. 4-
9B shows Tb-ProCA32 LERT signal changes during Tb3+ titration. In a parallel experiment, 5 mM 
DTPA without ProCA32 were titrated with Tb3+ as background control (Fig. 4-9A). Rhod-5N sig-
nal were also monitored at each titration point (Fig. 4-9C). As shown in Fig. 4-9AB, Tb3+-ProCA32 
LERT happened in the Tb-DTPA buffer system, which indicates that ProCA32 is able to bind to 
Tb3+ concentration is between 10-23 and 10-19 M. We next calculated the Kd using Hill equation 
(Fig. 4-9E). Interestingly, ProCA32 has a KdProCA32,Tb of 1.21 × 10
-21 M.  
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Figure 4-9. Determine Tb3+ and Gd3+ binding affinity to ProCA32 by Tb3+-DTPA buffer system 
and Gd3+ competition assay. 
Terbium fluorescence spectrum changes after adding Tb3+ into 5 mM DTPA with out protein in 
50 mM HEPES with 100 mM NaCl. B. Terbium fluorescence spectrum changes after adding Tb3+ 
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into 5 mM DTPA with 30 µM ProCA3 in 50 mM HEPES with 100 mM NaCl at pH 7.2. C. Rhodmin 
5N fluorescence changes after adding Tb3+ into 5 mM DTPA with 0.06 Rhodmin 5N in 50 mM 
HEPES with 100 mM NaCl. D. Fluorescence intensity does not change during Tb titration in 
Rhodmin 5N and DTPA. E. Fluorescence intensity with background subtraction increases during 
Tb3+ titration in ProCA32 and DTPA. The Kd of Tb
3+ to ProCA32 was calculated by Hill Equation. F. 
Determine Gd3+ binding affinity to ProCA32 by Gd3+ competition assay.  
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We next determined Gd3+ binding affinity to ProCA3 variants by completion experi-
ments. 10 µM of Tb3+ and 5 µM ProCA3 variants were incubated with different concentrations 
of Gd3+ at room temperature over night. The Tb-FRET fluorescence signal changes were meas-
ured the next day at excitation 280 nm and emission at 545 nm. As shown in Fig. 4-9 F, Gd3+ can 
compete Tb3+ out of ProCA32 with a decrease of FRET upon graduately addition of Gd with an 
apparent Kd (Kapp) of 5 µM. We then calculated Kd between Gd
3+ and ProCA3 variants. As shown 
from Table 4-3, the Gd3+ binding affinity of ProCA30, ProCA 31, ProCA 33, ProCA35 has KdGd 
around 10-12 M, while ProCA32 has a KdGd of 2.79 × 10
-22 M. This is an exciting result because 
ProCA32 has very similar Gd3+ stability compared with most clinical MRI contrast agents, such 
as Gd-DTPA, multihance, and Eovist. and much higher Gd-stability than Ominiscan and 
optimark. 
4.2.1.4 Determine Zn2+ binding affinity of ProCA3 variants using Fluozin-1 competition. 
Zn2+ is another physiological metal ion potentially inducing transmetallation for contrast 
agents. We determined the Zn2+ binding affinity to ProCA3 variants using Fluozin-1 competition 
methods.103 Zn2+ and Fluozin-1 were first incubated in 50 mM HEPES, 100 mM NaCl, pH 7.2. 
Then, ProCA3 variants were titrated into the solution. The Fluorescence signals of Fluozin-1 
were collected in each titration point. Due to competition, Zn2+ will be removed from Fluozin-1 
during ProCA titration and the fluorescence intensity of Fluozin-1 deceased until reach to a 
plateau (Fig. 4-10). Interestingly, Zn2+ binding affinity of ProCA32 variants varies from 6.0 × 10-8 
M to more than 1 × 10-5 M (Table 4-3). Interestingly, ProCA32 has the highest Zn2+ binding affin-
ity, which may caused by additional negatively charged mutation (S56D) inducted in EF-hand I.  
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Figure 4-10. Determine Zn2+ binding affinity to ProCA32 by Fluozin-1 competition assay. 
A. Fluozin-1 fluorescence spectrum changes during ProCA32 titration. The solution contains 50 
mM HEPES, 100 mM NaCl and 1 µM Fluozin-1 at pH 7.2. B. Fluorescence intensity changes dur-
ing ProCA32 titration. The apparent Kd of Tb3+ to ProCA32 was calculated by competition equa-
tion (equations 2-8 an 2-9).  
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 Table 4-3. Metal binding affinity and selectivity of PV-based MRI contrast agents. 
 
The binding affinities of ProCA3 variants were determine at in 50 mM HEPES 100 mM NaCl at 
pH 7.2.  
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4.2.1.5 Metal selectivity ProCA3 variants. 
Contrast agents with high metal stabilities are highly desired for the development of 
contrast agents, since other physiological ions could compete Gd3+ out of the binding pocket. 
After obtained the binding affinity of ProCA variants to metal ions such as Zn2+, Ca2+ and Gd3+, 
we calculated their metal selectivities. Our best contrast agent, ProCA32, has pGd/pCa of 13.1 
and pGd/pZn of 14.3, which is much higher than all of the clinical MRI contrast agents and the 
first generation of ProCA, ProCA1. These results indicate that ProCA32 could be resistant to 
transmetallation in vivo and ProCA32 could be much more stable than clinical MRI contrast 
agents injected in vivo. 
4.2.1.6 In vitro transmetallation study of ProCA32 and clinical MRI contrast agents 
 In the physiological condition, Zn2+ and Po4
3- are the major molecules to compete Gd3+ 
from contrast agents. To study the transmetalizaiton of ProCA3, we measured the relaxation 
rate changes over time of contrast agents in the presence of Zn2+ and Po4
3-. Consistant with lit-
erature data (Fig. 4-11A), clininial MRI contrast agents has different transmetallation rate in this 
solution. The linear noncharged MRI contrast agent, Ominiscan, has highest transmetallation, 
while macrocyclic non-charged MRI contrast agents, such as Gadavist and Prohace, have no 
trasmetalization in the presence of Zn2+ and PO4
3- for at least 4 days based on the study reprted 
by Laurent et al,.192 Intestertingly, different ionic linear MRI contrast agents has different 
transmetallation rate, even through the number of negative charge and ligand type are very 
similar. 
 We applied the similar experiemnts to test the transmetallation properties of ProCA32 
in the presence of Zn2+ and PO4
3-. Due to the high relaxivity, 25 times lower Gd3+ concentration, 
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25-50 times lower chelator concentration was used in this study. To better compare the 
transmealization properties of ProCA32 with clinical MRI contrast agent, we apply this study 
using 25 time lower concentration of Zn2+ and PO4
3-. As show from Fig. 4-11B, the relaxation 
rate of ProCA32 is not changed in the presence of Zn2+ and PO4
3- for at least 4 days, indicating 
that ProCA32 has no transmelization at this condition. 
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Figure 4-11. Transmetallation study of clinical MRI contrast agents and ProCA32. 
Transmetallation study of clinical MRI contrast agents (A. at 37   C,  B. at 60   C) and ProCA32 (C. 
50 µM of ProCA32, 100 µM Gd3+, 2.5 mM Zn2+, and 30 mM  PO4
3-; D. 55 µM (open dots) or 110 
µM (open square) of ProCA32, 100 µM Gd3+, 100 µM Zn2+, and 1.2 mM  PO4
3-). 
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4.2.2 Relaxivity study of ProCA3 variants 
The relaxivity of ProCA3 variants were measured in the buffer containing 50 mM HEPES, 
100 mM NaCl, pH 7.2 at 37 ˚C. We fixed the Gd3+ concentration as 100 µM and mixed with dif-
ferent concentration of ProCA3 variants from 5 µM to 200 µM.  We then calculate the per Gd3+ 
relaxivity of each fixed contrast agent concentration. The final relaxivity were calculated when 
the ratio between Gd3+ and ProCA3 were 2:1.  
5.2.3.1 The relaxivity of ProCA30 at 37 ˚C 1.4 T 
Fig. 4-12 shows the r1 and r2 measurement of ProCA30. We fixed Gd
3+ concentration at 
100 µM. r1 and r2 started with 5 and 22 mM
-1s-1, respectively, which is the relaxivity of free Gd3+ 
without any ProCA30. After adding 5-25 µM of ProCA30, the r1 and r2 keep increase. Since 
ProCA30 has two Gd3+ binding sites, r1 and r2 measured in these conditions should be the com-
bination of both free Gd3+ relaxivity and Gd3+-ProCA30 complex relaxivity. All of the Gd3+ bind to 
ProCA30, when ProCA30 concentration is equal to or above 50 µM. In such conditions, the r1 
and r2 is the per-Gd relaxivity of Gd
3+-ProCA30 complex. Interestingly, the per Gd3+ r1 and r2 of 
ProCA30 is 32 and 42 mM-1s-1, which is about 8 fold higher than clinical MRI contrast agents 
with r1 = 3.5 mM
-1s-1 and r2 = 5 mM
-1s-1.Since ProCA30 binds two Gd3+, the per particle relaxivity 
is 64 for r1 and 84 mM
-1s-1 for r2
  (Fig. 4-12). 
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Figure 4-12. Relaxivity of ProCA30. 
r1 and r2 relaxivities of 50 µM Gd
3+ at different concentration of ProCA30 were measured by 1.4 
T relaxometer in 50 mM HEPES 100 mM NaCl at pH 7.2. A T1 relaxiation time of 50 µM Gd
3+ at 
different concentrations of ProCA30 in 50 mM HEPES 100 mM NaCl at pH 7.2. B. r1 relaxiavity of 
50 µM Gd3+ at different concentration of ProCA30 in 50 mM HEPES 100 mM NaCl at pH 7.2. C. 
T2 relaxiation time of 50 µM Gd
3+ at different concentrations of ProCA30 in 50 mM HEPES 100 
mM NaCl at pH 7.2. D. r2 relaxiavity of 50 µM Gd
3+ at different concentrations of ProCA30 in 50 
mM HEPES 100 mM NaCl at pH 7.2. 
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4.2.2.1 The relaxivity of ProCA32 at 1.4 T 37 ˚C. 
We next determined the r1 and r2 of ProCA32 at 1.4 T, using similar methods at 37 ˚C to 
minic animal body temperature. Gd3+ concentration of the each testing conditions was fixed at 
100 µM. We then measured T1 and T2 of the water in the presence of 100 µM of Gd
3+ and dif-
ferent concentration of ProCA32. As shown from Fig. 4-13, the T1 and T2 relaxiation time of wa-
ter decrease when titrating ProCA32. However, when Gd3+ is saturated by ProCA32 
([ProCA32]=50 µM), continuing titrating ProCA32 increase the relaxation time. The r1 and r2 
relaxivity first increase, then when ProCA32 concentraion is larger than 50 µM, the r1 and r2 de-
crease when adding ProCA32. These results indicate that ProCA32 has different Gd3+ binding 
sites when compare to ProCA30. When Gd3+ concentration is higher than that of the Gd3+ bind-
ing pocket in ProCA32, all of the Gd3+ binding pockets in ProCA32 are occupied, which cause the 
shorter relaxiation time and high relaxivity. The relaxivity of ProCA32 at this condition is similar 
to that of ProCA32. The lowest T1 and T2 were achieved when the Gd
3+ concentration is the 
same as the concentration of Gd3+ binding pocket in ProCA32. Then r1 and r2 determined at this 
concentration is the r1 and r2 of ProCA32. As shown from Fig. 4-13, ProCA32 has the similar 
relaxivity comparing the WT ProCA32. Per Gd3+ r1 and r2 of ProCA32 are 30 and 40 mM
-1s-1, re-
spectively. Similar as ProCA30, ProCA32 has two Gd3+ binding sites. Therefore, the per particle 
r1 and r2 of ProCA32 are 60 and 80 mM
-1s-1, respectively.  
Interestingly, the T1 and T2 increase when ProCA32 concentration is higher than 50 µM 
(corresponding to 100 µM of the Gd3+ binding pocket in ProCA32). T1 and T2 reached to plateau, 
when ProCA32 concentration is higher than the Gd3+ concentration. Fig. 4-13 also shows that 
when ProCA32 binds to one Gd3+, the relaxivity is much lower than that of ProCA32 which binds 
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two Gd3+ions.  These results indicate that Gd3+ binding patterns to ProCA32 are different when 
it binds to one or two Gd3+. ProCA32 may have two very different Gd3+ binding pockets. One of 
the Gd3+ binding pockets may have high relaxivity but low Gd3+ binding affinity and another 
Gd3+ binding pocket may have low relaxivity but high Gd3+ binding affinity. It is also possible 
that Gd3+ binding to two binding sites changes overall metal affinity due to coopertivity. 
4.2.2.2 The relaxivity of ProCA35 at 1.4 T 37 ˚C. 
Fig. 4-13 shows the relaxivity of ProCA35. These ProCA32 variant has three mutations at 
S56D, E60D and F103W. Same measurement conditions, like Gd3+ concentration, HEPES buffer 
and salt strength were applied to determine the relaxivity of ProCA35. T1 and T2 decrease is 
much more significant than that of ProCA30 and ProCA32, and it reachs to a plateau when the 
protein concentration is equal to or higher than Gd3+ concentration (100 µM). Interestingly, the 
per Gd r1 of ProCA35 are 57 and 53 mM
-1s-1 when [Gd3+]/[ProCA] are 1 to 2 and 1 to 1, 
repectively. The per Gd r2 of ProCA35 is 77 and 70 mM
-1s-1 when [Gd3+]/[ProCA] are 1 to 2 and 1 
to 1,respectively. As discussed in Chapter 3, we hypothesize that mutation E60D introduces one 
more additional water ligand to ProCA3. These results support our hypothesis, since increased 
water number will increase relaxivity as shown from Equation 1-2.  
4.2.2.3 The relaxivity of other ProCA3 variants at 1.4 T 37 ˚C. 
The relaxivity of ProCA31, ProCA33 and ProCA36 were also measured by this method 
with the exactly same conditions (Fig. 4-13).  ProCA31 only has F103W mutation. There is no 
modification of Gd3+ binding pocket in ProCA3. The relaxivity of ProCA31 is very similar to that 
of ProCA30. The per Gd3+ r1 and r2 for ProCA31 is 32 and 42 mM
-1s-1 when [Gd3+]/[ProCA] are 1 
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to 2 and 1 to 1. The per Gd3+ r2 of ProCA32 is 31 and 40 mM
-1s-1 when [Gd3+]/[ProCA] are 1 to 2 
and 1 to 1. These results indicate that F103W mutation does not change the relaxivity of 
ProCA3 variants. 
ProCA33 has two mutations at E60D and F103W. Position of EF-hand I of ProCA33 is 
modified by mutation E60D. We hypothesis that E60D replace the side chain ligand for Gd3+ at 
position 9 to be water ligand, which cause increased relaxivity. Consistent with our hypothesis, 
the per Gd3+ relaxivity of ProCA33 is much higher than that of ProCA30 and ProCA31. The per 
Gd3+ r1 and r2 for ProCA31 is 43 and 57 mM
-1s-1 when [Gd3+]/[ProCA] are 1 to 2 and 1 to 1. The 
per Gd r2 of ProCA33 is 40 and 52 mM
-1s-1 when [Gd3+]/[ProCA] are 1 to 2 and 1 to 1. 
ProCA34 has two mutations at G99D and F103W. G99D is the mutation at position 9 of 
EF-hand II. We hypothesis that this mutation make all the binding ligand in EF-hand II same as 
EF-hand I with S56D and E60D double mutant (ProCA33). However, G99D mutation does not 
change the ligand type for Gd3+ in the EF-hand II. Consistent with our hypothesis, the per Gd3+ r1 
and r2 for ProCA31 is 32 and 42 mM
-1s-1 when [Gd3+]/[ProCA] are 1 to 2 and 1 to 1. The per Gd r2 
of ProCA34 is 31 and 40 mM-1s-1 when [Gd3+]/[ProCA] are 1 to 2 and 1 to 1. These relaxivity val-
ues are the same as that of ProCA30 and ProCA31, indicating that mutation G99D does not 
change the Gd3+ binding pocket in EF-hand II. 
ProCA36 contains three mutations: S56D, G99D and F103W. The mutations on ProCA36 
is the combination of ProCA32 and ProCA34. The relaxation time changes of ProCA36 during 
titration are very similar to that ProCA32. Both T1 and T2 decrease when ProCA36 concentration 
increases. However, when ProCA36 concentration is higher than 50 µM, continue adding 
ProCA36 increase both T1 and T2. The per Gd
3+ r1 and r2 for ProCA36 is 32 and 42 mM
-1s-1 when 
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[Gd3+]/[ProCA] are 1 to 2 and 1 to 1. The per Gd r2 of ProCA36 is 20 and 28 mM
-1s-1 when 
[Gd3+]/[ProCA] are 1 to 2 and 1 to 1. Both ProCA32 and ProCA36 contains S56D mutation indi-
cating that S56D mutation cause the relaxivity decreasing at high concentration of ratio be-
tween ProCA and Gd3+. 
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Figure 4-13. Relaxivity of ProCA32. 
r1 and r2 relaxivity of 50 µM Gd
3+ at different concentrations of ProCA32 in 50 mM HEPES 100 
mM NaCl at pH 7.2. A T1 relaxiation time of 50 µM Gd
3+ at different concentrations of ProCA32 
in 50 mM HEPES 100 mM NaCl at pH 7.2. B. r1 relaxiavity of 50 µM Gd
3+ at different concentra-
tions of ProCA32 in 50 mM HEPES 100 mM NaCl at pH 7.2. C. T2 relaxiation time of 50 µM Gd
3+ 
at different concentrations of ProCA32 in 50 mM HEPES 100 mM NaCl at pH 7.2. D. r2 relaxiavity 
of 50 µM Gd3+ at different concentrations of ProCA32 in 50 mM HEPES 100 mM NaCl at pH 7.2. 
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Figure 4-14. Relaxivity of ProCA3 variants. 
r1 (A) and r2 (B) relaxivity of 50 µM Gd
3+ at different concentrations of ProCA3 variants in 50 
mM HEPES 100 mM NaCl at pH 7.2 using 1. 4 T relaxometer at 37   C 
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Figure 4-15. r1 and r2 relaxivities ProCA3 variants incorporated with 1 or 2 Gd
3+ ions. 
Therelaxivities were measured variants in 50 mM HEPES 100 mM NaCl at pH 7.2 using 1. 4 T 
relaxometer at 37   C 
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4.2.2.4 The relaxivity of ProCA32 after PEGlytion. 
Since ProCA32 has highest Gd binding affinity and metal binding selectivity, it could be 
potentially used as MRI contrast agents. PEGlytion of protein could optimize the biocompatibili-
ties of protein drugs including increasing the solubility and decreasing immunogenicity. We 
previously reported that PEGlyation of ProCA1 can increase both r1 and r2 at different field 
strength, so we test whether PEGlytion of ProCA32 also increase the relaxivity.  
ProCA32 was PEGlyated using the methods described in Chapter 2. 3-5 PEG-40 was con-
jugated to ProCA32 through lysine residues. The PEGlyted ProCA32 is called ProCA32-P40 (or 
ProCA32M). The r1 and r2 of ProCA32-P40 were measured at 1.4 T 37 ˚C using similar methods 
for ProCA32. Gd3+ concentration of the each testing condition were fixed at 100 µM. We then 
measured T1 and T2 of water in the presence of 100 µM of Gd
3+ and different concentration of 
ProCA32-P40. As shown from Fig. 4-16, the T1 and T2 relaxiation time of water decreased when 
titrating ProCA32-P40. However, when Gd3+ is saturated by ProCA32-P40 ([ProCA32-P40] = 50 
µM), continuing titrating ProCA32-P40 increase the relaxation time. The r1 and r2 relaxivity first 
increase, then when ProCA32-P40 concentration is larger than 50 µM, the r1 and r2 decrease 
when adding ProCA32-P40. As shown from Fig. 4-16, ProCA32-P40 has the similar relaxivity 
comparing with the ProCA32-P40. The per Gd r1 and r2 for ProCA32-P40 is 30 and 40 mM
-1s-1 
when [Gd3+]/[ProCA] are 1 to 2 and 1 to 1. The per Gd r2 of ProCA32-P40 is 12 and 16 mM
-1s-1 
when [Gd3+]/[ProCA] are 1 to 2 and 1 to 1. 
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Figure 4-16. Effects of PEG conjugation on the relaxivity of ProCA32. 
A. r1 relaxiavity of 50 µM Gd
3+ at different concentration of ProCA32 or ProCA32-P40 in 50 mM 
HEPES 100 mM NaCl at pH 7.2 at 37   C. B. r2 relaxiavity of 50 µM Gd
3+ at different concentration 
of ProCA32 or ProCA32-P40 in 50 mM HEPES 100 mM NaCl at pH 7.2. C, D. r1 (C) and r2 (D) 
relaxivity of PEGlyated and non-PEGlyted ProCA32 with 1 or 2 Gd3+ molecular.  
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4.2.2.5 The relaxivity of ProCA32 at high magnetic field 
With the improvement of technology, MRI scanner with high magnetic field strength has 
been applied for both clinical and preclinical studies. The currently developed MRI contrast 
agents, however, are mainly focused on the application at regular magnetic field (0.5 T – 1.5 T). 
However, the relaxivity and sensivity of these contrast agents has dramatic drop at high mag-
netic field. Thus, there is an urgent need to develop MRI contrast agents with high relaxivity at 
high magnetic field (3 T – 9.4 T). According to the SMB theory, we carefully simulated the 
relaxivity of MRI contrast agents at high magnetic field using different τR and τm, and a τR of 0.5- 
2 ns is optimized for the high relaxivity of MRI contrast agents at high magnetic field (3 T – 9.4 
T). We next compared the relaxivity of ProCA32 and Gd-DTPA at 7 T MRI. We prepared a set of 
phantom containing different concentration of Gd-DTPA or ProCA3 varianrs. The T1 relaxiation 
time were measured by inversion recovery sequences with different inversion time. Then, the 
relaxivity were calculated based on different relaxiation time in certain concentrations.  The 
relaxivity ProCA32 is around 18 mM-1s-1 (Fig. 4-17), which reach the theorical maxium value of 
relaxivity at high magnetic field. Due to unoptimized τR and τm, the relaxivity of Gd-DTPA is only 
around 4 mM-1s-1. Thus, ProCA32 is promising to be applied as a sensitive MRI contrast agent at 
high magnetic field. 
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Figure 4-17. Relaxiation time differences between GdDTPA and ProCA32 at different concen-
tration in the 7 T MRI scanner. 
Inverstion recovery with different inversion time were used to calculate the relaxation time of 
water containing different concentration of Gd-DTPA or ProCa32. Then, the relaxivities of 
ProCA32 and Gd-DPTA were calculated by fitting the linear equation using 1/T1 as y-axis and 
Gd3+ concentration as x-axis. 
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4.2.3 Water number study of ProCA3 
The relaxivity of contrast agents is influenced by water number, the number of water 
molecular interact with Gd3+ at the same time. The water number measurement also reveals 
the special arrangement of the Gd3+ binding ligands. To test our hypothesis that the relaxivity 
and metal binding affinity of ProCA3 variants can be tuned by changing water number, the wa-
ter number of ProCA3 is measured by the Tb3+ luminescence life time experiments.172, 173 As 
shown in Fig. 4-18, the fluorescence decay of the Tb3+ is caused by the radiative decay (Г) and 
non-radiative decay (K). Non-raditive decay contains many factors, such as molecular collation, 
quenching, energy transfer. H2O is one of the major factors which causes the non-radiative de-
cay of the Tb3+ fluorescence, whereas D2O does not cause non-radiative decay of Tb
3+ fluores-
cence. Therefore, the difference of the decay rates of Tb3+ in the presence of H2O and D2O 
(ΔKobs) reflects the number of water molecular interact with Tb
3+-ProCA3. 
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Figure 4-18. The mechanism of water number determination by luminescence life time exper-
iments. 
The fluorescence decay of the Tb3+ is caused by the radiative decay (Г) and non-radiative decay 
(K). Non-raditive decay contains many factors, such as molecular collation, quenching, energy 
transfer. H2O is one of the major factors which cause the non-radiative decay of the Tb
3+ fluo-
rescence, whereas D2O does not cause non-radiative decay of Tb
3+ fluorescence.172, 173 There-
fore, the difference of the decay rates of Tb3+ in the presence of H2O and D2O (ΔKobs) reflects 
the number of water molecular interact with Tb3+-ProCA3. 
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To determine the exact number of water number of ProCA3 variants, we use organic 
chelators (NTA, EDTA, DTPA) and Tb3+ in aqueous solution to make a standard curve. The num-
ber of NTA, EDTA, DTPA and Tb3+ and aqueous solution were reported in literature, where the 
water numbers of these chelators were determined by X-ray diffraction. 172, 173   
To determine the standard curve, Tb-DTPA, Tb-EDTA, Tb-NTA and free Tb3+ are prepared 
in H2O and D2O solution. Tb
3+ fluorescence were excited at 280 nm and the fluorescence decays 
were measured at 545 nm. The fluorescence decay was fitted by single exponential decay Equa-
tion. The decay rate (Kobs) and life time (τ) of Tb3+ in H2O and D2O were calculated by this fit-
ting (Fig. 4-19). We then draw the standard curve based on the reported water number of these 
chelators and difference of Kobs in H2O and D2O (ΔKobs). 
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Figure 4-19. The luminescence decay of Tb3+ in H2O or D2O in aqueous solution or chaleted by 
DTPA, EDTA or NTA. 
Tb3+ and chelators were mixed with 1 to 1 ratio. The final concentration for Tb3+-chelators were 
20 µM in H2O or D2O at pH 7.0. The experiments were performed at PTI fluorometer in H2O or 
D2O in aqueous solution without any salt.  
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Figure 4-20 The luminescence decay of Tb3+ in H2O or D2O chaleted by ProCA32 (left) or 
ProCA35 (right). 
Tb3+ and ProCA3 variants were mixed with 2 to 1 ratio. The final concentration for Tb3+-ProCA3 
variants were 20 µM in water at pH 7.0. The experiments were performed at PTI fluorometer in 
H2O or D2O in aqueous solution without any salt. To prepare ProCA3 variants in D2O.  20 µM of 
ProCA3 variants in H2O were  rst freeze at -80   C and then all the water was removed by spin 
vacuum. The protein powder was then dissolved in the same volume of D2O. This process was 
repeated three times to completely remove of H2O. 
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Figure 4-21. Water number of Tb3+ loaded ProCA3 variants. 
Tb3+ and ProCA3 variants were mixed with 2 to 1 ratio. The final concentration for Tb3+-ProCA3 
variants were 20 µM. The experiments were performed at PTI fluorometer in H2O or D2O in 
aqueous solution without any salt at pH 7.0.  
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The ΔKbos of Tb
3+ in ProCA3 variants were determined using the similar methods. Then 
the water number of the ProCA3 variants were calculated based on the standard curve and 
ΔKobs of each varients (Fig. 4-20).  WT PV has averaged water number of 1.3 (Fig. 4-21), which is 
consistent with reported value.174 Interestingly, the water number of ProCA35 increase to 1.6, 
the increase of water number in ProCA35 is consistent with the increase of relaxivity in ProCA35. 
To our surprise, the water number of ProCA32 (introducing S56D mutation) decreases from 1.3 
to 0.4 (Fig. 4-20), while the relaxivity of ProCA32 (S56DE60D) does not decrease. All these re-
sults indicate that mutation of S56D introduces more ligands from protein to interact with Gd3+, 
which increase Gd3+ binding affinity and decrease the number of water to interact with protein. 
4.2.4 In vitro serum stability study of protein based MRI contrast agents 
Since ProCA32 shows the best metal stability and good relaxivity, ProCA32 and 
PEGylated ProCA32 is promising to be applied as a novel MRI contrast agents. It is extremely 
important that the ProCA3 will not be cleaved by the enzyme in the serum and maintain intact 
structure before secreted out of the body. In order to evaluate the stability of ProCA32 and 
PEGylated ProCA32, ProCA32 and PEGylated ProCA32 were incubated in the 50% serum and 
then detected by SDS-PAGE, western blot and Mass spectrum. ProCA32 is very stable in the se-
rum for at least 3 days (Fig. 4-22). After three day, the native protein in the blood began de-
grading, but ProCA32 still existed in the blood serum even after 12 days. Immuno blot and Mass 
spectrum are also applied to detect the ProCA32 and P40CA32 serum stability. All of these data 
indicates that ProCA32 and PEGylated ProCA32 are stable in serum for at least three days.  As 
shown in Fig. 4-22, ProCA32 and PEGylated ProCA32 and stable for even up to 12 days. All these 
data indicate that ProCA32 and PEGylated ProCA32 are very stable in the serum, and PEGylated 
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ProCA32 has a half-life of 2.9 hours in the blood, most ProCA32 is excreted out one day after 
injection. Thus, it is very important that ProCA32 is stable for at least 2 days in order to the 
safely used in vivo.  
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Figure 4-22. Serum stability of ProCA32 or ProCA32-P40. 
A, B. Serum stability tests of ProCA32 by SDS-PAGE (A) or immune-blot (B). C.  Serum stability 
tests of ProCA32-P40 by immune-blot. Gd3+-ProCA32 (400 µM) was mixed with mice serum with 
1:1 ratio, and then incubated at 37 ˚C for different time point. SDS-PAGE and immunoblot were 
applied to detect the remaining Gd3+-ProCA32 after incubate in the serum for each time point. 
The protein separated by SDS-PAGE is stained by coomassie brilliant blue or immunoblot. 
CA32      Serum       0 h            2 h             4 h           6 h           8 h           24 h           2 D           4D            6 D          8 D           10 D        12 D
CA32      Serum       0 h            2 h             4 h           6 h           8 h           24 h           2 D           4D            6 D          8 D           10 D        12 D
CA32 mixed with mice serum
P40CA32 mixed with mice serum
ProCA serum   0 h       2 h          4h        8 h        1 d       2 d      3d        
A
B
C
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4.3 Discussion  
4.3.1 Developed new metal binding methods using metal-chelator buffer system allow us to 
acuately measure strong metal binding affinity. 
EF-hand I in wild type PV has four carboxyl ligands (D52, D54, E60 and E63) and one 
noncharged oxygen liagnd (S56) to interact with Ca2+. X-ray structure (Fig. 3-1) and other tech-
nique showed that position 9 in EF-hand I (E60) of PV directly use side chain carboxyl group as 
oxygen ligand to interact with Ca2+, however, most other EF-hand proteins use water as oxygen 
ligand to interact with Ca2+. Mutation S56D introduces additional one more negative charge to 
form pentacarboxylate structure. Since charge is one of the key determinants for the metal 
binding affinity, we further studied the effects of pentacarboxylate EF-hand on Gd3+ binding af-
finity. Fluorescence competition methods and metal buffer system methods are applied to de-
termine the dissociation constant between Gd3+ and ProCA3 (Fig. 3-2). Interestingly, introducing 
one negative charge dramatically increases Tb3+ and Gd3+ binding affinity for more than 106 
folds, which indicates the desired Gd3+ binding pocket in protein are formed by introducing 
more negative charged residues in EF hand I. We further modified the Gd3+ binding sites by 
E60D mutation in both WT and S56D mutants. X-ray structure of Ca2+ indicates that E60D intro-
duced one water ligand to interact with Ca2+, while carboxyl side chain in this position moved 
away. By this way, number of carboxyl groups for metal binding in EF-hand I decreased. PVE60D 
does not show dramatic metal binding affinity change compared to wild type, while 
PVS56DE60D showed the increase of Ca2+ binding affinity and dramatically decreased Gd3+ and 
Tb3+ binding affinity compared with PV S56D and WT. EF-hand II of PV WT are formed by the 
four carboxyl group (D91, D93, D95, E102) and one water ligand (G99) to bind Ca2+.  G99D and 
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G99E mutants are generated to study the charge effects on the metal selectivity of EF-hand II. 
We hypothesize that G99E directly interacts with metals, while G99D, like WT, utilizes one addi-
tional water ligand instead of carboxyl group. EF-hand II of G99E is very similar to S56D in EF-
hand I. Interestingly, since EF-hand II of G99D is very similar to the EF-hand I of S56DE60D, the 
binding affinity of G99D is very similar to that of mutants. Zn2+ binding affinity of PV variants are 
measured by Fluozin-1 competition methods. PV-based MRI contrast agents shows excellent 
metal selectivity between Gd3+ and Zn2+ with log(pGd/pZn)= 10.5 for ProCA32. All these data 
indicates that pentacarboxylate structure in EF-hand is strongly favorable to bind to Gd3+ and 
Tb3+ over Ca2+ and Zn2+. Interestingly, ProCA32 has a much higher metal selectivity than DTPA 
and ProCA1, which is essential for the in vivo application because Zn2+ is considered as one the 
the major metal ion to compete Gd3+ out of chelators. 
Tb3+ luminescent life time decay in H2O and D2O solvents is measured to characterize 
the water number of the inner sphere of metal binding sites. WT PV has averaged water num-
ber of 1.3, which is consistent with reported value. Interestingly, the water number of ProCA35 
increases to 1.6, the increase of water number in ProCA35 is consistent with the increase of 
relaxivity in ProCA35. To our surprise, the water number of ProCA32 decreases from 1.2 to 0.4, 
while the relaxivity of ProCA35 does not decrease. All these results indicate that the mutation 
of S56D introduce more ligands from protein to interact with Gd3+, which increase Gd3+ binding 
affinity and decrease the number of water to interact with protein. The per Gd3+ and per parti-
cle relaxivity of ProCA32 with improved metal binding affinity  and decreaed water number do 
not decrease compared with ProCA30 is very interestingThese results suggest ind that different 
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from first coordination shell, secondary hydration shell or /and reduction of local motion by im-
proved metal binding affinity may be further contribute to the increase of relaxivity. 
4.3.2 Tune the relaxivity of ProCA3 variants by protein design. 
We are able to tune the relaxivity of ProCA3 variants through protein design. Positions 1, 
3 5, 7, 9 and 12 in EF-hand are the key residues for metal binding. Among them, positions 1, 3, 5 
and 12 usually use side chain oxygen as metal ligand. Position 9 of EF-hand always bridges with 
one water molecular. Glutamate 60 is located in the position 9 in the EF-hand I of PV. 
Interestingly, X-ray structures of PV shows that Glutamate acid 60 directly interact with metals 
without water bridge, we hypothesis that mutation of E60D will introduce water ligand to 
position 9. Consistent with our hypothesis, the water number of S56DE60D increase to 1.8, 
while the WT PV only has a water number of 1.3. Interestingly, the relaxivity of ProCA35 
(S56DE60DF103W) dramatically increase to 57 and 77 mM-1s-1, which is increase about 100% 
comparing the ProCA30 (wild type PV) , ProCA31 (PV with F103W mutations) and ProCA32 (PV 
with S56D F103W mutations). This is the first time that we can increase the realxivity by directly 
control the the ligand coordination of ProCA3. Interestingly, r1 and r2 of ProCA33 increased 
about 50%, the increase of the relaxivity could also be caused by the introducing water ligand in 
the position 9.  
Position 9 of EF-hand II in PV is occupied by a water ligand. Interesting, mutations in 
G99D in EF-hand II decrease the water number. These results indicate that aspartic acid in EF-
hand II decrease the water binding in position 9. However, the relaxivity of this mutant is the 
same as WT PV, suggesting that second shell of coordination water plays important roles on the 
relaxivity. 
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4.3.3 The advantage of ProCA3 for MR imaging due to high relaxivity.  
The MRI signals are generated based on the different relaxation properties of protons. 
However, such differences are very small among organs in vivo. As we can imagine, changing 
the water relaxation properties is not a trivial task, since water has a concentration of 18 M, 
and the relaxivity different of organs could be very similar. Because of this reason, the contrast 
agent and sensitivity of MRI is much lower than other imaging modalities, such as PET/SPECT. 
The contrast and sensitivity of MRI can be improved by administrate the contrast agents. MRI 
contrast agent works as “catalyst” to catalyze the relaxation properties each water molecule. By 
differential distribution in vivo, MRI contrast agents made the relaxation properties difference 
in each organ. 
In order generate considerable contrast in vivo, the relaxation time of water should be 
decrease to 100 ms. For clinical MRI contrast agents, such as Gd-DTPA has a relaxivity less than 
5 mM-1 s-1, the effective concentration of Gd-DTPA should be as high as 100 µM in order see the 
clear differences between each tissue.10 The lowest concentration of clinical MRI contrast 
agents is 30 µM in order to clearly show the difference. In order generate such high Gd3+ con-
centration in vivo, the clinical contrast agents is recommended to injection 0.1-0.2 mmol/kg 
body weight.10 
The application of MRI for molecular imaging is jeopardized by the detection limits of 
MRI contrast agents, since the disease biomarker usually has very low concentration. The bi-
omarker expression level is usually less than 106 biomaker/cell.  Assuming a cell has a volume of 
1000 µm3, the local concentration of this biomarker is only 1 nM.136 Such low expression of bi-
omarker made molecular imaging very hard for MRI.  It would still be very hard even if consid-
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ering the effects of endocytosis. Sherry simulated the relationship between relaxivity and de-
tection limits. The detection limits for clinical MRI contrast agents is more than 10 µM with r1 
relaxivity of less than 5 mM-1 s-1. The detection limits of contrast agents are pushed to about 1 
µM, when the relaxivity of the contrast agent is about 20 mM-1 s-1. When the relaxivity of the 
contrast agent is higher than 100 mM-1 s-1, the detection limits of MRI contrast agents is further 
pushed to less than 1 µM.45  
Improving the relaxivity of the contrast agents has two advantages. First, increase the 
relaxivity of the contrast agents can decrease injection dosage required, which could potentially 
decrease the Gd3+ accumulation in vivo. Second, improve the relaxivity can potentially improve 
the detection limits for MRI contrast agent, which greatly benefits the molecular imaging using 
MRI. 
As shown from Fig. 1-1, the relaxivity of the contrast agents can be influenced by many 
factors. Water molecular directly interacts with metal ion such as Gd3+ to change the relaxiation 
properties. Based on the distant between water molecule and Gd3+, the relaxivity can be further 
divided into inner sphere relaxivity, second sphere relaxivity and outer sphere relaxivity. The 
overall relaxivity of the contrast agents is the combination of inner sphere, secondary sphere 
and outer sphere relaxivity. The inner sphere and second sphere relaxivity can be characterized 
by SMB equation.10   The outer sphere relaxivity of the contrast agents can be characterized by 
hard-sphere model, when the water is considered as passive diffusion.10  In general, relaxivity of 
the contrast agents are influenced by τR, τm and q. For example, the bioresponsive contrast 
agents were designed based on the changes of these parameters at different physiological con-
ditions.10  
158 
To develop a MRI contrast agent with high sensitivity, high relaxivity is highly desired. 
ProCA3 has more than 10 times higher relaxivity than commercial contrast agents at clinical 
MRI field (1.4 T), which provides a more sensitive tool for the MR imaging for clinical and pre-
clinical diagnostics. Furthermore, due to careful design, the ΤR of the ProCA3 was optimized for 
the use in the high magnetic field. The r1 relaxivity of ProCA3 is 18 mM
-1s-1 at 7 T, which is up to 
the theoretical relaxivity value of Gd3+ based MRI contrast agents. The relaxivity of ProCA3 
decrease at high temperature, which indicates that ProCA32 also has optimized fast water 
exchange. Only 2.5 μM of ProCA3 in the test tube can be detected, which is much lower dosage 
than that of Gd-DTPA. High relaxivity of ProCA3 at both clinical and high magnetic field will have 
two advantages. First, increased relaxivity improves the detection of MRI which will benefit the 
molecular imaging using MRI, since biomarkers always shows limited expression levels and only 
can be detected by very sensitive probes. Second, increased relaxivity of ProCA3 can effectively 
reduce the injection dosage, which could decrease the metal release caused toxicity. 
4.4 Summary 
First, we have developed a novel method to determine metal binding affinity and selec-
tivity using metal-buffer sytem and Tb-LET of proteins with stronger metal binding affinity and 
selectivity constants that can not be accurately determined by current avalibale methods. Cur-
rently there is no valaible assay allows to determine high metal stability strongly required in the 
clinical diagnostics for the MRI contrast agents. This developed method can be used for deter-
mining metal binding affinities and selectivity for other metalloproteins or macromolecules.  
Second, we have determined all the metal binding affinity and selectivity of designed 
ProCA3 variants. We have shown that ProCA32 with mutation S55D on the metal binding sites 
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has extremely high Gd3+ binding affinity (Kd = 2.8 ± 0.3 × 10-22 M) that is improved than ProCA1 
and is similar to clinical approved contrast agents DTPA etc.  More important, ProCA32 has 
metal selectivities for Gd over physiological metal ions such as Zn2+, Mg2+ and Ca2+are more 
than 1011, 500, 150 fold greater than DTPA.  Pegylation of ProCA32 does not change metal sta-
bility. Serum stability studies also further support that ProCA32 and ProCA32-P40 is stable in 
blood and resistant to the enzyme cleavage, which provide another solid support for the clinical 
application of ProCAs with high safety.  
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5 PROCA3 ENHANCED MRI OF MUTIPLE TISSUE ORGANS AND TUMOR METASTASIS 
5.1 Introduction  
 A contrast agent with high relaxivity is essential for improving the detection limits of the 
MRI contrast agents. Dr. Sherry and his colleagues45 found that a contrast agents with an r1 = 5 
mM-1s-1 has a lowest detection limits above 20 µM, and the detection limit improved to 680 nM, 
when the relaxivity increase to above 100 mM-1s-1.  
Improvement of the detection limits of the MRI contrast agents could be essential for 
MRI. It dramatically reduces injection dosage and decreases the toxicity of the MRI contrast 
agents. It also improves the sensitivity of the MRI contrast agents for the molecular imaging. 
Since the biomarkers usually have low expression level in the range of nM or pM, imaging bi-
omarker using MRI is largely hampered by the lack of MRI contrast agents with high relaxivity, 
low detection limits and targeting specificity. 
Due to the selective tissue distribution, MRI contrast agents are applied for the imaging 
of kidney, CNS, liver and blood. Clinical MRI contrast agents are also applied to evaluate lesions, 
infrared, stroke and tumor due to its unique distribution in these tissues in vivo compared to 
the normal tissue. However, due to the lower detection limits, non-specific distribution, and not 
optimized pharmacokinetics, the clinical MRI contrast agents are not optimized for imaging the-
se tissues. Dynamic contrast enhanced-MRI (DCE-MRI) is a usefully methods to evaluate tumor 
vasculature.  The reliability and stability of this technique, however, is affected by the inaccu-
rate measurement of the real-time concentration of the contrast agents in serum due to the 
short blood retention time and low relaxivity of contrast agents.  
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As discussed in chapter 1, MR imaging of tumor metastases has great advantage than 
other imaging techniques. For example, MR imaging of liver provides more sensitivity and relia-
bility than other imaging techniques.14, 193-196 In principle, MRI can also non-invasively evaluate 
tumor properties, such as size, oxygen level, water diffusion, and blood vasculature. Gadolinium 
compounds are the most frequently used MRI contrast agents due to high paramagnetic prop-
erty and asymmetric electronic ground state of Gd3+, rendering the ability to create bright MR 
images by decreasing T1 without causing substantial line broadening. However, clinical MRI con-
trast agents, such as Gd-DTPA, have relaxivities less than 5 mM-1 s-1 which require high injection 
doses of 0.025-0.2 mmol/kg of clinical MRI contrast agents to generate a detectable contrast 
with a local Gd3+ concentration of about 100 μM. This is significantly lower than theoretical val-
ue around 100 mM-1s-1 for one water molecule coordinated in the Gd3+ inner shell.197 They suf-
fer a risk of Nephrogenic Systemic Fibrosis (NSF) due to metal toxicity for patients with renal 
dysfunctions.22 There are additional challenges for developing contrast agents for liver imaging 
due to its fast circulation.  Gd-EOB-DTPA (Evoist US; Primovist, Europe, Bayer) and Gd-BOPTA 
(Multihance, Bracco) with 50% and 5% hepatocyte up take, respectively, are the most common-
ly used clinically approved liver contrast agents.  In addition to similar per Gd relaxivity (r1) val-
ues around 4-6 mM-1s-1, their very short retention time in the liver (1 min for Multihance and 30 
min for Eovist) largely restrains a narrow time widow to achieve high quality MR imaging and 
limited time for MRI-guided liver  intervention and local treatment. On the other hand, iron ox-
ide nanoparticle contrast agents such as Ferumoxides are taken up by functioning Kupffer’s 
cells creating T2 /T2* effects on the normal liver, however it is less applicable due to imaging 
artifacts. Increasing relaxivity of small metal chelators by increasing exchangeable water num-
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ber q in the Gd coordination shell often resulting the tradeoff metal stability.  Increasing corre-
lation time τc by conjugating to the polymer or macromolecules do not yield expected increase 
of relaxivity. Therefore, there is an urgent need to develop contrast agents with significantly 
improved relaxivity and metal stability, pharmacokinetics to enable the detection capability of 
smaller size tumor extending to less than 1 cm with good confidence. 
 Challenges in developing contrast agents with high relaxivity in in vivo imaging capabil-
ity of liver metastasis are due to several criteria:  1). An ideal MRI contrast agents should have 
high relaxivity 2). An ideal MRI contrast agents should have high distribution in liver. 3). An ideal 
MRI contrast agents should have permeability to the liver tissue but low permeability to the 
metastatic tumor tissue. These features can improve ratio of MRI liver signal intensity to tumor 
signal intensity. 4). An ideal MRI contrast agents should be able to alter the signal from both T1- 
and T2- weighted MR images, so that detected tumor under T1 weight MRI can be further vali-
dated by T2- weight MRI. If the tumor too is small, T2-weighted MRI without contrast agent is 
not able to show the tumor enhancement, a MRI contrast agent with good r2 is able to decrease 
the liver signal which can improve the tumor detection using T2 weighted MRI sequences. 5). An 
ideal MRI contrast agents should have stability and strong metal selectivity to avoid Gd3+ re-
lease. 6). An ideal MRI contrast agents should have good pharmacokinetics. 7) An ideal MRI 
contrast agents should have no toxicity. 
Our previous work shows that the protein-based MRI contrast agents has more than 10 
times higher r1 and r2 relaxivities, optimized blood circulation, good solubility and bio-
compatibilities. Protein-based MRI contrast agents were also fused with targeting moieties, 
such as HER-2 affibody or GRP peptide, for in vivo MRI of biomarkers by target tumor bi-
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omarkers with high specificities and high affinity. However, such study is only limited to T1-
weighed MRI. In addition, these contrast agents only embrace one Gd3+ binding sites and the 
purification methods for ProCA need to be further improved. In my Ph. D. study, I developed a 
new class of MRI contrast agents with multiple Gd3+ binding sites, extremely high affinity, opti-
mized blood and liver retention time for in vivo MRI of multiple organs. I also optimized the ex-
pression purification and GMP-like procedures for ProCA production. In addition, the 
paharmacokinetics of different protein-based MRI contrast agetns were carefully studied. Be-
cause ProCAs has both high r1 and r2 relaxivity, we further applied the T2/T1 ratiometric imaging 
and bi-briliant imaging for the MRI of primary and metastatic tumors in the liver with high 
confidency. These works are of great vaule for the clinical diagnosis of disease by MRI with im-
proved MRI contrast agents and impoved methodology.   
 Our work discussed in Chapter 4 has shown that ProCA3 variants have 10 fold higher r1 
relaxivity than that of clinical contrast agents at 1.47 T. More strikingly, due to the optimization 
of τR, τm, ProCA3 reached the maximum value of r1 at high magnetic field, such as 7 T. As shown 
in Fig. 5-1, since ProCA32 variants has high relaxivitiy with r1 = 30 mM
-1s-1 at 1.4 T and r1 = 19 
mM-1s-1 at 7 T, it should has much lower detection limits for MRI imaging than clinical MRI con-
trast agents. These unique features made ProCA3 as one of the most suitable candidates as 
sensitive MRI contrast agents not only for clinical application but also good for the preclinical 
application at high magnetic field.  
In this chapter, we will first explore the lowest detection limits of ProCA32 under MRI. 
Then, we will report mice imaging of ProCA32 of multiple organs, such as kidney, liver, blood 
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vessel imaging. At last, we will report our progress of imaging liver metastases of unveal mela-
noma using ProCA32 with bi-briliant dual weighted MRI methodology.    
 
5.2 Results 
5.2.1 In vitro detection limit of ProCA3 
Less contrast agents are acquired to acquired good image enhancement when the 
relaxivity of the contrast agent improved. Since our contrast agents show about 10 times higher 
relaxivity at 1.4 T and more than 4 times higher relaxivity at 7 T compared with that of Gd-DTPA, 
we further studied the detection limits in vitro and in vivo. To test the in vitro detection limits, 
ProCA3 with different concentrations were scanned using T1-weighted spin echo sequence (spin 
echo sequence with TR = 500 ms, TE = minimium, thickness = 1 mm) at 7 T. As shown from Fig. 
5-1, 2.5 µM of ProCA3 showed much higher signal intensity compared with buffer only. This re-
sult indicates the detection limits for ProCA3 is at least 2.5 µM, which is more than 10 times 
sensitive than that of clinical MRI contrast agents.  
5.2.2 In vivo detection limits of ProCA3 
We further tested the in vivo detection limits for the detection of kidney, liver and blood 
enhancement by injection of a series concentration of ProCA3 in different mice. To optimize the 
best conditions for MRI data collections, The MRI images of kidney were collected at different 
repetition time (TR) from 300 ms to 700 ms. 400 ms to 600 ms TR shows the best enhancement 
of the ProCA3 in kidney. Then, the MR images of kidney were collected by varian 7 T MRI scan-
ner using spin echo sequence with TR = 500 ms. The mice without injection of ProCA3 or other 
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contrast agents were used as control. Different concentrations of ProCA3 were injected in mice 
through tail vein, and then kidney MR images were collected 10 min post injection of the con-
trast agents. Clear kidney enhancement were obtained with a injection dosage of 0.8 µmol/kg 
ProCA32M, a concentration more than 100 times lower than the clinical injection of Gd-DTPA. 
As a comparison, 1.6 µmol/kg Gd-DTPA was injection in a separate mice, which has the same 
Gd3+ concentration as 0.8 µmol/kg of ProCA32M. Interestingly, 1.6 µmol/kg Gd-DTPA do not 
show any significant kidney enhancement under MRI. These results indicate that ProCA32 has 
much lower detection limits than Gd-DTPA in vivo.  
To determine the lowest injection dosage of ProCA3 for liver and blood, 0.8 - 33 
µmol/kg of ProCA3M were injected into CD1 mice (25 – 30 g) through tail vein. The blood and 
liver images were collected at 20 min post injection of ProCA3M using 3D-gradient echo se-
quence (TR = 40 ms, TE = 2.9 ms, slice thickness = 1 mm). 3D MRI of liver shows that the liver is 
heterogeneously enhanced with the injection of 1.6 µmol/kg of ProCA3M. Thus, using the injec-
tion dosage of 1.6 µmol/kg of ProCA3M, we are able to detect liver enhancement. 
Although 1.6 µmol/kg of ProCA3M is able to enhance the liver, such injection dosage 
can not enhance the blood vessel. 3D MRI of liver shows that the lowest injection dosage to 
enhance the blood vessel is 33 µmol/kg of ProCA3M. However, the MRI signal in blood is highly 
dependent on the time point after injection, and we could see the blood vessel signal changes 
with lower injection dosage at earlier time point. 
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Figure 5-1. The relaxivity, detection limits of ProCA32 in vitro and in vivo. 
A. In vitro study of MRI in the phantom of ProCA32 in different concentration. B. Relaxiation 
time differences between GdDTPA and ProCA32 at different concentration in the 7 T MR scan-
ner. C. In vivo MRI of the mice kidney before and after injection of 0.8 µmol/kg ProCA32. D. 
percentage of signal increase in mice kidney after injection of 0.8, or 16 µmol/kg ProCA32 or 1.6 
µmol/kg  Gd-DTPA. The MRI images were processed by MRIcro. The MRI signal intensity of kid-
ney were measured from at least three slides. The error bar refers to the standard deviation of 
MRI intensity increase measured from at least three slides. 
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5.2.3 MR angiography (MRA) before and after injection of ProCA32M  
To investigate ProCA32 on MR imaging for different organ, 3D MR images were acquired 
at pre injection, 50 min, 2 hr, 25 hr and 49 hr post injection of 33 µmol/kg of ProCA32M using 
3D gradient echo sequence (TR = 40 ms, TE = 2.9 ms, slice thickness 1mm, matrix 256 × 256 × 64, 
Fov 8 cm × 4 cm × 6.4 cm). ProCA32M shows excellent enhancement of blood vessel even at 50 
min post injection (Fig. 5-2 at 4.7 T). Interestingly, ProCA32M is able to enhance the blood ves-
sel with a diameter less than 1 mm. No blood vessel was enhanced before injection of 
ProCA32M, and the blood vessel is immediately enhanced at the first time point of data collec-
tion. The blood vessel enhancement dramatically decreased 2 hr post injection of the ProCA 
and the blood vessel intensity returned to the original stage when the data were collected 1 
day and 2 day post injection. We then analyzed the Gd3+ distribution and ProCA32M protein 
distribution by ICP-OES and immune blot respectively (Please see chapter 7 for details). These 
results indicate that ProCA32M is a good contrast agent for MRA, and ProCA32M can be poten-
tially used as a powerful diagnostic tool for the blood vessel disease. 
5.2.4 MR imaging of kidney, bladder and liver before and after injection of ProCA32M using 
T1-weighted 3D gradient echo sequence 
Using the same procedures as 3D gradient echo (3DGE) sequence image of blood vessel, 
the kidney of the mice was enhanced after injection of ProCA32M. However, the enhancement 
of the kidney is much slower than that of the blood vessel (Fig. 5-2). The highest enhancement 
for kidney was observed at 1 day post injection of ProCA32M. The signal of kidney returned to 
the original state 2 days post injection of contrast agents. 3DGE image shows great enhance-
ment of bladder at 50 min post injection of ProCA, which indicate ProCA32M started excretion 
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through kidney. Liver also got enhancement after injection of the ProCA32M. The liver is imme-
diately enhanced after injection of ProCA32M and the signal return to the original state 2 day 
after injection of ProCA32M. These results indicated that ProCA32M has great potential for the 
imaging of liver and kidney disease, such as liver metastasis and renal malfunction. 
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Figure 5-2. Maxmium intensity projection images of three dementional MRI before (Pre) and 
after injection of ProCA32M for different length of time (44 min, 3 h, and 25 h).  
MRI were colletected at 4.7 T MRI scanner before and after injection of ProCA32M (0.02 
mmol/kg) with 3D gradient echo echo sequence with TR = 40 ms and TE = 2.9 ms. 
 
  
Pre                   44 min                   3 h                     25 h
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5.2.5 Imaging normal mice liver using T1-weighted or T2-weighted sequences 
Since r2 of ProCA32 is 40 mmol
-1 s-1, ProCA3 could also be applied for the T2-weighted 
MRI image. Fig. 5-3 shows that the liver of the mice became darker two hours after injection 
imaged by T2-weighted sequence at 3 T clinical scanners. Interestingly, the liver of the same 
mice shows enhancement using T1-weighted sequence at 3 T clinical scanners. These results 
indicate that ProCA32M can be as both T1-weighted MRI contrast agents and T2-weighted MRI 
contrast agents. 
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Figure 5-3. T1 or T2 weighted MRI with and without ProCA32M injection. 
Images of dead mice were collected at 3 T clinical MR scanner with ProCA32 M (0.02 mmol/kg) 
injection for 2 hours or without ProCA32M injection. T1-weighted MRI shows signal enhance-
ment in the mice liver (left) and T2-weighted MRI shows signal decrease in the mice liver (right). 
Data collected from University of Alabama at Birminham with the help from Drs. Kim and Zhai. 
MRI of mice post CA3 injection at 3T
T1W MRI of liver (axial view) T2W MRI of liver (axial view)
Liver 
(control)
Liver 
(PROCA)
Liver 
(control)
Liver 
(PROCA)
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Figure 5-4. T2 mapping of mice liver with and without injection of ProCA32M. 
T2-weighted MEMS image the mice liver with different TE. B. Liver intensity of mice with and 
without injection of ProCa32M at 15, 30, 45 or 60 ms of TE. C. Blood intensity of mice with and 
without injection of ProCa32M at 15, 30, 45 or 60 ms of TE. 
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Similarly, T2-weighted MRI images of mice liver were collected at 7 T Varian MRI scanner. 
The mice were scanned after injection of 0.02 mmol/kg ProCA32 or saline for 30 min. T2-
weighted MEMS sequence (Multi-echo-multi-slides sequence) with different echo time (TE) 
were applied to acquire MRI images of liver. As shown from Fig. 5-4, the liver the mice became 
darker after injection of ProCA32M. The biggest differences of the liver between ProCA32M in-
jected mice and saline injected mice were obtained using MEMS with TE=15 or 30 ms. We also 
compared the blood vessel signal differences in T2-weighted MR images. The optimized TE to 
see the differences of blood vessel in ProCA32M injected mice and saline injected mice are 45 
and 60 ms. In summary, ProCA32M is able to decrease the signal of liver after injection of 
ProCA32M in both 3 T clinical scanner and 7 T preclinical scanner. Thus, ProCA32M can also be 
used as T2-weighted MRI contrast agents due to high r2 relaxivity. 
5.2.6 Imaging liver metastasis using ProCA 
Liver is one the major organ for the tumor metastasis, such as melanoma, breast cancer 
and pancreatic cancer. Our preliminary data shows that ProCA32M is able to accumulate liver 
and imaging liver with high intensity, high efficiency and low injection dosage. We next evaluate 
if ProCA32M can detect tumor metastasis in liver. The mice melanoma cells were implanted in 
the eye of the PEDF knockout mice. The tumor implanted mice were continuously grown for 
two weeks. We then imaged the mice liver under MRI with T2-weighted fast spin echo and T1-
weighted spin echo sequence. The mice were imaged before and injection of the contrast 
agents. Liver metastasis of melanoma cannot be detected without injection of the contrast 
agents. We clearly see more than 10 liver metastasis in liver after injection of ProCA32 with hy-
po-intensity of tumor in T1-weighted spin echo (Fig. 5-5 B, E) and hyper-intensity of tumor in T2-
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weighted fast spin echo sequence (Fig. 5-5 A, D). Interestingly, the MR imaging of liver metasta-
sis correlates well with HE staining (Fig. 5-5 C, H), where the tumor in dark blue/purple color 
and normal liver is pink color. The location of the tumor under MRI were further confirmed by 
IHC staining of S100 (Fig. 5-5 I), which is a typical biomarker for melanoma. To further explore 
the mechanism of hypo-intensity of tumor under MRI, the optical (Fig. 5-5 J) and fluorescent 
(Fig. 5-5 K) images of mice liver with melanoma metastasis were taken by fluorescent dissecting 
microscope 30 min post I.V. injection of fluorescein-labeled ProCA32M. The liver tissue showed 
enhanced green fluorescence, while melanoma matastasis doesn’t show any fluorescence. The-
se results indicate that after injection for 30 min, ProCA32M is accumulated in liver tissue, while 
due to lack of blood vessel, no ProCA32M can be penetrated in to the melanoma. Moreover, 
we are able to clearly detect liver metastasis with a size less than 0.25 mm, while most of cur-
rent MRI test can only detect tumor with a size more than 10 mm with high accuracy. Thus, 
ProCA32M shows the great advantages for the imaging tumor metastasis in liver. Thus, 
ProCA32M show great potential for the early diagnostics of liver metastasis. Early diagnosis of 
liver metastases is essential for the effective drug treatment of tumor. 
We further compared the MRI liver ehance of Evoist and ProCA32 in mice under the T1-
weighted spin echo sequence (Fig. 5-6). With the injection of same concentration of Eovist or 
ProCA32, ProCA32 has significant high liver enhancement at 10 min and 50 min post injection of 
the contrast agents. The intensity for Eovist decreases very fast. As show from Fig 6-6B, more 
than 50% liver signal decrease after injection of Evoist 50 min. ProCA32, however, shows much 
stable liver enhancement. There are no significant signal entensity differences after injection 
for 10 min and 50 min. ProCA32 is also able to be applied for T2-weighted MRI with improved 
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tumor detection. Taken together, ProCA32 show great potential as a promising MRI contrast 
agents for the imaging of liver and liver metastasis with a size more than 10 times less than that 
of clinica MRI contrast agents in the clinical tumor diagnostics.  
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Figure 5-5. MR imaging of melanoma metastasis to liver with a size less than 2 mm after injec-
tion of ProCA32M. 
A, D. T2-weighted fast spin echo sequence after injection of  ProCA32M with hyper-intensity of 
tumor metastasis. B, D, T1-weighted spin echo sequence after injection ProCA32M  with hypo-
intensity of  liver metastasis. A and C are the same position of mice liver imaged by two differ-
ence MRI sequences. B and D are the same position of mice liver imaged by two difference MRI 
sequences. Tumor metastasis were indicated by red cycle (A, B) or green arrows (D, E). C and H. 
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HE staining of liver with melanoma metastasis. Melanoma metastasis shows dark blue color/ 
purple colorF. primary melanoma implanted in the eye of eye mice. G. The mice with melanoma 
metastasis to the liver, one the of tumor can be visualized on the liver surface (green arrow). H. 
is the enlarged picture of HE staining of liver. Image was collected with 40x magnification. I. 
Immunohistochemistry staining of S100A in the liver metastases. S100A (dark brown color) is a 
biomarker for melanoma. Positive staining of S100A indicate that this liver tumor is metastasis 
from uveal melanoma. J. Dissecting microscope imaging of liver with melanoma metastasis. 
Melanoma metastases is indicated by red arrow. K. Fluorescence imaging of liver with melano-
ma metastasis (same position as J). The mice were euthanized 30 min post injection of  
fluorecein-ProCA32M. Fluorescence imaging was taken with excitation at 488 nm with 
fluorecein filter. ProCA32M is distributed in the liver tissue, while no ProCA32M is distributed in 
tumor due to the low permeability of melanoma to ProCA32M. These results confirm that hy-
po-intensity of tumor and hyper-intensity of liver under T1-weighted MRI post injection of 
ProCA32M for about 30 min. 
 
 
  
178 
 
Figure 5-6. Comparision of the liver enhancement of MRI before and after injection of ProCA3 
or Evoist. 
MRI images at 4.7 T (left) show that ProCA32 has much higher liver enhancement than that of 
Eovist at both 10-17 min and 48-50 min. ProCA32 has siginificant higher MRI signal intensity 
than that of Evoist (right) and liver enhanment is much stable than Evoist. At 48-50 min Evoist 
has more 50 % drop of the enhanced MRI signal intensity, while ProCA3 has no MRI signal de-
crease compared with 10-17 min post injection.  
A B
179 
5.2.7 T2/T1 Ratiometric imaging for the early diagnosis of metastatic tumors in the liver 
One of the major chellagenes of MRI is lack of contrast between tissues and interested 
lesions with desired dynamic range and signal to noise ratio. In addition, soft tissues such as 
liver and heart are largely suffered from motion artifact. As shown in Fig.4-15, since ProCAs has 
both about 10 times higher r1 and r2 relaxivities than that of clinical MRI contrast agents, 
ProCAs could be potentially used as either T1-weighted MRI contrast agents or T2-weighted MRI 
sequence based on the different settings of TR and TE. In the section 5.2.5 and 5.2.6 of this 
chapter, we demonstrate that ProCA3 variants can be used as T1-weighted MRI and T2-
weighted MRI for liver imaging and liver shows increased signal intensity in T1-weighted MRI 
and decreased intensity in T2-weighted MRI, while the tumor intensity doesn’t change mainly 
due to the low contrast agent uptake within 1 hour. This is a great achievement because Gd3+ 
based MRI contrast agents are mainly used as a T1-weighted MRI contrast agents, and Gd
3+-
based MRI contrast agent are not used as T2-weighted MRI contrast agents in general.  
We hypothesize that ProCAs can function as T2-weighted MRI contrast agents with de-
creased MRI signal because of the high r2 relaxivity and a ratiometric method can increase the 
dynamic range of MRI signal. To test this hypothesis, we simulated the MRI signal intensity of 
phantom filled with different concentrations of MRI contrast agents in typical T1-weighted and 
T2-weighted MRI sequence.  Fig. 5-7 shows our simulation results based on the relaxivity theory. 
Consistant with experimental data, both Gd-DTPA and ProCA32 shows enhanced MRI signal in 
the T1-weigthed MRI (TR= 500 ms, TE = 13 ms), and the signal enhancement of ProCA32 is much 
higher than that of Gd-DTPA. In the T2-weighted MRI sequence, ProCA32 shows a small increase 
of MRI signal intensity at a Gd3+ concentration less than 20 µM and shows a dramatic signal de-
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crease the Gd3+ concentration is increased to more than 50 µM. On the other hand, Gd-DTPA 
shows small increase of MRI signal intensity in the T2-weighted MRI when the Gd
3+ concentra-
tion increased from 0 to 100 µM. The T2-weighted MRI signal in 200 µM of Gd
3+ is still higher 
than water without MRI contrast agents.  
Our the simulation results shown in Fig. 5-8 suggest that ProCA32 can be used as both 
T1-wieghted and T2-weighted MRI contrast agents, while clinical MRI contrast agents, such as 
Gd-dTPA, can only be used as T1-weighted MRI contrast agents. To test our simulation, we 
scanned T2-weighted MRI of phamtom filled with different concentration of MRI contrast 
agents (Eovist, Magnevist and ProCA). Consistant with simulation, Eovist and Magnevist shows 
enhanced MRI signal when the Gd3+ concentration increase, while ProCAs shows the decreased 
MRI signal when the concentration of the contrast agents increased to more than 20 µM.  
Because ProCA variants can increase the signal in T1-weighted MRI and decease the sig-
nal in T2-weighted MRI, we hypothese that the ratio of T1/T2 or T2/T1 (named as T1/T2 or T2/T1 
ratiometric imaging) after injection of ProCA can further increase the dynamic range of MRI. 
According to the simulation of liver intensity of different concentration of MRI contrast agents 
in Fig. 5-8, increasing Gd3+ concentration of ProCA32 from 0 µM to 50 µM Gd3+ decreases MRI 
signal from 0.45 to 0.40, while the T2/T1 intensity ratio decreases from 1.4 to 0.8. On the con-
trary, Gd-DTPA shows the T2 MRI signal decrease from 0.45 to 0.43 and T2/T1 signal decrease 
from 1.4 to 0.8, when Gd-DTPA concentration increase from 0 µM to 50 µM. Thus, this simula-
tion results support our hypothesis that ratio of T1/T2 or T2/T1 ratiometric imaging method can 
dramatically increase the dynamic range of MRI compare with T1-weigthed or T2-weighted MRI.  
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Next, we examed the T2/T1 ratiometric imaging in vivo. As shown in Fig. 5-5, ProCA32M 
can enhance the liver in T1-weighted MRI and suppress the liver signal in T2-weighted MRI, 
while the tumor signal did not change in both T1-weighted and T2-weighted MRI due to the less 
accumulation of MRI contrast agents within 1 hour. We hypothesis that ratiometric imaging can 
further improve the tumor detection because of the larger dynamic range (Fig 5.9 A). Fig. 5-9 B, 
C, D, E shows the MRI of mice liver with melanoma metastasis before and after injection of MRI 
contrast agents. After the ratio of T2/T1, the liver signal dramatically suppressed and tumor 
shows much higher enhancement (Fig 5.9 F) than T2 weighted MRI (Fig 5.9 D). Fig 5.10 shows T1 
weigthed, T2-weighted and T2/T1 ratio imaging of other slices of the same mice. All these images 
shows that T2/T1 ratiometric imaging has the best enhancement of the tumor by supress the 
liver signal. Interesting, we are able to identify small tumors with a size less than 0.25 mm be-
cause of the improved dynamic range. Thus, ratiometric MRI with the injection of ProCA32M 
can improve the tumor detection in liver by dramatically decrease the liver signal.  
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Figure 5-7. Simulation and experimental data of the phantom filled with different concentra-
tion of MRI contrast agents. 
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Figure 5-8. Simulation of MRI signal changes in the liver with different concentration of Gd-
DTPA or ProCA32. 
The dynamic range of these methods are defined as the differences between signal intensity 
with 50 µM of Gd3+ in Gd-DTPA or ProCA32 (red dash line) and the signal intensity without any 
contrast agents (blue dash line). 
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Figure 5-9. Liver tumor detection by T2/T1 ratiometic changes after injection of ProCA. 
If live and tumor has similar T1 and T2, then we are not able to differeciate the MRI signal be-
tween liver and tumor without injection of the MRI contrast agents in neither T1-weighted MRI 
nor T2-weighted MRI. After injection of ProCA, the T1 and T2 of liver decreased because 1) ProCA 
has 10 times higher r1 and r2 compared with clinical MRI contrast agents; 2) Liver has more 
ProCA than tumor within one hour post injection of ProCA. Thus, tumor shows hypo-intensity in 
T1-weighted MRI and shows hyper-intensity in T2-weighted MRI.The ratio of the MRI intensity of 
T2-weigthed MRI over T1-weighted MRI further improves the signal differences between liver 
and tumor in both model and real experimental data. 
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Figure 5-10. Ratiometic MRI can detect tumors less than 0.25 mm in liver. 
Uveal melanoma was implanted in the eye of the PEDF knockout mice. These melanoma metas-
tasis to liver two days after implantation. To imaging these metastatic melanoma, ProCA32M 
were injected from the mice tail vein and MRI were done before and after injection of 
ProCA32M. T1-weighted spin echo sequence and T2-weighted fast spin echo sequences were 
applied in the same section of the liver. Then we did the ratio of T2/T1 intensity. Row 1, 2, and 3 
stand for three different slice of mice tumor and column 1, 2, and 3 stand for T1-weighted, T2-
weighted, and T2/T1 ratiometric imaging of MRI of liver slices, respectively. 
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5.2.8 Dual weighted Bi-brilant imaging of tumor detection with improved dynamic range. 
As show in the previous sections, ProCA variants can alter the MRI signal in T1-weighted 
MRI and T2-weighted MRI. The ratio of T2/T1 or T2/T1 intensity after injection of ProCA further 
improves the dynamic range of MR signal. With the help of Dr. Xiaoping Hu in Emory University, 
we developed a novel MRI sequence with encoded both T1 and T2 feature of the MRI contrast 
agents. We call this MRI sequence as dual weighted bi-briliant imaging.  
The dual weighted bi-briliant MRI sequences can be described as an inversion recovery 
(IR) seuqnces with a special inversion time (TI) and long TE (Fig. 5-12). The TI of inversion recov-
ery sequence is carefully selected to decrease the organ with contrast agents. The TI time is in-
fluenced by the contrast agent concentration and the r1 relaxivity of the contrast agents. Be-
cause of the decrease T1 value of the tissue due to ProCA accumulation, the MRI signal of ProCA 
accumulating organs could be suppressed to extremely low level in certain TI in the IR sequenc-
es. Because ProCA accumulating tissues has short T2, long TE in this dual weighted bi-briliant 
MRI sequence further decrease MRI signal. Thus, theortically, the dual weighted bi-briliant MRI 
sequence can further show the difference between ProCA accumulating tissue and ProCA-non-
accumulating tissue.  
To test this dualweighted bi-briliant sequence, Evoist and ProCA32 with different con-
centration and water were immobilized in argar plate and scanned for T1-weighted spin echo, 
T2-weighted fast spin echo and bi-briliant sequence with differnet TI. As show in Fig. 5-13, 
ProCA3 shows much enhanced MRI signal than that of Eovist in T1-weighted MRI. 75 µM of 
ProCA3 shows decrease MRI signal in T2-weighted MRI, while Eovist does not decrease MRI sig-
nal even concentration of Eovist increase to 150 µM. This result indicate that ProCA3 can be 
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used for both T1-weighted MRI and T2-weighted MRI, while Eovist can only be applied in the T1-
weighed MRI. In addition, we scanned dual weighted bi-briliant MRI with different TI time 
(0.001 ms, and 0.251 ms). The phantom with 75 µM of ProCA shows extremely low signal inten-
sity at TI = 0.251 ms compared with Eovist and water. 
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Figure 5-11. A demenstrion of Bi-briliant MRI sequence. 
The bi-briliant sequence contains an inversion recovery sequence (left) followed by long TE 
(right). If liver accumulates more ProCAs than that of tumor, liver has much shorter T1 and T2 
relaxiation time in liver than that of tumor. By apply an inversion recovery sequence with TI = 
T1liver*ln2, (T1liver stands for the T1 of liver tissue), the liver signal is suppressed. After inversion 
recovery sequence, the MRI was collected with long TE. Because liver has shorter T2 than that 
of tumor, long TE will further decrease liver signal. By ProCAs injection and applying inversion 
recovery sequence with long TE, we will be able to double suppress the liver signal and enhance 
the tumor signal. 
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Figure 5-12. in vitro study of bi-briliant imaging with diffent concentration of Eovist, Gd-DTPA 
and Eovist. 
MRI of phantom with different concentrations of contrast agents labeled on top(µM)  or water 
were collected by T1-weighted spin echo sequence (A), T2-weighted fast spin sequence (B), and 
bi-briliant sequence with TI= 0.001 ms (C) and TI= 0.251 ms (D).  
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Next, we tested the dual weighted bi-briliant methodology in vivo using melanoma implanted 
model. The melanoma mice model was generated by following the animal protocols from 
IACUC in Emory University. Melanoma cells were dierectly injected into the liver the mice, and 
liver will generate tumors with a size between 5 mm to 20 mm within two weeks after injection. 
0.03 µmol/kg of ProCA35 were I.V. injected in mice with implanted melanoma in liver. As show 
in Fig 5-14, ProCA35 shows the enhanced liver signal in T1 weighted MRI and shows the de-
crease liver signal in T2-weighed MRI. As a result, melanoma can be identified in both T1-
weighted MRI and T2-weighted MRI after injection of ProCA. Because of the intrinsic properties 
of tumor, this malanoma also shows higher intensity than that of liver even without injection of 
the MRI contrast agents. The differences between tumor and liver increased in T2-weighted MRI 
after injection of ProCA35, which is very helpful to confirm the tumor.  
After scanning, we euthnised the mice and take the liver out for MRI scanning. This liver 
already has high concentration of ProCA35. The tumor implanted liver tissue also shows hyper-
intensity of liver and hypo-intensity of tumor in T1-weighted MRI and hypointensity of liver and 
hyperintensity of tumor in T2-weighted MRI. Thus, the T1 and T2 of liver decreased after injec-
tion of MRI contrast agents. We next tested the dual weighted bi-briliant methodology of the 
same melanoma implanted liver tissue. As shown in Fig 5-14, bi-brilant MRI shows more dra-
matic difference differences between liver and tumor compared with that of T1-weighed or T2-
weighted MRI.  
Interesting, because ProCA35 accumulating liver has much short T2 than that of tumor, 
bi-briliant imaging with longer TE (28 ms) shows much lower liver signal than that of shorter TE 
(11 ms). These results indicating that by utilizing both high r1 and r2 relaxivity of ProCA variants, 
191 
dual weighted bi-briliant MRI methodology shows great advantage in improving the tussue con-
trast differences after injection of ProCAs. This dual weighted bi-briliant MRI methodology is 
very promising for the early and sensitive detection of metastatic tumors. 
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Figure 5-13. Bi-briliant imaging for the detection of liver cancer. 
MRI imaging of mice liver with transplanted melanoma before (A for T1W, C for T2W) and after 
injection of MRI contrast agents using T1-weighted spin echo (B for live animal, E for liver tissue), 
T2-weighted fast spin echo (D for live animal, F for liver tissue), bi-brilliant methodology with 
two different TEs (G, H). The liver signal is dramatically suppressed, while the tumor signal does 
not decrease dramatically. The difference between tumor and liver improved ~8 times by this 
method. Green arrow stand for tumor. 
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Figure 5-14. MRI and histology correlation study for metastatic melanoma detection. 
Liver specific MRI contrast agent MRI helps to detect liver metastasis but cannot detect tumor 
size <10 mm with accuracy. ProCA enables to detect early mouse melenoma liver metastasis 
(mediametastases) tumor size from > 2 cm to 0.25 mm or less (blue and red arrows) with high 
sensitivity using both T2/T1 ratiometric (top left) imaging at 4.7 T. The HE staining of the same 
mice liver section (top right and bottom right) shows similar tumor size and location as MRI im-
ages (red and green arrows). In addition, tumors with a less than 0.25 mm can be detected in 
MRI (yellow arrows), which can also be confirmed from HE staining (yellow arrows on bottom 
left).  
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5.3 Discussion 
Since ProCA32 has high relaixivity and stability, it is promising to apply ProCA32 in vivo for 
the disease diagnosis. With 10 times lower injection dosage than that of clinical MRI contrast 
agents, ProCAs is able to image blood vessel, liver, kidney. The small blood vessels with a diam-
eter of less than 1 mm are able to be clearly imaged; therefore, ProCA32 has great potential for 
MRA. Supported by both 3DGE images and DCE-MRI, ProCA32 has much longer blood circula-
tion time. Longer blood circulation of ProCA will benefit molecular imaging of tumor biomarkers, 
since the interaction between targeting moieties and biomarkers requires optimized blood cir-
culation time. Long blood circulation time of ProCA32 in blood also promising for the applica-
tion of DCE-MRI. AIF in DCE-MRI experiment is the key experiment for successful calculating 
tumor permeability. However, it is hard to accurate determine AIF of clinical MRI contrast 
agents, since the blood circulation time of clinical MRI contrast agents is too short198. ProCA32 
has longer blood circulation time, and AIF of ProCA32 is easily to be determined by both MRI 
and blood sampling. Thus, ProCA32 will be a powerfully and reliable probe for tumor permea-
bility using DCE-MRI. 
ProCA32 is able to enhance the kidney in all type of T1-weighted MR images. 3DGE images 
show that the kidney is enhanced after injection of ProCA32, and the highest enhancement 
were obtained 2 day post injection. After 2 days, the kidney intensity decrease to the original 
intensity without injection of ProCA32.  Thus, ProCA32 is promising to be applied to evaluate 
the kidney lesions and kidney tumors. Kidney intensity changes function of time in DCE-MRI of 
kidney can be applied for the evaluation of renal function.  
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We are also able to image the contrast agent accumulation in bladder indicating that con-
trast agents were able to be excreted out through renal clearance. DCE-MRI of kidney also 
shows that ProCA32 start to enhance the kidney within 1 minute post injection, which is a 
strong evidence of ProCA32 excretion through kidney. 
Liver tissue is evenly enhanced under T1-weighted MRI after ProCA32 injection. Since 
ProCA32 also has high r2, livers also show decreased intensity under T2-weighted MRI post 
ProCA32 injection. Due to such unique features, ProCA32 is superior for the imaging of liver 
tumors with both T1- and T2- weighted sequences. We evaluated the imaging capability of 
ProCA32 on the liver tumor diagnostics. Mice melanoma was implanted in the eye of the mice, 
and the tumor metastasis to liver organ 2 weeks after tumor implantation. With 10 times lower 
injection dosage of than clinical MRI contrast agents, ProCA were able to image the liver metas-
tasis in both T1- and T2- weighted images. Since liver metastasis has less penetration to ProCA32, 
liver metastasis shows hyper-intensity in T2- weighted MRI and shows hypo-intensity in T1- 
weighted MRI. Interestingly, we are able to detect tumor metastasis with a size less than 0.25 
mm, whereas clinical diagnostics only can detect liver metastasis with a size larger than 10 mm 
with high confidence. Thus, ProCA32 proved a very good diagnostic tool for the early detection 
of liver metastasis. 
5.4 Summary 
First, we have shown that the the lowest detection concentration of ProCA32 can reach 
0.8 µM at 7 T using T1-weighted spin echo sequences due to the high relaxivity. This largely ex-
tended the reported detection limit of 30 µM for [Gd(HP-DO3A)(H2O)] by Wedeking.18 
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Second, we  have shown that the the lowest injection dose for us to detect in vivo 
mouse kidney is 0.0008 µmol/kg that is more than 100 fold lowever injection dosage than that 
of clinical MRI contrast agents (0.1 - 0.2 mmol/kg). 
Third, ProCA32 shows great potential for assess blood vasculature properties of tumor 
using the DCE-MRI due to its high relaxivity and longer blood circulation time.  
Fourth, based on detailed histologic analysis and imaging analysis, ProCA32M is able to 
detect liver uveal melanoma metastases with a size less than 0.16 mm with high accuracy using 
both T1 and T2 ratiometic methd we developed in this chapter. These detected tumor sizes are 
correlated to the micrometastasis which are 10 - 100 times smaller than the reported detection 
size. Current detection with good confidence for liver human metastasis or primary tumor are 
at about 2 cm that are at late stages of cancer (stage  3 or 4  out of 4). Thus, our developed 
contast agents and methodology are expected to fill in the major gap for early diagnosis and 
treatment of liver metastases. 
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6 DYNAMIC-CONTRAST ENHANCED MRI (DCE-MRI) WITH INJECTION OF PROCA3 VARIENTS 
6.1 Introduction 
Tumor has abnormal blood vasculature than normal tissue. The growth rate of the tu-
mor is much faster than blood vessel, therefore the rapid proliferation of tumor cells force 
blood vessel apart. The leakage size of the tumor vasculature varies in different tumors, and it 
could be reached to more than 100 µm. Tumor and stroma cells also secret enzymes and 
growth factors, such as VEGF, to facilitate the formation of new blood vessel and rebuilt extra-
cellular matrix. This process called angiogenesis. On the other hand high interstitial fluid pres-
sure in tumor forms a barrier for drug and imaging reagent penetration to the tumor from 
blood vessel199.   
Dynamic-contrast enhanced MRI (DCE-MRI) is a non-invisive tool to probe tumor vascu-
lature by methmatically modeling and calculating contrast accumulation in the tumor over 
time. The clinical MRI contrast agents, such as Gd-DTPA has been applied to evualte the tumor 
vasculature of many types of cancers, such as breast cancer, pancreatic cancer 200. This tech-
nique is very helpful to monitor the tumor vasculature changes of the patients after tumor 
treatment with angiogenesis drugs. DCE-MRI is also widely applied as an advanced technique in 
the preclinical field to evaluate the effects of angiogenesis drugs200. Due to the non-invissive 
properties, applications of DCE-MRI decrease the number of animals and cost in preclinical drug 
development. 
Current DEC-MRI methods still have some limitations. First, in order to accurately calcu-
late the blood volume and blood vessel permeability, most DCE-MRI methods requires having 
accurate measurement of arterial input function (AIF), the artery contrast agents concentration 
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at different time points post injection.  The AIF of clinical MRI contrast agent, however, is ex-
tremely difficult to be measured very accurately due to their fast excretion of clinical MRI con-
trast agents198. For example, the blood half life for Gd-DTPA is only 2 min in mice and 10 min in 
human. It has a lot of technique difficulties to deterime accurate contrast agents in such a short 
time. Second, due to the small size and fast tumor penetration, DCE-MRI is not able to differen-
tiate the leakage size using clinical MRI contrast agents. Third, clinical MRI contrast agnets has 
short time accumulation and short time release in tumor, which retrict enough data collection 
in the limitate time period.  
In order to evaluate tumor vasculature with high accuracy and high reliability, ideal MRI 
contrast agents for DCE-MRI requires following features: 1). The contrast agents concentration 
in blood should be relatively stable, so that arterial input function can be accurately determined. 
2). The contrast agents should have a tumor size between 2 – 10 nm, so that contrast agents 
can selectively penetrate to the tumor based on the size of leakage of the tumor blood vessel. If 
the contrast agents are too small, then they will penetrate to the tumor without any capability 
to reflect the size of derentiating tumor blood vessel leakage. On the other hand, if the contrast 
agents are too big, its penetration to the tumors with small vessel leakage is largely limited. 3). 
The contrast agents should have high relaxivities, so that trace amout of contrast agents distri-
bution in tumor can be detected.    
Compared with clinical MRI contras agents, ProCAs has their own advantages for the 
DCE-MRI study. 1). The contrast agents concentration in the blood is relatively stable, which 
made it easier to measure AIF with small error. 2). ProCA3 should have much longer accumula-
tion and release time in tumor. Since the blood contrast agents always gave lowerer than tumor 
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contrast agent’s concentration for at least 2 hours post injection of ProCAs, the mathmetical 
model for DCE-MRI can be simplified. 3) Due to the larger size, ProCA can only selective pass 
through blood vessel with a leakage larger than ProCAs (Fig. 6-1).  4) ProCAs has higher 
relaxivity, which could improve the sensitivity and dose efficiency of contrast agents. Taken to-
gether, ProCAs is a promising probe for the DCE-MRI of tumor blood vessel. Since DCE-MRI can 
also be applied to imaging other abnormal tissue, ProCAs can also be used for the imaging the 
DCD-MRI of the abnormal blood vessel of other type of diseases, such as stroke and liver kid-
ney201, 202. 
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Figure 6-1. Carton demonstration of the application of ProCA variants and Gd-DTPA-BMA for 
the evulation of blood vessel abnormalities using DCE-MRI. 
Normal tissue has well organized blood vasculature, while tumor tissue has abnormal vascula-
ture due to angiogenesis. After treatment with anti-angiogenesis drugs, the blood vescular in 
tumor tissue can be normalized. Hoever, after treatment with anti-angiogenesis drugs, tumor 
can reduce the blood vessel desity as a way resistant to the drug treatment. DCE-MRI is a prom-
ising technique to to evaluate blood vesculture. Due to large sizer size, ProCA has great poten-
tial to be applied to DCE-MRI for the evaluation of tumor vasculature. 
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6.2 Results 
6.2.1 DCE-MRI by ProCA32 or Gd-DTPA 
Since ProCA32 has high relaxivity and sensitivity at high magnetic field than than of na-
noparticles and small molecular MRI contrast agents. We measured the AIF differences of mice 
at 9.4 T bruker MRI scanner. Five baseline images without injection of contrast agents were col-
lected before injection of MRI contrast agents. Then, 0.025 mmol/kg ProCA were injected in 
mice throught tail vein. MRI imagings were continuously collected by another 85 min. As shown 
from Fig. 6-2, ProCA32 has very clear AIF. The blood vessel of the mice is enhanced for at least 
85 min. On the other hand, Gd-DTPA only has very short AIF with a half life less than 1 min (Fig 
7-2 C). Due to such fast decrease of Gd-DTPA in blood vessel, it is extremely hard to collect AIF 
of Gd-DTPA correctly for DCE-MRI study198. Thus, ProCA32 has a trenmendous advantage for 
the evlautation of tumor vascularture by DCE-MRI. 
We next compared the in vivo properties between ProCA32 and Gd-DTPA to probe 
blood vessel and kidney enhancement by DCE-MRI. To evaluate the dynamic enhancement of 
ProCA32, T1 map of the same slice are collected by FESMS sequence with different length of TR 
(Fig. 6-3). Then, MR images are collected every 7 seconds by FLASH sequence (TR = 18.44 ms, TE 
= 2.83 ms, thickness=2 mm, matrix 128 × 128, Fov 4 cm × 4 cm). After collecting 20 slides as 
baseline, 0.015 mmol/kg ProCA32 were injected in mice followed by an injection of 150 µl sa-
line through tail vein (Fig. 6-4). 130 slices were continuously collected. The concentration of 
ProCA3 in tissue are calculated based on the relaxivity of ProCA3 at 7 T and the signal intensity 
differences between the baseline images and images post injection of the contrast agents. The 
ProCA3 concentration in blood reached to the plateau within 2 min post injection of ProCA3 
202 
and the contrast agent concentration keep constant for at least 10 min and ProCA3 concentra-
tion decrease after 10 min post injection with blood retention half life around 15 min in mice. 
As comparison, 0.2 mmol/kg Gd-DTPA were for DCE-MRI in mice. Due to the short blood reten-
tion time, the peak enhancement of blood post injection of Gd-DTPA is not observed, which 
was mainly caused by the extremely short blood retention time for Gd-DTPA. Compared with 
Gd-DTPA, our contrast agents shows extremely good blood vessel enhancement with much 
longer blood retention time. This is extremely significant, our contrast agent can enhance the 
blood vessel image with longer time and with 1/10 dosage of injection of contrast agent com-
pared with Gd-DTPA. We compared MR images of kidney after injection of Gd-DTPA (0.2 
mmol/kg) or Gd-ProCA32 (0.02 mmol/kg). The time of kidney enhancement by Gd-DTPA is very 
short. The enhancement of cortex and  modulla reach to maximum within than 1 min then half 
of the signal decreased to less than 50%  within the next 1 min, which left only limited time 
window for data acquirement. The enhancement of kidney by ProCA3.2 is slower than that of 
Gd-DTPA. The cortex enhancement reached to the maximum after 1 min post injection and 
modulla enhancement is slower, which take 2 min to reach to the maximium. The half of the 
ProCA3 image is much longer. The slow kenetics of ProCA32 in kidney provide new insight to 
devolvement to study kidney function.  
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Figure 6-2. Aterial imput function study of ProCA and Gd-DTPA. 
A. MRI signal enhancement of the vein in the nick of mice. MRI imaging were collected every 1 
min.  Five baseline images without injection of contrast agents were collected before 
injectionfo MRI contrast agents. Then, 0.025 mmol/kg ProCA were injected in mice throught tail 
vein. MRI imagings were continuously collected by another 85 min. B. Aterial input function of 
ProCA in mice. The MRI signal intensicity changes of the vein during DCE-MRI study before (0-5 
min) and after (5-85 min) injection of ProCA.   C. Simulated aterial input function of Gd-DTPA in 
mice with compartmental model for Gd-DTPA (Cp(t)=D[a1 exp(-m1t) + a2 exp(-m2t)]) by Toft et 
al., 203 (D is the injection dosage, a1 and a2 are the amplatudes of the compatments, m1 and 
m2 are the rate constant for Gd-DTPA).   
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6.2.2 T1 Map calculation 
FSEMS saturation recovery sequence was applied to measure T1 map of mice with the 
same slices previous used for DCE-MRI study. To aquire T1 value of each picsle, multiple TR 
were applied in the FSEMS saturation recovery sequence (TR=0.35, 0.5, 0.7, 0.9, 1, 2, 3, 5 (s)). 
We then use Equation (6-1) by imageJ plugin to fit the T1 value of each pixel:  
             
   
  
            (6-1) 
A cutoff of 4 s was applied for T1 map measurement. This is because T1 value of tissue is 
usually less than 4 s at 7 T in mice temperature. Fig. 6-3 shows our calculated T1 map from one 
slide of mice. The kidney has a T1 value between 1-1.5 s, which is consistant with reported val-
ue.202, 204-206 
I then calculated the relaxation time of tissue based on DCE-MRI and T1 map. After got 
T1 map, I use the Equation (6-5) to calculate T1 and 1/T1 from each DCE-MRI scan. The Equation 
6-5 is obtained from Equation (6-2) and (6-3). 
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Then (2)/(3), 
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Equation (6-4) was further simplified to be Equation (6-5). 
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Where, S0 is the signal intensity of ROI before injection of the contrast agents, Sx is the 
signal intensity of the RIO of each slides after injection of the contrast agents. T10 is the T1 of 
RIO in the T1 map.T1x is the T1 of RIO after injection of the contrast agents. Θ=25 degree. 
From Equation (6-5), we can see that S0, Sx, T10, and Cosθ is known. We can calculate T1x 
based on Equation (6-5) in the attached excel file. Fig. 6-4 shows the signal intensity of blood, 
kidney center, kidney cortex and muscle. After calculation of the relaxation time of ROT in tis-
sues and T1 map values, the T1 and R1 values changes of these organs in every 7 s before and 
after injection of contrast agents. [Gd3+] changes at each time point were also calculated based 
on the relaxivity Equation (2-10).  
Fig. 6-4 C and Fig. 6-5 shows the Gd3+ concentration changes in the blood vessel, kidney 
(center and cortex) and muscle at each time point. Due to the quick injection of ProCA, Gd3+ in 
blood has a sharp increase of the Gd3+ concentration to above 120 µM, and then quickly de-
creases to less than 20 uM. The Gd3+ concentration in blood then gradually increase to a stable 
stage with a concentration around 40 µM for about 8 min. Then the Gd3+ concnetation gradual-
ly decrease. The blood Gd3+ concentration decrease to 20 µM 15 min post injection of ProCA32. 
Kidney is the major organ for the Gd3+ excretion. As shown from Fig. 6-5, Gd3+ concentration in 
kidney cortex and centrer gradually increase to 10 and 20 µM respctively with in first 2-3 min 
after injection of ProCA3. Then, Gd3+ concentration in kidney is always around 10 - 20 µM in the 
next 12 min. Since kidney is the major organ, these results provide another the evidence that 
ProCA3 is excreted from kidney. Fig. 6-4 also shown that Gd3+ in the muscle is usually very low, 
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which is also consistent with our distribution data. In the future, I will explore the potention 
application of ProCA in kidney function and disease by applying our dynamic imaging data to  
renal DCE-MRI model. 
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Figure 6-3. T1 map of mice kidney section without injection of MRI contrast agents. 
To calculate T1 map of the mice, the mice kidney sections were by FSEMS saturation recovery 
sequence with multiple TR (TR=0.35, 0.5, 0.7, 0.9, 1, 2, 3, and 5 (s)). We then use the following 
Equation by imageJ plugin to fit the T1 value of kidney imaging:  
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Figure 6-4. Relaxiation time (A), relaxiation rate (B) and Gd3+ concentration (C) changes of 
mice organ during DCE-MRI experiements with ProCA32 injection.   
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Figure 6-5. MRI enhancement of kidney over time before and after injection of (0.015 
mmol/kg) ProCA32 or (0.2 mmol/kg) Gd-DTPA. 
Top: DCE-MRI of mice kidney before and after injection of (0.015 mmol/kg) ProCA32 or (0.2 
mmol/kg) Gd-DTPA.  
Bottom: the R1 / injection dosage of blood and kidney over time. Black dots stands for ProCA32 
signal. Open dots stand for Gd-DTPA signal. 
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6.3 Discussion 
Angiogenesis is an essential process for the tumor development and metastasis. Inhibi-
tion of angiogenesis is an effective way for the tumor therapy. However, the discovery of anti-
angiogenesis drugs is hampered by the lack of sensitive methods for monitor the drug treat-
ment for the patients. DCE-MRI is a promising technique to monitor the tumor structure chang-
es under drug treatment. The evaluation of tumor vasculature by DCE-MRI is achieved by the 
permeability rate and volume of contrast agents from blood to tumor tissue after a bolus injec-
tion of MRI contrast agents. Clinical MRI contrast agents, such as Gd-DTPA, have been exten-
sively applied to evaluate tumor vasculatures of brain tumors in mice, rat, dogs and human pa-
tents198, 207, 208. DEC-MRI is also extensively applied for the development of novel anti-tumor 
drugs209, 210. However, the contrast agents used in DCE-MRI, Gd-DTPA, have many disad-
vantages. 1). A reliable DCE-MRI evaluation is highly dependent on arterial input function, the 
real-time contrast agents’ concentration in blood after a bolus injection of MRI contrast agents. 
However, clinical MRI contrast agents has very small size and very short half-life  in blood, and 
arterial input function of clinical MRI contrast agents is extremely hard to measure correctly. A 
MRI contrast agents with prolonged half-life can improve the AIF measurement, which can fur-
ther improve the accuracy and reliability of MRI contrast agents in blood. 2). An ideal MRI con-
trast agents should have high relaxivity and high sensitivity. The currently MRI contrast agents, 
however, only have a relaxivity around 5 mM-1s-1. In order to be detected by DCE-MRI, a local 
contrast agent concentration of 30 µM is required. If the relaxivity of MRI contrast agents in-
crease to 100 µM, only a local concentration 0.69 µM of contrast agent is sufficient to be de-
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tected under DCE-MRI. Therefore, a MRI contrast agent with longer circulation time and high 
relaxivity is strongly required for the DCE-MRI field208.  
In this study, we demonstrate that protein-based MRI contrast agents is a promising 
contrast agents for DCE-MRI due to signicant longer blood circulation time and significant high-
er signal intensity. The blood half life of ProCA3 in mice is more than 100 times long than that of 
Gd-DTPA, which made AIF, the date set for DCE-MRI analysis, easier to obtain with high accura-
cy and reliability than that of Gd-DTPA. As shown from Fig. 6-5, the blood signal intensity is 
dramatically improved after injection of ProCA3 instead of Gd-DTPA. ProCA3 also shows about 
5 times higer signal intensity in kidney, indicating a potential application of ProCA3 for the eval-
uation of kidney function by DCE-MRI. 
In our current study discussed in Chapter 5, our contrast agents can detect liver tumor 
with a size less than 0.25 mm, which is 80 time higher resolution than smallest size of tumor 
which can be detected by any non-invasive imaging technique. Since brain is one of the major 
organs for tumor metastases, primary tumors also developed in brain with high frequency, we 
would like to explore the capability of ProCA to brain tumor detection and assessment. Angio-
genesis is an essential process for the tumor development and metastasis. Inhibition of angio-
genesis is an effective way for the tumor therapy. However, the discovery of anti-angiogenesis 
drugs is hampered by the lack of sensitive methods for monitor the drug treatment for the pa-
tients. DCE-MRI is a promising technique to monitor the tumor structure changes under drug 
treatment. However, the contrast agents used in DCE, Gd-DTPA, have many disadvantages. This 
small chelator-based contrast agent after injection changes too fast to capture the details in the 
region of interests. In addition, small molecular MRI contrast agents. Therefore, a contrast 
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agent with longer circulation time and high relaxivity is strongly required for the DCE-MRI 
field208. Our preliminary data shows that ProCA has more than 10 times higher r1 relaxivity than 
that of Gd-DTPA. Since r2 of ProCA is more than 120 mM
-1s-1, ProCA can also be applied for T2-
weighted MRI. The clinical MRI contrast agent, such as Gd-DTPA, usually is not good for T2 
weighted MRI. In addition, ProCA has a blood half-life of 2.8 hours in mice, while Gd-DTPA has a 
blood half-life less than 30 seconds in mice. Thus, AIF of ProCA is much easier to be collected, 
which provide another advantage for the DCE-MRI with improved reliability. Since ProCA has 
much longer blood half-life than that of Gd-DTPA, we easily obtained the AIF after injection of 
ProCA. On the contrary, the AIF cannot be easily obtained by Gd-DTPA injection, even 10 times 
higher injection dosages of Gd-DTPA than that of Ca2+ were administrated.  
We hypothesis that ProCA can be applied to evaluate blood vasculature of brain tumor 
and follow the drug treatment related with tumor vasculature changes with higher sensitivity 
and reliability than that of Gd-DTPA.  
In the future, we will test our hypothesis by evaluating brain tumor blood vasculature in 
U-87 MG xenograft and othotrpic mice model by DCE-MRI using clinical MRI contrast agents 
and our novel designed ProCA. We will first study the ProCA biodistritbuion and tumor accumu-
lation at different time points using MRI and ICP-OES. We will also compare the smallest tumor 
we can detect by Gd-DTPA or ProCA in the xenograft model; we will also determine the lowest 
injection dosage for ProCA and Gd-DTPA for the tumor detection. Then, we will compare the 
AIF and Ktrans, Ve of clinical MRI contrast agents and ProCA in both U-87 MG xenograft and or-
thotropic mice model. We will further use avastin as a chemotherapy model to evaluate the 
potential application of non-targeted ProCA on monitoring the drug treatment. Each mouse will 
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be implanted with two U-87 MG tumors. We will first scan U-87 MG xenograft mice under MRI 
to evaluate the tumor size and structure. We will further measure the tumor blood volume and 
blood vessel permeability by dynamic enhanced MRI technique. To evaluate the chemotherapy 
effects, mice with/without avastin treatment will be imaged under MRI using previously de-
scribed process. Dr. Dhamala will collaborate with us for the MRI data analysis. In the mean-
time, we are exploring the GMP-like methods for large scale expression and purification of 
ProCA. With the collaboration of Dr. Zhao and Platt in UGA, we are in a good position to full ex-
plore the DCE-MRI properties of ProCA for the evaluation of brain tumors in dogs. 
6.4 Summary 
The application of DCE-MRI for disease diagnostics is limited by the lack of MRI contrast 
agents with high relaxivity, high metal binding affinity and selectivities, proper blood retention 
time. Clinical MRI contrast agents all have very limited relaxivity, and very short blood half-life, 
which made the DCE-MRI data collect very unreliable. Our current develop MRI contrast agents 
has more than 10 times high relaxivity, a blood half-life of 2.8 h, with a size about 2-4 nm. In 
this chapter, we show that ProCA3 has longer blood circulation time, which made more easy 
and quantitative to accurately measure AIF. In addition, we are able to calculate ProCA3 con-
centration in different tissues based on the DCE-MRI data and T1 map. These features made 
ProCA3 as the ideal candidate for evaluate tumor vasculature, renal perfusion by DCE-MRI. 
  
214 
7 BIODISTRIBUTION, PHARMACOKINETICS AND SAFETY STUDIES OF PROTEIN-BASED MRI 
CONTRAST AGENTS 
7.1 Introduction 
Contrast-enhanced magnetic resonance imaging using MRI contrast agents is an exciting 
method with many clinical applications. The biodistribution, safety profile and pharmacokinet-
ics of clinical MRI contrast agents are well studied. Based on the distribution, clinical MRI con-
trast agents can be divided into three classes: non-specific MRI contrast agents, liver specific 
MRI contrast agents, and blood pool MRI contrast agents. Magnevist, Omniscan, ProHance, 
Optimark, Dotarem belongs to the non-specific MRI contrast agents. Due to the small size and 
no interaction with biomolecules, these contrast agents is distributed mainly in blood vessel 
and extracellular-extravesicular spaces with a blood half live less than 5 min in mouse and less 
than 30 min in human. These contrast agents were mainly accumulated in kidney for the renal 
excretion. Therefore, these contrast agents can be applied to image kidney with high efficiency. 
This class of MRI contrast agents also accumulated in the lesions and disease tissues with blood 
vessel damage. Such properties are applied to image disease such as cancer, and stroke.  
Multihance and Eovist are liver specific MRI specific MRI contrast agents. The difference 
between these contrasts and non-specific MRI contrast agents is that Multihance and Eovist is 
covalently incorporated with one hydrophobic moiety, which facilitates liver accumulation of 
these contrast agents. Clinical study shows that, 10% Multihance and 50% of Eviost is excreted 
from liver.13 Another liver specific MRI contrast agent is Mn-DPDP. Since DPDP has the similar 
structure as vitamin A, it can be uptake by liver cells. The accumulation of Mn-DPDP dramatical-
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ly increases the MR signal in liver. However, it is unclear if DPDP is degreed in the liver and 
cause Mn2+ release.211  
MS-325 is a new FDA approved blood pool MRI contrast agents, which reversibly binds to 
serum albumin. The binding of albumin increase the relaxivity of the contrast agents and bind-
ing of albumin also elongate the blood circulation time of the contrast agents. Due to such 
unique blood distribution, MS-325 has been approved to imaging blood vessel abnormalities.212 
Besides clinical MRI contrast agents, nano-sized MRI contrast agents, such as dendrimers, 
liposome, nanotubes, and emulsions were developed with dramatically different pharmacoki-
netics and distributions. The pharmacokinetics, distribution and excretion of these contrast 
agents were largely influenced by the size, charge and targeting moieties of the contrast agents. 
Contrast agents with a size larger than 7 nm cannot be eliminated from renal filtration, and the 
blood retention time for these contrast agents are dramatically increased. Due to the phagocy-
tosis of immune-cells, liver and spleen are the major organs to accumulate these nanoparticles. 
Nanoparticles with molecular weight larger than 30 kDa is accumulated in the tumor tissue due 
to EPR effects.34, 169  
Pharmacokinetics is closely related with the safety of the MRI contrast agents. Long re-
tention in vivo faces the risk of free Gd3+ release.  NSF24, a disease found in the patients with 
impaired renal function after administration of clinical MRI contrast agents. Impaired renal 
function in these patents dramatically increased the blood retention time of the MRI contrast 
agents, which further cause free Gd3+ release from the contrast agents. Low kinetic stability of 
the contrast agents is another key factor related with NSF. Contrast agents with low kinetic sta-
bility, such as Omniscan, release more Gd3+ in the serum than  the  contrast agents with high 
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kinetic stability such as ProHance. This result is consistent with in vivo Gd3+ rentention in mice 
and correlates well with the clinical reported with the cases of NSF.   
Pharmacokinetics and blood retention time are essential for the success design of the 
MRI contrast agents for the molecular imaging of biomarkers of disease. Most biomarkers are 
expressed deep in the disease tissue. In order to the image these biomarkers, MRI contrast 
agents incorporated with biomarker targeting moieties should be able to penetrate to the dis-
ease tissue and then bind to these biomarkers. Unbounded MRI contrast agents should be easi-
ly washed away to reduce the background. Unbounded MRI contrast agents should be excreted 
efficiently to avoid unnecessary toxicity. Contrast agents with very fast clearance may not have 
sufficient time to reach  the disease tissue and interact with biomarkers. On the other hand, 
contrast agents with long in vivo retention could increase the background signal and cause un-
desired toxicity. Thus, pharmacokinetics is essential for the design of the MRI contrast agent for 
the molecular imaging of biomarkers.  
With high relaxivity, high blood circulation time and tumor targeting properties, Protein-
based MRI contrast agents is promising for the clinic diagnostics for liver metastases, blood ves-
sel abnormalities and renal functions. Understanding the biodistribution, pharmacokinetics and 
safety profile of the protein-based MRI contrast agents is the key step to push this class of con-
trast agents for clinical applications. In this chapter, we will show our recent study of the 
biodistriton, and safety profile of ProCA3 variants. We will also compare the pharmacokinetics 
of different MRI contrast agents.  
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7.2 Results 
7.2.1 Toxicity of MRI contrasts agents.  
7.2.1.1 Cytotoxicity of ProCA3 
To evaluate the cytotoxicity of the ProCA3, H441 and PC3 cells precultured on 96 well 
plates (103 cells /per well) are incubated with 30 or 50 µM Gd-DTPA and ProCA3.2. The cell 
variabilities after incubation over night were tested by MTT assay (Fig. 7-1). No significant dif-
ference is observed between nontreated group and the groups incubated with ProCA3, ProCA3-
Gd, which indicate that ProCA3 is not toxic for H441 and PC3 cells.  
7.2.1.2 Acute toxicity of ProCA3 
The acute toxicity of ProCA3 to CD1 mice were analyzed with the injection of 0.012 
mmol/kg ProCA3. The bloods of the mice were collected two days post injection. The blood 
from CD1 mice without injection of contrast agents were used as control. Based on the results 
from IDEXX from 2 mice in each group, there was no significant differences on creatine, ALT, 
ALP, cholesterol, triglycerol level differences between the control group and the group injected 
with ProCA3 indicating the kidney, liver, heart function were not affected by ProCA3 (Fig. 7-2). 
The albumin and total protein, total bili, K+, Na+, Ca2+, and Cl- level were at the same level as 
those of the control control. All these data indicates that ProCA3 has low chronic toxicity.  
7.2.1.3 Long term toxicity of ProCA3 
The long term toxicity of the contrast agents are associated with Nephrogenic systemat-
ic fibrosis (NSF), a serious syndrome find in renal impaired patients with the Gd3+ release after 
injection of clinical contrast agents. To assess the long term toxicity of the contrast agents, long 
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term Gd3+ retention in mice tissue were evaluated after injection of ProCA3. Since only injection 
of 0.8 µmol/kg of ProCA3 (equal to 1.6 µmol/kg of Gd3+) can clearly enhance contrast of MR im-
ages of kidney, 0.8 µmol/kg ProCA3, were injected in three groups of the mice. As a compari-
son, 1.6 µmol/kg of GdCl3 or 200 µmol/kg of Gd-DTPA was injected in the parallel group, re-
spectively. ICP-OES analysis indicates that Gd3+ retention in blood, liver, lung, kidney, spleen 14 
day post injection of ProCA3 was much less than that of Gd-DTPA and GdCl3. The Gd
3+ retention 
in skin and bone were comparable with that of Gd-DTPA and GdCl3. These results indicate that 
by increasing the dose efficiency and decreasing injection dosage, less Gd3+ will be accumulated 
in mice after injection of ProCA3 which cause less long term toxicity compared with Gd-DTPA.  
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Figure 7-1. Cyto-toxicicity study of ProCA32 and Gd-DTPA.  
The survival of H441 cells after incubation of 50 µM contrast agents overnight are analyzed by 
MTT assay (n = 3). 
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Figure 7-2. The acute toxicity study of ProCA3. 
The acute toxicity of ProCA3 obtained by the serum sample 2 days post injection of ProCA3 
(0.012 mmol/kg body weigtht). Results were collected from IDEXX using 2 mice in each group. 
Error bars stand for the standared deviation calculated based on the values of two repeats in 
each test.  
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Figure 7-3. Short term (top) and long term (bottem) Gd3+ distribution in mice after injection of 
GdCl3, ProCA32M or Gd-DTPA. 
0.8 M of ProCA32M (CA32M), 1.6 µmol/kg of GdCl3 or 200 µmol/kg of Gd-DTPA were injected 
in the parallel group, respectively. Gd3+ retention in blood, liver, lung, kidney, spleen for 10 min 
or 14 day post injection of ProCA3 were measured by ICP-OES. The average and standard devia-
tion were calculated based on the values measured from 5 mice in each group. 
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7.2.2 Biodistribution of ProCA in mice  
7.2.2.1 Biodistribution of ProCA measured by MRI signal intensity 
As shown Fig. 5-2 in Chapter 5, 3D MR imaging was acquired to obtain the imaging en-
hancement of the organ at different time points after injection of ProCA. As shown from Fig. 7-4, 
ProCA3M is distributed in blood, liver, kidney and bladder. The blood had highest Gd3+ distribu-
tion of 15 and 50 min post injection, the blood intensity rapidly decrease. No blood imaging en-
hancement was observed one day post injection of ProCA3M. These results indicate the ProCA3 
distribution kinetics in blood, with an estimated half life around 1 hour.  
The imaging enhancement of liver reached the highest intensity in 15 and 50 min, how-
ever, the degree of the enhancement from MR imaging is much less than that of blood. The en-
hancement of the liver also decreases 2 hrs post injection of ProCA3. After 2 days of injection, 
the liver intensity decreased to a value similar to that of prescan. These results indicate that 
ProCA3M distributed and low concentration of ProCA3 remains in liver two day post injection 
of ProCA. 
The images of kidney also enhanced 50 min post injection of ProCA3M. The enhance-
ment of kidney reached the highest intensity in 1 day after injection of ProCA. After 2 days of 
injection, the kidney intensity decreased to a value similar to that of prescan. These results in-
dicate that ProCA3M slowly accumulated in kidney and then decreased slowly. We clear see the 
enhancement of bladder at 44 min, which is an evidentce to support that ProCA3M is excreted 
from Kidney. 
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7.2.2.2 Biodistribution of ProCA measured by ICP-OES  
The distribution of Gd3+ and ProCA32 were analyzed by ICP-OES and western blot with 
antibody against PV. For ICP-OES studies, tissues were collected 30 min and 4 hr after injection 
of ProCA32. 30 min post injection of ProCA32, both of the Gd3+ and ProCA32 were mainly dis-
tributed in liver and blood, while some accumulation was also found in kidney(Fig. 7-4). The 
Gd3+ and protein distribution are consistent with 3D MR enhancement (Fig. 7-4).  The similar 
distribution of ProCA32 and Gd3+ after injection also indicates that Gd3+ and ProCA32 exist in a 
complex form in vivo. The distribution of Gd3+ in mice after injected with 0.015 mmol/kg of 
ProCA32 or 0.2 mmol/kg of Gd-DTPA for 4 h are analyzed by ICP-OES. Gd3+ was mainly detected 
in liver. While the Gd3+ concentration in blood is dramatically decreased from 0.2 mM at 30 min 
to 0.04 mM at 4 h. Since Gd-DTPA has very fast excretion time, the Gd3+ in tested tissues except 
kidney are very low.  
7.2.2.3 Biodistribution of ProCA measured by immunochemistry methods 
The distribution of the ProCA32 was also analyzed by western blot with antibody against 
PV. Consistent with MRI intensity, western blot shows the strongest bands in the serum, strong 
band in the tissue extracts of liver, kidney, heart and spleen, and not in the muscle (Fig. 7-4 D). 
The western blots are also consistent with the analysis of Gd3+ distribution (MRI and ICP-OES 
study) in such organs at the same time points, and protein of ProCA3M and Gd3+ distributed in 
the same location, indicating that ProCA3M is stable in vivo (Fig 7-5). 
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Figure 7-4. MRI image (A), biodistribution (B-D) and pharmacokinetics of ProCA32 (E). 
Biodistribution of ProCA32 are analyzed by MRI intensity (B), Gd3+ concentration by ICP-OES(C) 
and immunoblot with ProCA32 antibody (D).   
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7.2.3 Pharmacokinetics of ProCA3 
Pharmacokinetics of ProCAs, Gd-DTPA and GdCl3 were studied in mice. After injection of 
ProCAs, GdCl3 or Gd-DTPA, blood of the mice was collected from the vein. The Gd concentra-
tion in plasma was determined by ICP-OES. We calculated the half lives and volume distribution 
of ProCAs or GdCl3 by two compartment model. Clearance of ProCAs or GdCl3 were deter-
mined by Equation 7-1, 
   
   
 
           (7-1) 
where CL is the clearance, AUC is the area under the curve, and D is the injection dosage. 
7.2.3.1 Parmacoknetics of ProCA1.affiM 
 ProCA1.affi is HER-2 biomarker targeted protein based MRI contrast agents with a mo-
lecular weight of 17 kDa. This contrast agents is further modified with PEG-40, named 
ProCA1.affiM, to improve solubility, relaxivity and to decease immunogenicity. As show from 
Fig. 7-5, the blood retention of ProCA1.affiM is much longer than that of the other MRI contrast 
agents. The distribution half ProCA1.affiM is 0.6 hours and the elimination half life for 
ProCA1.affiM is about 89 hours. Long blood circulation time allow ProCA1.affiM to have suffi-
cient time to deeply penetrate in to the tumor and to interact with HER-2 biomarkers. On the 
other hand, such long circulation time may cause undesired background signal and toxicity. 
ProCA1.affiM has an initial volume distribution (Vc) of 0.05 l/kg, which further increase to 0.09 
l/kg in the steady state phase (Vdss).  The value of Vc and Vdss indicate that ProCA1.affiM is ini-
tially distributed in the blood vessel and then it restricted in the blood vessel and some extra-
cellular extra-vascular space. Compare to other ProCAs, ProCA1.affiM has a low clearance value, 
indicating that ProCA1.affiM requires longer time to be excreted.  
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7.2.3.2 Parmacoknetics of ProCA2.affi 
 ProCA2.affi is the second generation of protein-based MRI contrast agents with four 
Gd3+ and one HER-2 target sequence in one molecule. This contrast agent has a molecular 
weight of 23 KDa. ProCA2.affiM is ProCA2.affi modified with PEG-40 to improve in vivo proper-
ties.  
 As show from Fig. 7-5, ProCA2.affiM has a shorter blood circulation time than that of 
ProCA1.affiM and longer blood circulation time than that of ProCA3M and GdCl3. As show in 
Table 7-1, ProCA2.affiM has a distribution half life of 0.2 hour and elimination half life of 12.0 
hours. ProCA3.affiM has similar Vc and Vdss similar to that of ProCA1.affiM. Vc and Vdss of 
ProCA2.affiM is 0.05 and 0.09 l/kg, indicating that ProCA2.affiM may have similar distribution as 
ProCA1.affiM, and ProCA2.affiM was initially distributed in the blood circulation and restricted 
in the blood vessel and some extracellular extra-vascular space at equilibrium state. The clear-
ance of ProCA2.affiM is much faster than ProCA1.affiM but slower than ProCA3M. 
7.2.3.3 Pharmacokinetics of ProCA3M 
 ProCA3 is a non-targeted proteins based MRI contrast agent with two Gd binding sites 
and molecular weight about 11 kDa. ProCA3M was ProCA3 modified with PEG-40. As show in 
Chapter 4, PEG modification does not change the metal binding affinity and relaxivity of ProCA3. 
Our MRI imaging results (Chapter 5) show that ProCA3M can be used for the imaging of blood 
circulation, liver and kidney. The agentshows extraordinary advantage for the imaging for the 
early diagnosis of liver metastasis with 10 time smaller detection size than clinical diagnostics 
methods (Fig. 5-5). 
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 To understand the blood retention, distribution and clearance of ProCA3M, we did 
pharmacokinetics study of ProCA3M. Fig. 7-5 shows the Gd3+ concentration in the plasma of 
mice at different time points after injection of ProCA3M, ProCA1.affiM, ProCA2.affiM, GdCl3 or 
Gd-DTPA. ProCa3M had much shorter blood retention time than that of ProCA1.affiM and 
ProCA2.affiM but much longer blood retention time than that of GdCl3 and Gd-DTPA. ProCA3M 
has a distribution half life of 0.15 hour and elimination half life of 2.8 hours, which are much 
shorter than that of ProCA1.affiM and ProCA2.affiM. The volume distribution of ProCA3M is 
0.08 l/kg and 0.13 l/kg Vc for Vdss, respectively, indicating ProCA3M is mainly distributed in the 
blood circulation and some extracellular extravascular space, but the distribution of ProCA3M is 
larger than that of ProCA1.affiM and ProCA2.affiM. Interestingly, ProCA3M also has shorter 
clearance than that of ProCA1.affiM and ProCA2.affiM. Thus, ProCA3M has good pharmacoki-
netics allowing sufficient time for data collection and effect to excretion to prevent free Gd3+ 
release. 
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Figure 7-5. Gd3+ concentration in the blood of mice post injection of of ProCAs, Gd-DTPA and 
GdCl3 at the diffent length of time.   
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Table 7-1.  Pharmacokinetics of ProCAs and GdCl3. 
The pharcokinetics were calculated using two compartment model based on the Gd3+ concen-
tration in serum at difference time points after injection of GdCl3 or ProCA variants. The data 
were collected from 3 mice in each group.  
GdCl3 ProCA3M ProCA1.affM ProCA2.affiM 
Half lives (h) 
α-phase 0.35   0.07 0.15  0.02 0.60  0.47 0.20   0.11
β-phase 11.43  0.15 2.86  0.33 89.17  2.50 12.03  1.92
Distribution 
(l/kg) 
Vc 0.14  0.04 0.08  0.01 0.05  0.00 0.05  0.00
Vdss 0.79  0.51 0.13  0.01 0.09  0.01 0.09  0.01
Total Clearance 
(ml/min/kg) 
0.76  0.3 0.34  0.08 0.044  0.02 0.089  0.02
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7.2.4 Excretion pathways and clearance of ProCA 
Like other drugs, MRI contrast agents can be excreted from renal and hepatointestinal 
excretion systems. Among 9 approved Gd3+ contrast agents, 2 of them are excreted from both 
renal and hepatointesinal excretion systems and other contrast agents are excreted only from 
renal excretion system. 3D MR imaging (Fig. 7-4A) shows enhanced bladder and kidney indicat-
ing that ProCA3 can be excreted from renal excretion system. To further understand the excre-
tion pathways for ProCA3M, we I.V. injected fluorescein-labeled ProCA3M in mouse and fol-
lowed its distribution under fluorescent dissecting microscope. The mice were euthanized 1 
hour post injection. As show from Fig. 7-6, liver and gall bladder shows high green fluorescence 
and gall bladder has the highest intensity, which indicate that ProCA3M can be excreted from 
hepatointestinal excretion system. We also observed green fluorescence in the kidney and 
urine of the mice post injection of fluorescein-labeled ProCA3M. Thus, ProCA3M is excreted 
from both renal and hepatointestinal pathways.   
Gadolinium release and accumulation is believed to induce NSF. To further study the 
long term accumulation and clearance of ProCA3M. Gd3+ concentration in different organs were 
measured by ICP-OES 14 days post I. V. injection of GdCl3, Gd-DTPA or ProCA3M (0.0033 
mmol/kg ProCA3M, 0.0067 mmol/kg GdCl3 or 0.2 mmol/kg Gd-DTPA ) in mice. As show in Fig. 
7-4, Gadolinium from GdCl3 has much higher accumulation in bone, liver and spleen the major 
organs for the Gadolinium deposit. ProCA3M has lowest accumulation in liver, lung, and spleen 
among these three reagents. Thus, ProCA3M has lower long-term Gd3+ accumulation compared 
with GdCl3 and the clinical injection dosage of Gd-DTPA. 
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Figure 7-6. Excreation pathways of ProCA32M.  
Fluorescence labeled ProCA32M were IV injected in mice. A strong enhancement of kidney (A, B) 
and gall blader (D) indicate that ProCA32M is excreated from both renal and hepato-intestine 
pathways. The fluorescence enhancement of kidney is consistant with MRI of kidney after injec-
tion of ProCA32 (C).  
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7.3 Discussion 
The toxicity of MRI contrast agents is mainly caused by free Gd3+ release. Gd3+ has a sim-
ilar ionic radius as Ca2+, thus, Gd3+ can mimic Ca2+ to interact with Ca2+ binding proteins, such as 
Ca2+-ATPase, channels, receptors and enzymes.125 Gd3+ binding to the Ca2+-binding proteins 
changes the activity or kinetic properties of the protein. for example, Gd3+ can activate calcium 
sensing receptor and induce inward Cl- current.105  Free Gd3+ is toxic with a LD50= 0.1 mmol/kg 
in mice. NSF, a disease the patient with impaired rental function, is believed to be caused by 
the free Gd3+ release after administration of Gd3+-based MRI contrast agents. Therefore, a safe 
MRI contrast agent must have no Gd3+ accumulation after injection To facilates further poten-
tial of clinical application, the toxicity, pharmacokinetics, biodistribution and excretion of these 
agents must be carefully studied.  
MTT assay in H441 cells shows that ProCA3 with and without Gd3+ has no cytotoxivity. 
Our serum toxicity data shows that mice have normal liver, kidney, heart functions functions 
after contrast agents injection. The total protein concentration, albumin concentration, lipids 
concentration, Na+, K+, Ca2+, and Cl- level in mice are also similar to the control group injected 
with saline. These data provide strong evidence that ProCA3 is have no toxicity.  
We further studied the distribution and pharmacokinetics of ProCAs. To design a MRI 
contrast agents with high safety profile and capabl ity for molecular imaging, the contrast agent 
must have proper pharmacokinetics. If a contrast agent excretes too fast, it will have less time 
to interact biomarkers. On the other hand, if a contrast agent has very long half life, it may have 
undesired toxicity induced by free Gd3+ release. ProCA1.affiM, ProCA2.affiM and ProCA3M has 
difference elimination half lives from 3 hours to 89 hours. Such difference is probably caused by 
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the different charge, molecular weight and shape of these ProCAs. Due to the large size, ProCAs 
are mainly distributed in the blood vessel and some extracellular extravascular spaces. Such 
unique distribution made ProCAs able to penetrate in the tumor for the molecular imaging and 
promising fro evaluate blood vasculature by DCE-MRI.  
Free Gd3+ is accumulated in the bio-deposit site in vivo, such as lung, liver, spleen and 
bone. The accumulation of Gd3+ can cause serious disease, such as NSF.  Thus, MRI contrast 
agents must excreted efficiently after imaging. Clinical MRI contrast agents are excreted from 
renal and hepato-intestinal excretion system. Most of these contrast agents are excreted only 
from renal excretion system, which made these contrast agents good for the MR imaging of 
kidney. Multihance and Eovist are excreted from both renal and hepato-intestinal excretion sys-
tem. Due to such unique properties, Multihace and Eovist are applied for the imaging of liver 
disease. Our fluorescence imaging show that ProCA3M is excreted from both liver and kidney 
and this result is constant with MRI in mice. We further compared the Gd3+ long term accumu-
lation in different mice organs after injection of GdCl3 (0.0067 mmol/kg), ProCA3M (0.0033 
mmlo/kg containing 0.0067 mmol/kg Gd) and Gd-DTPA (200 mmol/kg). The reason that we use 
0.0033 mmol/kg ProCA3 to study Gd3+ long term accumulation is that 0.0033 mmol/kg already 
shows good MRI enhancement in kidney.  GdCl3 has the highest accumulation in the liver, 
spleen, lung among above three reagents and ProCA3M has the lowest accumulation in these 
organs. These data suggest that ProCA3M is efficiently excreted from renal and hepota-
intestinal excretion system with less Gd3+ accumulation in vivo due to high stability, short elimi-
nation half life, efficient excretion, high dose efficiency and low injection dosage. 
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7.4 Conclusion 
MRI contrast agents with good safety profiles are essential for both preclinical and clini-
cal applications. In this chapter, the toxicity, distribution, excretion and long term accumulation 
of ProCAs, especially ProCA3M were carefully studied. Compared with Gd-DTPA and GdCl3, 
ProCAs has difference biodistribution. ProCA3M are mainly distributed in the blood, liver, kid-
ney for the short time after injection, while ProCA3M has much lower accumulation in the Gad-
olinium bio-deposit sites. Lower Gd3+ accumulation in these sites indicate that ProCA3M has 
lower chance to cause NSF. Both cytotoxcity and blood test shows that ProCA3 has no toxivity 
in cell and in vivo. ProCAs has different pharmacokinetics. ProCA3M has elimination half liver 
around 2 hours, which is a desired for the imaging and elimination. Volume distribution studies 
indicate that ProCA3 and other ProCAs are mainly distributed in the blood vessel and extracel-
lular extravascular space. In conclusion, ProCA3M has low toxicity, low Gd3+ accumulation, con-
trolled distribution and such unique properties made ProCA3M a promising contrast agent for 
the clinical and preclinical diagnostics.  
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8 MOLECULAR IMAGING OF TUMOR BIOMARKERS USING PROTEIN-BASED MRI CONTRAST 
AGENTS 
8.1 Introduction 
Cancers are deadly diseases cause more 500000 deaths annually in the United States.213 
Although large effects have been made, the cancer therapy is limited by lacking of effective and 
reliable methods for early diagnostics and evaluation of tumor biomarkers. Therefore, it is criti-
cal to develop an effective way to detect the tumor and its biomarkers in the early stage.  
 Multiple approaches are applied for the tumor diagnostics. These methods include 
screening blood circulating biomarkers, such as VEGF, biopsy, and various imaging techniques. 
The blood circulating biomarkers have great potential for the tumor diagnostics. In the current 
stage, however, biomarker based blood test such as the PSA test, a standard for prostate can-
cer diagnostics, has low correlation with prostate cancer staging. Biopsy is an informative 
method. However, this method is invasive and with large errors due to sampling. The patients 
have to suffer from the great pain from the tissues are taken out from body for the analysis. 
The “golden-standard” the evaluation of angiogenesis is the mean vascular density (MVD), 
which estimate the blood vessel density by immunohistochechestry. However, tumor usually 
heterogeneous and MVD only quantify limited area in the collected tissue in the specific loca-
tion of tumor. Thus, the MVD of biosy tissue can be missleading.207, 214 On the other hands, im-
aging techniques are used to detect the angiogenesis. However, most of these techniques are 
not satisfy with the requirement for the tumor diagnostics. The fluorescence imaging lacks of 
the tissue penetration. As discussed in Chapter 1, the sensitive imaging techniques such as PET 
and SPECT are expensive and the number of instrument for PET and SPECT scan is limited. Be-
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sides, PET and SPECT scanning use radioactive isotopes, which could be potentially harmful to 
the patient.207   MRI is one of the promising techniques for the cancer diagnostics. Magnetic 
renascence Imaging (MRI) is an advanced diagnostic technique with high resolution, three di-
mensional properties. Due to the low sensitivity, 30% of the MRI tests require the administra-
tion of MRI contrast agents to improve the signal to noise ratio and obtain tissue specific imag-
es103. With 7 unpaired protons, high magnetic moment and long election relaxation time, Gd3+ 
became the best metal ion function as contrast agents. Gd3+-based MRI contrast agents were 
applied for clinical diagnostics for over two decades.  
 One of the disadvantages of MRI is that MRI is limited by the sensitivity. To imaging 
the biomarkers with limited receptor number, MRI contrast agents must be incorporated with 
target moieties and have high relaxivity. Unfortunately, most of the current contrast agents on-
ly have very low relaxivity (less than 5 s-1 mM-1 for Gd-DTPA), and the lowest detection limits for 
these contrast agent is 0.1 mM46. Therefore, it is hard to image the expression level of certain 
receptors when the receptor number is low. On the other hand, in order to targeting to the re-
ceptors, these contrast agents are uaually conjugated to antibody or peptide. However, anti-
body has a large molecular weight. Thus, contrast agents conjugated with antibodies have low 
penetration capability in tumor tissue.155  Protein based contrast agents has more than 10 fold 
higher relaxivity than clinical MRI contrast agents. By conjugating to small peptides or affibody, 
ProCA1s is able to imaging biomarkers, such as HER-2 and GRPR. 
 We design a new generation of protein base contrast agent with two metal binding sites 
with improved stability and pharmacokinetics. In this chapter, we introduce our current work 
for the imaging of cancer biomarkers by incorporating HER-2, GRPR or integrin targeting pep-
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tide in ProCA3M by MRI. The MR imaging results is confirmed by immunostaining and ICP-OES 
study.  
8.2 Results 
8.2.1 Molecular imaging of GRPR in cancer by ProCA3.bombesin 
8.2.1.1 GRPR is a biomarker for prostate, breast, small cell lung cancer 
There are three groups the GPCR exist in the bombesin receptor family. Among these 
receptors, the group 2 receptor, GRPR, is a promising biomarker for the tumor diagnostics. Dis-
covered in 1971 from amphibian, the natural ligand of GRPR, bombesin peptide, is found to be 
strongly and specifically bound to gastric-release peptide receptor (GRPR) with high affinity. Its 
human homolog, GRP, plays an important role on gastric acid secretion, muscle contraction, cell 
differentiation.215, 216 The interaction between GRP and GRPR could activate multiple signaling 
pathways including tumor cell proliferation, survival and differentiation. Due to the low expres-
sion level in normal tissue and high expression levels in tumor, GRPR become a promising bi-
omarker for the tumor diagnostics.163, 165 The high affinity interaction between GRPR and 
bombesin made bombesin a promising targeting peptide for the molecular imaging of prostate 
cancer, breast cancer and small cell lung cancer.  
8.2.1.2 in vitro testing of interaction between ProCA3.bombesin and GRPR  
We linked the bombesin sequence of the C-terminal ProCA3. We expressed and purified 
this novel protein-based MRI contrast agents, named ProCA3.bombesin, using the methods de-
scribed in Chapter 3. ProCA3.bombesin has a ProCA3 sequence, which binds two Gd3+ as 
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contracs agents. ProCA3.bombesin also has a GRPR targeting peptide, which binds to GRPR with 
high affinity (Fig. 8-1).  
To test the interaction between ProCA3.bombesin and GRPR, ProCA3.bombesin were 
incubated with H441 and PC3 cells for 30 min. MR imaging of these cells were collected after 
robust wash by PBS. H441 has a low expression level of GRPR, while PC3 has high expression 
level of GRPR.169 As shown from Fig. 8-2A, PC3 has higher MRI intensity, which means more 
ProCA3.bombesin binds to PC3 cells. Since PC3 cells have at least 10 fold higher GRPR expres-
sion than H441 cells, these results indicate that ProCA3.bombesin specifically binds to GRPR.  
To further confirm the internaction between ProCA3.bombesin to GRPR. We did immu-
nofluorescence staining of ProCA3 in PC3 and H441 cells after these cells were incubated with 
ProCA3.bombesin and robust wash. As show from Fig. 8-2B, PC3 cells has high staining of 
ProCA3.bombesin than that H441 cells indicate that ProCA3.bombesin specifically interact with 
GRPR. 
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Figure 8-1. Model structure of GRPR targeted protein based contrast agent, ProCA32-
bombsin.  
This picture is the combination of five predicited pictures of generated from Tasser. Red region 
indicate Gd3+ binding pockets. 
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8.2.1.3 MR imaging of GRPR expression in xenograft mice model 
We next imaged GRPR expression in xenograft mice model. H441 and PC3 nude mice 
xenograft are used to test the ability of tumor imaging using ProCA32.bomb. MRI experiments 
were carried out when the tumor size reached around 1 cm in diameter. ProCA3.bomb are la-
beled with Cy5.5 and PEGlytaed by PEG-40. The spin echo image (Fig. 8-3) shows that PC3 tu-
mor brightened 1 day after contrast agents injection, and decreased there afterward. NIR image 
shows that both H441 and PC3 tumors brightened up 1 days post contrast agents injection (Fig. 
8-3). The fluorescent intensity of tumor is consistent with the mice MRI image. Both H441 and 
PC3 tumor, along with kidney, spleen and liver have high cy5.5 fluorescence. Gd3+ distribution 
were analyzed by ICP-OES. Liver and spleen showed highest Gd3+ accumulation, PC3 tumor has 
slightely higher Gd3+ accumulation than that of kidney and H441 tumor (Fig. 8-3).  
Western (Fig. 8-4 C) and imunofluorescent staining (Fig. 8-4 B) of tissue extracts and tis-
sue sections confirms that the GRPR are highly expressed in both PC3 and H441 tumor, while it 
has very low expression in kidney, liver and heart. Imunofluorescent staining (Fig. 8-4) also indi-
cate that ProCA32-bombsin are existed in PC3 and H441 tumor, liver and kidney. These data 
indicate the ProCA3.bembesin can be applied for the molecular imaging of GRPR in tumors. 
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Figure 8-2. ProCA32.bomb target to GRPR high expression cells.  
GRPR-specific ProCA, ProCA32.bomb, target to to GRPR expressed cells using fluoresecence mi-
croscopy (A, B) or MRI PC3 cell pellets (C). A. Fluorescence imaging of ProCA32.bomb stainig for 
H441 cells after incubation with ProCA32.bomb at 37 °C for 30 min. B. Fluorescence imaging of 
ProCA32.bomb stainig for PC3 cells after incubation with ProCA32.bomb at 37 °C for 30 min. C. 
MRI of PC3 cells pellets after incubation with non-targeted ProCA32 or GRPR targeted ProCA32, 
ProCA32.bomb,  at 37 °C for 30 min followed by thoroughly washing. 
 
 
 
  
PC3H441
ProCA32
ProCA32.bomb
A                                          B                                         C
242 
 
Figure 8-3. MRI (A-D) and NIR (F,G) imaging of H441 (left red circle) and PC3 (right red cycle) 
tumor xenograft mice. 
ProCA3.bomb distribution in tumor and other tissues were analyzed by MRI signal enhance-
ment (E), NIR imaging (G) and ICP-OES(H). PC3 tumor shows significant enhancement in MRI 24 
h post injection of ProCA3.bombsin (C right red cycle). Both tumors enhanced in NIR imaging 1 
day after injection (F). H441 and PC3 tumors tissue shows similar intensity under NIR imaging 
(G). ICP-OES study shows that PC3 higher Gd3+ accumulation than that of H441 tumors (H). 
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Figure 8-4. Immunofluroesence staining study of ProCA3.bomb in the PC3 and H441 tumor or 
lung tissue (Negative control) 48 hours post injection of ProCA32. bomb. 
Red is the ProCA3.bomb stained by the home-made rabbit antibody against ProCA32 with 1:500 
dilution. Blue is the nucleus staining by DAPI.  
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244 
8.2.2 Molecular imaging of HRE-2 biomarker by ProCA3.affi 
Breast cancers are deadly diseases. According to national cancer institute, it is estimated 
that 39,510 weman will be diagnosed to have breast cancer and 39,510 women will dead of the 
diseases. HER-2 is a major prognosis biomarker that expressed in 30% breast cancer and 60-70% 
of DCIS tissue. Monitoring the spatial and temporal changes of several molecular biomarkers 
such as HER2/EGFR sharing the same signaling pathway during cancer progression and treat-
ment is the key for understanding the molecular basis of cancers, for early and accurate diagno-
sis, and for developing effective drugs with synergistic effects to treat this deadly disease. Bi-
omarkers such as the epidermal growth factor receptors EGFR and HER2/Neu are highly ex-
pressed in various diseases such as breast and ovarian cancers and play important roles in dis-
ease progression and survival. They are also major drug targets for targeted therapy. Since the 
clinical application of targeted therapy is largely limited due to the limitation of current meth-
ods for assessment of these cancer biomarkers. The effectiveness of the target therapy largely 
depends on the pre-selection of patients with over-expressing these biomarkers. To date, one 
of five HER2/Neu clinical tests, including biopsy and IHC, provides incorrect results, leading to 
improper selection of appropriate patients for personalized treatment using biomarker target-
ed therapies 134, 135. There is an urgent need to develop non-invasive and accurate methods for 
diagnosis and selection of patients and to monitor biomarker levels/distribution and their 
changes upon treatment by targeted drugs.  
Instead of using HER-2 antibody for molecular imaging, we linked HER-2 affibody at the 
C-terminal of ProCA3, named ProCA3.affi. The procedure of purification of ProCA3.affi is very 
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similar to that of ProCA3 purification shown in Chapter 3. We also covalently linked PEG-40 and 
cy5.5 at the lysine residues of the ProCA3.affi. 
We next test the MRI imaging of HER-2 biomarkers in cancer in two mouse models after 
injection of ProCA3.affi. In the xenograft model, SKOV-3 tumor were implanted in the flank the 
mouse. After the tumor size reached to about 1 cm, 0.03 mmol/kg of ProCA3.affi was I. V. in-
jected to the mice with the tumors. MR imaging were collected before injection and different 
time points after injection. As shown in Fig. 8-5, the contrast of tumor edge were significantly 
enhanced after injection of ProCA32.affi (Fig. 8-5 B-G) and the highest enhancement were 
shown at 49 hr post injection of ProCA32.affi (Fig. 8-5 F). Such enhancement is still can be de-
tect three days post injection (Fig. 8-5G), while the enhancement of other organs dramatically 
decreased from the original intensity. Since ProCA3.affi also carries cy5.5, ProCA3.affi can also 
be used for the near infrared imaging. As shown from Fig. 8-5 H, consistant with the MRI en-
hancement, the NIR of SKOV-3 tumor was enhanced after ProCA3.affi injection. Since 
ProCA3.affi enhance SKOV-3 tumor in MRI and NIR imaging, this contrast agents can be further 
applied non-invassively evaluate HER-2 expression levels in breast and ovarian cancers. 
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Figure 8-5. MRI (A-G) and NIR imaging (H) of HER-2 expresion in the xenografted SKOV-3 mice 
model. 
Tumor edge under MRI (red arrow head in the circled dash line) was significantly enhanced af-
ter injection of ProCA32.affi (B-G) and the highest enhancement were shown at 49 hr post in-
jection of ProCA32.affi (F). H. The SKOV-3 tumor in NIR imaging (blue dash cycle) is enhanced 49 
hours post injection of ProCA32.affi with Cy 5.5 conjugation.  
0  hr                          13 min                          44 min                   2.5 hour
35  hr                            49 hr                             72 hr
A                                     B                                   C                                    D  
E                                     F                                   G                                         H  
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Figure 8-6. MRI (A-G) and NIR imaging (H) of HER-2 expresion in MCF10-DCIS isotropic mice 
model. 
Small region of tumor adjacent to liver (red arrow head in the circled dash line) was enhanced 
at 27 hr post injection of ProCA32.affi (F). H. The SKOV-3 tumor in NIR imaging (blue dash cycle) 
is enhanced two days post injection of ProCA32.affi with Cy 5.5 conjugation.  
0  h                            12 min                            43 min                         2.7 
h
4.5  h                               27 h                                50 h                            76 
hr
A                                     B                                   C                                    D  
E                                     F                                   G                                         H  
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We next test the MR imaging of HER-2 in the breast cancer isotropic tumor model. MCF-
10DCIS tumors were implanted in the nipple of the mouse.  MRI and NRI imaging were per-
formed when tumor size is larger than 1 cm. As shown from Fig. 8-6 A-G, the MRI and MR sig-
nals of MCF-10DCIS tumor were enhanced 1 day after injection of ProCA3.affi and the imaging 
enhancement in MRI is consistent with those of NIR imaging(Fig. 8-6 H). These results indicate 
that ProCA3.affi can be used for the MRI and NIR imaging of HER-2 biomarkers. HER-2 is a prog-
nosis biomarker for the breast cancer. Our results open a new avenue to evaluate breast cancer 
progression noninvasively. 
8.2.3 Molecular imaging of angiogenesis by ProCA3.RGD 
Tumor requires nutrition to grow. When tumor grows more than 1-2 mm in diameter, 
the passive perfusion of nutrient is not sufficient enough for the tumor growth. The formation 
of new blood vessel, angiogenesis, is essential for tumor to overcome this growth restriction. 
On the other hand, angiogenesis also facilitate tumor metastases.213 It is essential to develop an 
effective way to monitor the tumor of angiogenesis. The methods for the angiogenesis diagnos-
tics are also valuable for monitoring the effects of the chemotherapy against angiogenesis. 
Integrins belong to a large family of integral membrane proteins expressed in animal 
cells. Two transmembrane subunits, α subunit and β subunit, are non-covalently interacting 
with each other to form functional integrin. By different combinations, they are able to form 
more than two dozen of different integrin pairs217. The extracellular domain of integrin binds to 
variety of proteins in the extracellular matrix, such as fibronectin, collagen, laminnin, collegan 
and I-CAM-1. The intracellular domain of integrin binds to signal transduction molecule and cell 
skeleton, such as talin, filamin, FAK. These molecule not only transfer the extracellular signal 
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from outside to inside of the cell, it also transfer the inside signal to the extracellular space.218, 
219 Integrin αvβ3 is expressed when the new blood vessel are formed. It is upregulated when 
certain tissue undergoes inflammation, wound, and necrosis and tumor formation. Integrin is 
one of the sensitive and high expression biomarkers of angiogenesis during tumor formation.220 
The natural ligands of integrin are vitronectin, fibronectin, fibrinogen, osteopontin. To interact 
with integrin αvβ3 most of these ligands contains a specific amino acid sequence, RGD. The bind-
ing affinity between RGD and integrin is about 10-6 M, which is strong enough to be used as a 
targeting peptide for the molecular imaging.221 
To develop a MRI contrast agent for imaging of integrin αvβ3, we linked 4-repeat-RGD 
peptide at the c-terminal of ProCA3, named ProCA3.RGD. ProCA3 has two Gd3+ binding sites 
and the RGD peptide is linked at the C-terminal of ProCA3 by GGG linker. 
We next test interaction between ProCA3.RGD to integrin αvβ3 high expression cells, UG-
87-MG. Immunofluorescence results from Fig. 8-7 show that ProCA3.RGD can bind to the UG-
87-MG. The cytoplasm staining of U87-MG staining by ProCA3 antibody indicates that 
ProCA3.RGD is robustly uptake by endocytosis. As a negative control, ProCA3 without targeting 
peptide was tested in a very similar conditions. These results indicate that ProCA3.RGD is a 
promising contrast agent for the molecular imaging of integrin αvβ3 in cancer.  
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Figure 8-7. Integrin αvβ3-specific ProCA32, ProCA32-RGD4, target to to U87MG cells.  
A. U87MG cells incubated with 1 μM non-targeted ProCA32 at 37 °C for 1 hour. B. U87MG cells 
incubated with 1 μM ProCA32-RGD at 37 °C for 1 hour. 
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8.3 Discussion 
MRI is an advanced imaging technique which collects real time, non-invasive, three di-
mensional imaging with high resolution, high depth penetration. MRI not only can collect ana-
tomic images, but also can collect functional data such as water perfusion, blood vasculature, 
and tissue oxygen levels. MRI is also the attractive imaging modalities for molecular imaging of 
disease biomarkers. The combination of these information collected by MRI will provide in-
formative guidance for disease diagnostics. 
The molecular imaging of diseases biomarkers, however, is limited by the lack of MRI 
contrast agents that specifically binds biomarkers and alter the signal intensities of MRI. The 
expression level of biomarkers is usually very low. For example, 105 GRPR molecules are ex-
pressed one PC3 cell. Assuming PC3 cell has a volume of 1000 µm3 (10 µm × 10 µm × 10 µm), 
then the local GRPR concentration is 1.7 µM. Clinical MRI contrast agents has a detection limits 
above 30 µM and do not have biomarker targeting moieties. Thus, clinical MRI contrast agents 
cannot image this biomarker. Even the clinical MRI contrast agent is engineered with GRPR tar-
geting peptide, the local concentration of contrast agents (1.7 µM assuming 1 to 1 binding) is 
lower the detection limits of clinical MRI contrast agents. Thus, MRI contrast agents with high 
relaxivity (low detection limits) and specific biomarker targeting sequence are essential for the 
success of molecular imaging of biomarker.  
The detection limits of MRI contrast agent is correlated with the relaxivity. Clinical MRI 
contrast agents with a relaxivity less than 5 mM-1s-1 only have a relaxivity above 10 µM. When 
the relaxivty increase to above 100 mM-1s-1, the detection limit of the contrast agents decrease 
to less than 690 nM.45 ProCA3 has a per particle r1 relaxivity about 60 mM
-1s-1. In Chapter 5, we 
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show that 2 µM of ProCA3 can enhance the MRI signal. Thus, ProCA3 is a good candidate for 
developing MRI contrast agents for the molecular imaging of biomarkers with limited expres-
sion level. ProCA3M has an elimination half-life around 3 hours. Therefore, this contrast agent 
have a good time window for the marker recognition, molecular imaging and excretion.  
We designed three ProCA3 based MRI contrast agents for the molecular imaging of tu-
mor biomarkers, such as GRPR, HER-2 and integrin αvβ3. ProCA3.bombesin selectively enhances 
PC3 tumors other than H441 tumor in xenograft mice model. Since PC3 cells have more than 10 
times higher GRPR level than that of H441, this result suggests that ProCA3.bombesin can semi-
quantitatively evaluate GRPR expression levels in different tumor. We also engineer HER-2 tar-
geted ProCA3 (ProCA3.affi). ProCA3.affi is able to image HER-2 receptor in both xenograft 
SKOV-3 model and MCF10-DCIS isotropic model. Thus, our contrast agents can be applied for 
the imaging of different biomarkers by engineering different biomarker targeting moieties. Tar-
geted ProCA3s has great potential to be applied for preclinical drug discovery and clinical tumor 
diagnosis and evaluation. 
8.4 Summary 
We developed tumor specific MRI contrast agents for the molecular imaging of tumor 
biomarkers. These novel targeted ProCA3s variant can binds to biomarkers such as GRPR, HER-2 
and integrin αvβ3 with high specificity.  
GRPR in mice tumor can be targeted by ProCA3.Bomb with high specificity of PC3 tumor 
cells, which has 10 times high expression level of GRPR than that of H441 cells. Because 
ProCA3.bomb carries a cy5.5. This probe can also be used for the NIR imaging. Consistent with 
MRI, PC3 tumors shows enhanced MRI signal in the NIR image.  
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HER-2 receptor can be imaged by ProCA3.Affi in xenograft and orthtropic mice model in 
both MRI and NIR, indicating that ProCA3.Affi can successfully target HER-2 receptors for the 
molecular imaging of HER-2 expression in tumors. 
In addition, prilimiary study shows that ProCA3.RGD can selectively target integrin. Thus 
this probe is promising for the molecular imaging of integrin. 
Molecular imaging of GRPR and HER-2 in mice model shows semi-quantitative en-
hancement of biomarkers in tumor. The success of MR imaging of GRPR and HER-2 suggest that 
targeted ProCA3s can be applied to imaging other important tumor biomarkers by engineering 
different biomarker targeting moieties. Integrin αvβ3 targeted ProCA32, ProCA32.RGD also able 
to target tumor cells with high expression of integrin αvβ3. Thus, targeted ProCA3 has great po-
tential to detect tumor location, tumor size, evaluate tumor progression by semi-quantitavie 
evaluate biomarker expression levels and facilitate personalized medicine for tumor treatment.   
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9     PEGYLATION, FERMENTATION STUDY OF PROTEIN-BASED MRI CONTRAST AGENTS 
9.1 Introduction 
Several in vivo properties are required to be carefully considered to design protein drug 
for the diagnostics and therapeutics of human disease. First, the protein drug can easily cause 
immonugencity.  Thus, the designer must carefully design and modify the desired protein drug 
to make sure no or low immunogenicity to limit side effects in vivo. Second, an effective drug 
must have optimized pharmacokinetics. For example, the imaging reagents must have a proper 
time window for imaging and excretion. Third, a commercialized drug must have reproducible 
and economic methods for the large scale production of the drug. 
PEGylation is one of the FDA approved methods for the drug modifications. By covalent 
conjugation of PEG, the solubility, immunogenicity and pharmacokinetics of the drugs can be 
dramatically improved. Our previous data shows that PEGlytion increases the relaxivity, de-
crease the immunogenicity and optimize the distribution of ProCA1, while the metal binding 
affinity and selectivity of ProCA1 remains unaffected by PEG.99, 155 
Humanization refers to modification of an amino acid sequence of protein drug from 
non-human protein sequence to human protein sequence. Humanization is essential for a pro-
tein drug to survive under the human immune system. This process is extremely important step 
for developing an antibody drug generated from non-human immune system.222, 223 Since 
ProCA3 is derived from rat PV, it is also very important to generate humanized ProCA3 to re-
duce the immunogenicity of the drug.  
Large scale production is another bottle neck for the commercialization of ProCA. An 
ideal method for ProCA3 production should contain several important features. First, the 
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method for the protein production should have very good repeatability so that drugs produced 
from differ batches have the same properties. Second, the methods for ProCA production 
should be easily adapted to higher volume system with no modification of the protocol. How-
ever, the ProCA3 expression methods in Chapter 3 contain heating and dialysis steps, which 
cannot be applied for the large scale protein purification. Third, the cost ProCA production 
needs to be reduced. For mice (20 - 30 g) study, 0.5 mg of ProCA3 is required as the minimium 
dosage for the enhancement of the kidney. Because dog and human has more than 1000 times 
high body weight than that of mice (20 kg for dog and 60 kg for human), by direct projection of 
the injection dosage by body weight, MRI requires 0.5 g and 1.5 g of ProCA3 for the injection in 
dog and human, respectively. Mice has much faster metabolism than that of human and dog, 
thus mice usually requires 20 times higher injection than that of human and dog. By considering 
the metabolism, it is still requires 250 mg and 750 mg of the ProCA3 as the minumium injection 
dosage for MRI. Thus, large scale expression and purification with GMP-like protocol is im-
portant for further potential applications of ProCA3 in large animals and human.  
In this chapter will first introduce our strategies for further modification of ProCA3 by 
PEGlytion. I will then discuss our effort inhumanization of PrcA3 series. Next, I will introduce 
our efforts on the large scale expression and purification of ProCA3 based on our intial studies 
on protein expression and purification discussed in Chapter 3. 
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9.2 Results 
9.2.1 PEGlytion of ProCA3 variants 
PEGLytion can increase the solubility, decrease immunogenicity of the protein drugs. To 
improve the in vivo properties of ProCA3, PEG-40 was covalently linked to ProCA3 through the 
lysine residues. The general procedure for PEGlytion is shown in Fig. 9-1. In brief, ProCA3 were 
dialysised aganist PBS or HEPES buffer to completely remove Tris with free amine. PEG was 
mixed with ProCA3 with 3:1 ratio. The mixture was incubated at room temperature for 2 hours 
with constant shaking. Then, the mixture was separated by FPLC. 
PEGlyted ProCA3 can be purified by High Trap Q column, after washing out the un-
bounded chemicals, the PEGlyted ProCA3 was eluted with 10 mM Tris/HCl, pH 8.5, 5 mM EGTA 
and 1 M NaCl. Both comassie brilliant blue and iodine staining of SDS-PAGE gel were used to 
detect FPLC fractions. Commassie brilliant blue were used to stain the protein bands and iodine 
were used to stain PEG moiety. As shown in Fig. 9-2, fraction 2-9 has a very large UV absorb-
ance from FPLC detector. This peak contains large amount of PEG and this peak only have very 
small amount of protein. Fraction 17-20 can be stained by both iodine and commassie brilliant 
blue, which indicate that fraction contains PEGlyted ProCA3. 
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Figure 9-1. General procedure for the PEGlytion of ProCA3 varients. 
ProCA3 varients were first dialyzed with PBS or HEPES buffere. Then the ProCA3 variants and 
PEG-NHS ester were mixed with 1:3 molar ratio and incubated at room temperature for 2 hour 
with constant shaking. Unreacted PEG-NHS ester were quenched by adding  Tris/HCl at pH 7.0 
with a final concentration of 10 mM. PEGlyted ProCA3 were further seperated by FPLC, staining 
by I2 and comassie briliant blue in SDS-PAGE. The fractions contains PEGlyted ProCA3 variant 
dialysised and concentrated for other type of studies. 
PEGylation
Dialysis the protein in PBS
Mix the protein and PEG with 1:3 ratio
Shake at room temperature for 2 hour
FPLC separation
Staining
Dialysis
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Figure 9-2. FLPC separation of PEGlyated ProCA3 variants. 
The FPLC fractions were analysised by UV detector equipped in FPLC (A), SDS-PAGE by I2 stain-
ing (B) and coomassie brilliant blue staining (C). 
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9.2.2 Humanization of ProCA3 variants 
Since our final goal is to apply our designed ProCA in clinical, it is extremely important to 
avoid immunogenicity. One strategy to avoid immunogenicity is humanization of the designed 
protein.  The original ProCA3 is derived from rat PV, and there are 9 residues differences be-
tween human and rat PV (Fig. 9-3).  Among these 9 residues, only 1 residue is located on our 
engineer metal binding sites. 
The DNA of Humanized ProCA32 was synthesized and incorporated in pBluescript plas-
mid by DNA synthesis. Nde I and Xho I cleavage sequences were designed at 5’ and 3’ terminal 
of ProCA32 DNA. The plasmid was amplified by E. coli DH5α strain. Humanized ProCA32 was 
digested by Nde I and Xho I and then inserted into PET22b vector. DNA sequencing results 
shows that humanized ProCA32 were inserted into pET22b vector.  
Next, we will express, purify humanized ProCA32 and test its in vitro and in vivo proper-
ties such as relaxivity, metal binding affinity and selectivity. We will further evaluate its proper-
ties for MRI. 
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Figure 9-3. Protein sequence alignment between rat_ProCA30, rat_ProCA32 and humanized 
ProCA32.  
Amino acids with red letter and yellow highlights indicate the amino acid difference btween 
human and rat ProCA32. Amino acids with green highlights indicate the key mutations in rat 
and human ProCA32 to improve the Gd3+ binding affinity. 
 
  
Rat_ProCA30        MSMTDLLSAEDIKKAIGAFTAADSFDHKKFFQMVGLKKKSADDVKKVFHILDKDKSGFIE 60 
Rat_ProCA32        MSMTDLLSAEDIKKAIGAFTAADSFDHKKFFQMVGLKKKSADDVKKVFHILDKDKDGFIE 60 
Human_ProCA32      MSMTDLLNAEDIKKAVGAFSATDSFDHKKFFQMVGLKKKSADDVKKVFHMLDKDKDGFIE 60 
                   *******.*******:***:*:***************************:********** 
 
Rat_ProCA30        EDELGSILKGFSSDARDLSAKETKTLMAAGDKDGDGKIGVEEFSTLVAES 110 
Rat_ProCA32        EDELGSILKGFSSDARDLSAKETKTLMAAGDKDGDGKIGVEEWSTLVAES 110 
Human_ProCA32      EDELGFILKGFSPDARDLSAKETKMLMAAGDKDGDGKIGVEEWSTLVAES 110 
                   ***** ******.*********** ************************* 
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9.2.3 Large scale expression and purification of ProCA3 variants 
To study the MRI properties of ProCA3 for larger animals and applications of ProCAs in 
various diseases, a good manufacturing practice (GMP)-like method with high efficiency, high 
repeatability and low cost for ProCA3 expression and purification are highly required. However, 
the current expression, purification cannot meet such requirement. A GMP-like methods should 
be low cost, and should be able to scale up without modification of the protocols. In cooperate 
with Dr. Pierce at Georgia State University, we established the GMP-like protocol for the large 
scale expression and purification of ProCA3 variants.  
9.2.3.1 Large scale expression of ProCA3 by fermentation.  
To large scale expression of ProCA3, ProCA32 DNA was first transformed in BL21-DE3-
plysS bacteria. ProrCA3 expressing cells were adapted to ECAM media from LB medium. 1 ml of 
a glycerol stock of ProCA32 expressing bacteria were then transferred to 100 ml ECAM and 
shake over night at 37 ˚C at 150 rpm. 10 ml of the culture was transferred to 250 ml ECAM me-
dium and incubate at 37 ˚C and 200 rpm for 6 hours. 120 ml of these bacteria were used as an 
inoculum for the bioreactor.  
The bioreactor were setup as follows: Initial glucose concentration 21g/L ; Batch media 
contained 50ug/ml carbenicillin; Vessel was inoculated to give 1.5x10-2 cells ; oxygen 
conenctration was set  to 30% and maintained with stirrer (min= 160 rpm, max = 450 rpm) and 
Gas Mix; Air flow was constant at 10LPM.  
Table 9-1 and Fig. 9-4 show the fermentation conditions during ProCA32 expression in 
bioreactor. The pH, temperature, oxygen level were kept constant during ProCA32 expression. 
The oxygen level was controlled by adjusting the speed of stirrer. 0.5 mM IPTG were added 
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when OD (AU) value reached 38. As show from Fig. 9-5, ProCA32 were expressed 1-3 hours af-
ter IPTG induction. The bacteria were harvest by Carr Powerfuge and the final yield is about 
1000 g bacteria pellet from 12 liters of media.  
  
263 
Table 9-1. Fermentation data during ProCA32 expression in bioreactor*. 
Time pH T  
(˚C) 
dO2 Air Flow 
(LPM) 
Stir-
rer(rpm) 
[G] 
g/L 
Feed rate 
(ml/min) 
OD (AU) 
Spec 
13:96 6.88 30.1 29.8 10.5 438 5 0 16 
14:30 7:03 30  10.5 289 0 10  
14:94 6.89 30 23.4 10.5 459 0 14  
15.39 7.00 30 53.2 10.5 360 0 18 35 
16.63 
(I) 
7.09 30 29 10.5 449 0 18 38 
17.69 6.95 29.9 33.7 10.5 396 0 18 42 
18.69 6.92 30 29.7 10.5-11.14 402 0 18 48 
19.90 6.92 30 29 9.67-15.81 459 0 18 56 
* Data were collected by Trudy and Yaoyao from Dr. Pierce’s lab at GSU. 
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Figure 9-4. Fermentation data during ProCA32 expression in bioreactor. 
Difference color shows the real time conditions of temperature, oxygen level, pH, air flow, stir 
rate and glucose level in the bioreactor. 
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Figure 9-5. ProCA32 expression by fermentation. 
No ProCA expessed before IPTG induction. ProCA32 with a molecular weight of 11 kDa pointed 
by arrows were expressed 1 hour post IPTG induction and highest level of ProCA32 expression 
can be found 3 hour post IPTG induction.  
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9.2.3.2 Explore the methods for large scale purification of ProCA3 by fermentation. 
To ensure the production of same quality of protein, a method for large scale purifica-
tion of ProCA3 variants is highly required. Such method must be easily adapted to the GMP-like 
system without change of the protocol. This method should also cost less. With the help from 
Fengkun Du from Dr. Peirce’s lab at GSU, we established a new purification methods with less 
cost and ability to purify huge amount of protein.  
Figure 4-6 shows our procedure of the new protocol for the protein purification. In brief, 
different concentration of PEG-8000 was added to the supernatant of the cell lysate. Due to the 
differences of the solubility and molecular weight, different proteins will be precipitated at dif-
ferent concentration of PEG-8000. The concentration of PEG-8000 for ProCA32 precipitation 
were determined by SDS-PAGE.  
As shown from Fig. 9-7, the majority of junk proteins were precipitated at PEG-8000 
concentration below 250 mg/l. ProCA32 was mainly precipitated at PEG-8000 concentration 
between 250 and 400 mg/l. However, only about 80 % purity of ProCA32 was achieved after 
PEG-8000 precipitation.   
We then use FPLC to further purify this protein. ProCA32 precipitate by PEG-8000 was 
dissolved in HEPES buffer at pH 7.0. These protein solution were load to Hi-trap Q column. After 
binding to the column, the unbounded components were first washed out with 7 column vol-
ume (CV) of buffer A (10 mM HEPES buffer at pH 8.0). Then, buffer B (10 mM HEPES buffer, 1 M 
NaCl at pH 8.0) concentration were increase to 25 % within 7 CV. We further wash the column 
with 25% of buffer B for 2 CV and then increase to 100 % of buffer B of 1 CV to wash out every 
component bounded to the column. At last, the column were requilibrium with 100% buffer A 
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for 5 CV. As show from Fig. 9-8 ProCA32 was eluted from peak 20-24 and peak 37-33 with im-
proved the purity. Other peaks contain unwanted protein and/or DNA.   
At last, since ProCA32 is very stable at 90 ˚C, we further incubate the purified ProCA32 
at 90 ˚C for 20 min and followed by a centrifugation at 6000 rpm for 30 min to remove residue 
from final products. As shown from Fig. 9-7, above 99% purity of ProCA32 were achieved after 
this step. Therefore, an efficient method for large scale purification of ProCA32 was established. 
We will further compare the in vitro and in vivo properties of ProCA32 purified from different 
purification methods. 
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Figure 9-6. New procedure for the ProCA32 purification. 
After lysate the cell, different concentration of PEG-8000 was added to the supernatant of the 
cell lysate. Due to the differences of the solubility and molecular weight, proteins and other bi-
omolecules will be predicated at different concentration of PEG-8000. The concentration range 
of PEG-8000 for ProCA32 precipitation was determined by SDS-PAGE. We further use FPLC to 
purify ProCA32. At last, FPLC frac ons with ProCA32 elu on were incubated at 95   C water bath 
for 10-20 min followed by centrifugation to further remove unwanted proteins. 
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Figure 9-7. ProCA32 purification by PEG precipation. 
Red arraw indicate the position of ProCA32 on SDS-PAGE. The majority of junk proteins were 
precipitated at PEG-8000 concentration below 250 mg/l. ProCA32 was mainly precipitated at 
PEG-8000 concentration between 250 and 400 mg/l. However, only about 80 % purity of 
ProCA32 were achieved after PEG-8000 precipitation.   
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Figure 9-8. FPLC purification of ProCA32 after PEG separation. 
A. After injection, 6 peaks, marked as P1, P2, P3, P4, P5 and P6 were eluted out of from HiTrap-
Q colume under different concentration of buffer B (10 mM HEPES, 1 M NaCl at pH 8.0). B. SDS-
PAGE analysis of each peaks eluted out from Q column. M: marker; 1. frac on P2 and heat at 
95   C for 10 min; 2. Frac on P5 and heat at 95   C for 10 min 3. fraction P2 without heat; 4. frac-
tion P4 without heat. 
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9.3 Discussion 
9.3.1 PEGlytion 
PEGlytion greatly improved the solubility and decrease the immunogenicity of the pro-
tein drugs. PEGlytion on ProCA1 also increase the relaxivity by optimizing water numbers and 
exchange rate of Gd3+. Using the similar procedure, we modified the ProCA3 variants with PEG-
40. To our surprise, the PEGlytated and Gd3+-loaded ProCA3 can be concentrated as high as 8 
mM without precipitation.  
In our study, we use PEG-40-NHS ester to react with lysine residues of ProCA3. By our 
conjugation methods, we can conjugate 1-4 PEG-40 into ProCA3. Since the molecular weight of 
each PEG-40 is about 2.4 kDa, the total molecular weight of PEGlytated ProCA3 is between 13.4 
- 20.6 kDa. A protein with a molecular weight less than 60 kDa can easily filtered by the xx cells 
in kidney. Therefore, PEGlytated ProCA3 should be excreted through kidney. We are also inter-
ested to test the changes of relaxivity in ProCA3 after PEGlytion. 
ProCA3 has 16 lysine residues. Therefore, it is very hard to control the numbers of PEG 
being conjugated and it is also very hard conjugate PEG at specific lysine residue. An alternative 
way is to conjugate PEG at Cys. We added a Cys at the C terminal of ProCA3 variants. We will 
specifically conjugate PEG to this ProCA3 variants through the interaction between SH group 
and maleimide group in PEG. 
The length and number of conjugated PEG are closely related with in vitro and in vivo 
properties of ProCA3, such as relaxivity, blood retention time, excretion, and tumor tissue pen-
etration. We will further optimize our conjugation protocols such as the conjugation ratio, resi-
dues and size of PEG to optimize the in vitro and in vivo properties of ProCA3.  
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9.3.2 Humanization of ProCA3 
Humanization is another important method for us to further reduce the immunognecity 
of ProCA3. ProCA3 is derived from rat PV with several mutations on the metal binding sites. The 
human PV sequence, however, has 9 amino acid differences from rat PV. Thus, to further re-
duce the immunogenicity, we synthesized the human ProCA3 DNA and inserted this human 
ProCA3 DNA in the pET22b vector for protein expression in E. coli.  
Our next step is to express and purify the humanized ProCA3 from bacteria and test the 
in vitro and in vivo properties of humanized ProCA3. We will measure the metal binding affinity, 
metal selectivity, relaxivity, serum stability, immunogenicity of humanized ProCA3 and compare 
the differences between rat ProCA3 and human ProCA3. Since these is no protein sequence dif-
ferences on the Gd3+ binding sites between human and rat  ProCA3, we expect that the metal 
binding affinity, metal selectivity and relaxivity of human ProCA3 are the same as rat ProCA3. 
Due to the amino acid differences, human ProCA3 should have better in vivo properties. 
9.3.3 Large scale expression and purification of ProCA3 
The expression of ProCA32 by LB medium with constant shaking is time consuming and 
low efficient. Only about 5 g of bacteria pellets can be obtained from 1 liter LB media.  Using 
fermentation methods, about 1000g bacteria pellets were expressed from 12 liter medium with 
continuous feeding of glucose, which is about 15 times higher yield than that of LB medium 
with constant shaking. SDS-PEGE results show that ProCA3 are highly expressed in this bioreac-
tor. Thus, we could obtain 15 time higher amount of ProCA3 using fermentation within two 
days. Moreover, such GMP-like fermentation methods can be easily scale up to the bioreactor 
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with much larger the culture volume. Such unique feature made this new method easily applied 
for the large scale expression of ProCA3 in the factory. 
The previously ProCA3 purification methods includs heating and dialysis steps. Such 
steps cannot be applied for ProCA3 purification when the sample volume increases.  In our new 
purification methods, ProCA3 and different unwanted proteins were precipitated at different 
concentration PEG, ProCA3 and small amount of unwanted were precipitated when the PEG 
concentration reaches 250 mg/ml. We then dissolve the precipitated ProCA3 fraction in buffers 
and further purify this protein by FPLC. In principal, this new purification procedure can be ap-
plied to the large scale purification ProCA3. 
9.4 Conclusion 
In this chapter, the ProCA3 is optimized by PEGlytion and humanization. A protocol for 
PEGlyation and GMP-like expression and purification of ProCA3 was established. This expres-
sion of ProCA3 using fermentation method shows more than 20 times high yield of the protein 
expression. 
 We also successfully established GMP-like mehod for protein purification. This new es-
tablished method use PEG to precipate ProCA3 and then further purified by FPLC Qcolumn. This 
new method does not have limitation for scale up, because all the limitation factor for large 
scale purification such as dialysis and high temperature incubation.Thus, we are able to pro-
duce ProCA3 with fewer costs and we could potentially also decrease the immunogenicity of 
ProCA3.  
We further compared the in vitro and in vivo properties between humanized ProCA3 
and rat ProCA3. Our preliminary data of UV, fluorescen, NMR and Tb3+ binding assay shows that 
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there are no differences in the protein structures and metal binding of proteins purified from 
traditional methods in Chapter 3 and new methods in Chapter 9. 
In addition, we constructed the human sequence of ProCA32 by DNA synthesis. We will 
express, purify and test its in vitro and in vivo properties of the humanized ProCA32 in the near 
future.  
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10 MAJOR DISCOVERY AND SIGNIFICANCE 
 As discussed in Chapter 1, the current application of MRI with advangae of non-invasive 
and depth tissue penetration without using radiation are largely due to the limitations of avail-
able MRI  contrast agent especially low relaxivity assocated with low sensitivity and specificity 
and unble to apply for molecular imaging in vivo. In the past 10 years, our lab developed a nov-
el class of MRI contrast agents using protein as Gd3+ chelator. The protein-based MRI contrast 
agents (ProCAs) have more than 10 times higher r1 and r2 relaxivity than that of clinical MRI 
contrast agents. Such high relaxivity improves the dose efficiency in vivo. In addition, because 
of the high relaxivity and longer blood rention time, the targeted ProCA1 variants can be ap-
plied for molecular imaging of biomarker using MRI for the cancer diagnosis. However, the 
metal stability and metal selectivity of the first generation of ProCA needs to be improved for in 
vivo application.  In our effort in improving metal binding affinity and addition of multiple bind-
ing sites for the first generation of contrast agent, we encoured problems associated with lim-
ited solubility and protein stability. The large scale of protein production as well as the applica-
tion of ProCAs for the diagnosis has not been fully explored.  
In my Ph.D. dissertation studies detailed in Chapters 2 to 9, I have developed a novel 
class of MRI contrast agents, ProCA3 series, by protein engineering in collaboration with 
collabrators and team members to address the pressing needs for better MRI contrast agents. 
Various techniques have been applied to answer several key questions in developing new types 
of contrast agents:  
1). Can we develp a new generation of MRI contrast agents with multiple Gd3+ binding sites? 2). 
Can we improve the metal stablity and metal selectivity of ProCA so that we can prevent the 
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Gd3+ resease in vivo? 3). Can we tune the relaxivities of ProCAs by protein design? 4). Can we 
design MRI contrast agents for liver imaging? 5). How early the metastatic tumor can be de-
tected by MRI? 6). What is the smallest size of tumors can be detected? 7). Can we improve ac-
curacy and specificity of tumor detection by taking advantage of both r1 and r2 values of ProCAs?  
We developed a novel class of MRI contrast agents, ProCA3 series, by protein engineer-
ing. By introducing single mutation S56D in EF-hand I of PV, the Gd3+ binding affinity increase 
more than 1010 fold, while the binding affinity to physiological metal ions, such as Ca2+ and Zn2+, 
only has less than 10 fold increases. This is the first study shows that Gd3+ binding affinity can 
be improved 1010 fold by single mutation with highly desired metal selectivities. We also devel-
oped a novel method to measure Gd3+ binding affinity of contrast agents with controlled Tb3+-
DTPA buffer system. Using this metal-chelator system, the free Gd3+ concentration can be accu-
rately controlled between 10-23 and 10-17 M. The Gd3+ binding affinity measured by this novel 
approach, 2.79 × 10-22 M, is the reported lowest Gd3+ binding affinity in the literature (Chapter 
4).  
By protein design, we are also able to control the relaxivity of protein contrast agents. A 
single mutation E60D from ProCA32 increases the per Gd r1 relaxivity from 30 mM
-1s-1 to 59 
mM-1s-1. We further demonstrated that such robust increase of relaxivity is caused by introduc-
ing additional water ligand interaction to the designed MRI contrast agents (Chapter 4). 
Due to high relaxivity, ProCA3 has detection limits of 2 µM, which is 15 times higher 
than the reported detection limit of clinical MRI contrast agents.10 Considering such high 
relaxivity, we are able to imaging kidney with an injection dosage of 60 fold lower than the clin-
ical injection dosage of Magnevist (0.1-0.2 mmol/kg) (Chapter 5).  
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We demonstrated that non-targeted ProCA3 can be applied for the imaging of blood 
vessel, liver and kidney with about 10 times lower injection dosage than that of clinical MRI 
contrast agents. By both T1-weighted and T2-weighted MRI, ProCA3 variants are able to image 
liver metastases of uveal melanoma with a size less than 0.25 mm, while current clinical ap-
proach can only detect tumors with high confidence with a size larger than 1 – 2 centimeters. 
(Chapter 5) ProCA3 variants also has a lot of advantage to be applied to the dynamic contrast 
enhanced MRI (Chapter 6).In addition, we developed bi-briliant dualweighted imaging method-
ology, which utilizes both high r1 and r2 properties of our contrast agents for the improvement 
signal differences between tumor and liver. Our work opens a new avenue for the early diag-
nostics of tumor metastases to liver, and has great influence for the tumor early detection and 
treatment. Our work also demonstrate that targeted ProCA3 variants can be applied to semi-
quantitative evaluation of tumor biomarkers using MRI, and targeted ProCA3 variants have 
great potential to detect tumor and evaluate tumor progression and facilitate personalized 
medicine for tumor treatment. 
We also show that ProCA3 has longer blood circulation time, which made more easy and 
quantitative to accurately measure AIF. In addition, we are able to calculate ProCA3 concentra-
tion in different tissues based on the DCE-MRI data and T1 map. These features made ProCA3 as 
the ideal candidate for evaluate tumor vasculature, renal perfusion by DCE-MRI. (Chapter 6) 
In this work, we demonstrate that ProCA3 shows excellent safety profile and pharmaco-
kinetics for MRI imaging. ProCA3 has no toxicity to cells and mice. With the lower dose of injec-
tion, ProCA3 shows less Gd3+ accumulation than GdCl3 and Gd-DTPA in the natural Gd
3+ 
biodeposit organs, such as liver, spleen, lung and bone. Our safety and pharmacokinetics stud-
278 
ies will facilitate the clinical application of ProCA3 for the early diagnostics of cancer. (Chapter 
7)  
We developed tumor specific MRI contrast agents for the molecular imaging of tumor 
biomarkers. These novel targeted ProCA3s variant can binds to biomarkers such as GRPR, HER-2 
and integrin αvβ3 with high specificity and targeted ProCA3 has great potential to detect tumor 
location, tumor size, evaluate tumor progression by semi-quantitavie (Chapter 8) 
We also successfully established GMP-like mehod for protein purification. This new 
method does not have limitation for scale up, because all the limitation factor for large scale 
purification such as dialysis and high temperature incubation.Thus, we are able to produce 
ProCA3 with fewer costs and we could potentially also decrease the immunogenicity of ProCA3. 
In addition, we constructed the human sequence of ProCA32 by DNA synthesis. These effects 
pave the way for the potential clinical application of ProCA3 variants for MRI diagnosis. 
The development of designed contrast agents and in vivo imaging methodology is ex-
pected to significantly improve sensitivity and specificity for liver tumor imaging. It enables non-
invasive early detection primary liver tumors and metastatic tumors at 0.1 mm from the current 
threshold of 20 mm or larger. Such improvement will greatly facilitate the development of 
proper treatment strategies, such as liver transplantation or locoregional treatment. It will sig-
nificantly increase the accuracy of image-guided biopsies and regional treatment. Hence, This 
work will bring improvement to a large segment of the patients afflicted with HCC or metastatic 
liver malignancy. Finally, the reagents developed in this application could have far-reaching im-
plications in the diagnosis of other malignancies, which in turn would facilitate development of 
targeted treatment along with effective monitoring of reduction of tumor burden.  
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APPENDICES  
Appendix A. Identification of Ca2+ - binding sites in rotavirus 
Appendix A.1 Introduction 
Rotavirus infection is the most common cause of diarrhoea whcich causes 20 - 60 deaths 
in the United States and around 610,000 deaths globally eververy year. In addition, rotavirus 
infection cause more than 600,000 and 24 million of outpatient visit in the United States and 
the whole world, respectively.224 Thus, understanding the physiological and pathological mech-
anism of rotavirus replication, preliferation and duplication of rotavirus is very important.  
Rotavirus is a double-strend RNA virus in the family Reovirididea. The genome of rota-
virus encodes 7 viral proteins (VP) and 6 nonstructural proteins (NSP). The viral proteins of ro-
tavirus form three layers of capsid to encapsulate RNA genome. The outer capsid of rotavirus is 
formed by VP4 and VP7. Timers of VP4 form the outer capsid spikes. The infectivity of rotavirus 
in increased when VP4 is cleaved to be VP5* and VP8*. VP7 is an outer capside glycoprotein, 
which also determines the type of rotaviruses. VP6 is the major protein forms the middle capsid 
of rotavirus and VP6 is also involved in the rotavirus transcription. VP1, VP2 and VP3 are locat-
ed the inner capside of rotavirus. VP1 is a RNA-dependent RNA polymerase. It binds to single-
strand RNA and forms a transcription complex with VP3. VP2 is the inner capsid protein, which 
regulate the replicase activity of VP1. In addtions, rotavirus also encodes 6 nonstructural pro-
teins. Althought these nonstructureal proteins are not a component of the viral structure, non-
structural proteins plays essential roles on almost every aspect of the viral replication, 
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preliferation, invasion. Among these nonstructural proteins, NSP4 has been identified as a vrial 
enterotoxin inducing diarrhoea.225 
Intracellular and extracellular Ca2+ plays important roles on the rotavirus induced diar-
rhea. The structural proteins of rotavirus form viral capsid in the high concentration of Ca2+, 
while these proteins disassembled at low concentration of Ca2+. Such phanomonan is closely 
related with physiological condition of rotavirus infection. The calcium concentration in the ex-
tracellular space is around 1 mM and rotavirus is well packed as triple-layered particle at such 
conditions. When the rotavirus entere the cell through endocytosis, the Ca2+ concentration of 
rotavirus decrease. As a result, the outer layer of the capsid is solubilized at low concentration 
of Ca2+ abd the double-layered particle is released into the cytosol of the cell. In addition, NSP4 
can disrupt Ca2+ homostasis by two ways. Fisrt, NSP4 is believed to form the membrane Ca2+ 
channel which increase intracellular Ca2+ concentration because of Ca2+ entery from ER or ex-
tracellular space through this channel. Second, NSP4 is able to intrigue membrane receptors, 
such as integrin, to activate PLC-γ. The activated PLC-γ converts PIP2 to be IP3. IP3 can induce ER 
calcium release by activating ryanondine receptors. This process can further cause secretory 
diarrhea because the intracellular Ca2+ homostasis is disrupted. 
Although Ca2+ plays essential roles on the rotavirus replication, proliferation and infec-
tion, the Ca2+ binding sites on rotavirus is not clear.  Ca2+ were loaded in the x-ray structure of 
intersubunit of VP7226 Gajardo and coleagues227 report two prolin redidues are essential in the 
calcium binding activity of VP7. However, this paper does have direct evidence to sopport that 
an EF-hand like motif in VP7 binds Ca2+. Our lab develop a series of computational approach to 
predict the Ca2+ binding sites in proteins based on the primary sequence and x-ray or NMR 
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structures.115 We also developed grafting approach and Tb3+-LRET assay to identify the predict-
ed Ca2+ binding sites. Here, we will report our preliminary data of the indentification of Ca2+ 
binding sites in VP1 and VP7 of rotavirus. 
Appendix A.2 Meterial and Methods 
The calcium binding sites of rotavirus were predicted by MUG software developed in 
our lab.115 The pdb structures of rotavirus proteins were downloaded and inputed into the 
MUG software (http://chemistry.gsu.edu/faculty/Yang/Calciomics.htm). The MUG software 
then predicted calcium binding sites based on the oxygen position and distance of inputed 
structures. Three and one Ca2+ binding sites were predicted from VP1 and VP7 of rotavirsus, 
repectively.  
The predicted calcium binding peptides were then inserted between S52 and G53 posi-
tion of domain 1. pGEX2T-CD2 plasmid was used as a template for this insertion by PCR. The 
correct insertions were identified by DNA sequencing. The proteins were expressed by E. coli, 
BL-21-DE3-plysS cell strain and then purified by GST column.  
To identify Ca2+ binding sites in these purified proteins, 2 µM of protein were added into 
10 mM PIPS buffer at pH 6.8. Then, Tb3+ were titrated to the buffer with gradually increase of 
concentration. Fluoresecent spectrum was collected in every titration steps at excitation wave-
length of 280 nm and emission wavelength between 520 – 580 nm. The dissociation constants 
of these grafting proteins were calculated by 1 to 1 binding Equation based on the fluorescence 
intensity over different concentration of Tb3+. 
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Appendix A.3 Results and Discussion 
To predice calcium binding sites in rotavirus, all the pdb structures of rotavirus were 
downloaded and inputed into the MUG predication software. The predicted results from MUG 
were further evaluated by the number of negatively charged residues, electrostatic static sur-
face environment. Three Ca2+ binding sites were predicted from VP1 (pdb: 2R7O) (Fig. Appedix-
1) and one Ca2+ binding site was predicted from VP7 (pdb: 3FMG) (Fig. Appendix-1).  
The predicted site 1 (519 THR, 520 ASP, 525 ASP, 629 ASP, 631 ASP, 632 ASP) has been 
reported as a Mg2+ binding site in the x-ray structure of VP1,228 this is understandable as Mg2+ 
and Ca2+ shares similar but the exact same metal binding sites and calcium binding site in na-
ture could also binds Mg2+ in nature. In addition, the predicted Ca2+ binding sites in VP7 are 
consistent with the reported regions which are essential in the calcium binding activity of VP7. 
These results strongly indicate that our prediction method is acturate.  
Interestingly, we finding additional two predicted Ca2+ binding sites is the VP1 structure. 
The reseasions why these Ca2+ binding sites are not visualized in the x-ray stucture are probably 
due to weak Ca2+ bindig or conditions for growing crystals.  
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Figure Appendix-1. The predicted Ca2+ binding sites in rotavirus VP1 (top) and VP7.  
Three Ca2+ binding sites were predicted from VP1 (pdb: 2R7O) and one Ca2+ binding site was 
predicted from VP7 (pdb: 3FMG) by MUG based the geometry information of oxygen. The MUG 
predicted results were further analyzed and identified based on the residue type and electro-
static environment.  
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Grating approached coupled with Tb3+-LRET assay were applied to further identify the 
predicted Ca2+ binding sites in VP1 and VP7. 2 µM CD2 grafted with predicted Ca2+ binding site 
in VP1 (site 3) an VP7 shows much dramtic fluoresecence increase compared with CD2 without 
any insertion (Fig. Appendix-2). Both of VP1 and VP7 insertion peptide shows Tb3+ binding with 
Kd of 13.8 µM and 42.5 µM, respectively.  Since the VP7 peptide has been reported to involves 
in the calcium binding activity of VP7, our result provide additional support that this peptide 
directly binds to VP7 through residue 270 ASP, 271 ILE, 272 THR, 274 ASP,  and 277 THR. In ad-
dition, a novel Ca2+ binding site in VP1 of rotavirus  (376 GLU, 377 GLU, 378 PRO, 379 VAL, 380 
LYS, 382 ASP, 383 ASP) is identified by MUG prediction and Tb3+-LRET assay. Since VP1 envolves 
in RNA synthesis, single chain RNA binding, and transcription, our identified Ca2+ binding sites in 
VP1 should involves in the regulation of these functions. However, this results are preliminary 
studies. More expriments, such as Ca2+ competitation, should be applied to further confirm that 
these two sites bind Ca2+ and have physiological functions. 
Appendix A.4 Conclusion 
Two Ca2+ binding sites in rotavirus were identified by computational approaches and 
fluorescence spectroscopy. The identified Ca2+ binding sites may involve in the rotavirus assem-
bling, RNA synthesis, single chain RNA binding, and transcription. 
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Figure Appendix-2. Identification of Ca2+ binding site in rotavirus by grafting approach (A) and 
LRET assay (B, C).  
A. A carton represention of grafting approach. The predicted Ca2+ binding peptide is inserted 
into the CD2 between position S52 and G53.112 B. Tb3+-fluorescence increase with the increase 
of Tb3+ concentration. C. Calculation of dissociation constant of Tb3+ to VP1 peptide and VP7 
peptide by fitting 1 to 1 binding Equation. As a control, wild type CD2 shows much less fluores-
cence increase compared with the CD2 grafted with predicted VP1 or VP7 binding peptide. 
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Appendix B. Prediction of Ca2+ binding sites in neuronal proteins 
Ca2+ is a unique signal moelcular which regulate almost every aspect of the cellular activ-
ities including gene replication, cell perliferation, fertilization, secretion, migration, and apopto-
sis. The Ca2+ homostasis is well maintained by calcium channels, pumps, exchangers, receptors, 
calcium buffer proteins and Ca2+ proteins in different part of cellular environment.  Errors in any 
step of Ca2+ signaling could cause abnormal cell activities.112 Ca2+ also plays important roles on 
the neuron activities. Prediction and identification of Ca2+ binding sites in neuronal proteins is 
an important step to uncoding the physiological functions of these proteins. 
Some Ca2+ responsive proteins, such as calmodulin (CaM), regulate cell functions by interacting 
with other proteins in a Ca2+ dependent manner.CaM is reported to interact with more than 
100 hundred proteins to regulate the function of these proteins. CaM binding motifs are divid-
ed into five classes: 1–10 class, 1–14 class, 1–16 class, IQ class and others. Among them, the 
first three classes have been found to interact with CaM almost exclusively in a Ca2+-dependent 
way while, IQ motif binds to CaM in a Ca2+ independent manner. A web-based served named 
calmodulin targeting data base has been developed to predict the possible CaM binding sites in 
proteins.115 
In the past ten years, our lab developed serveral computational methods to predict Ca2+ 
binding proteins in the different type of biological system. We also developed in vitro and in 
vivo experimental methods to identify these predicted Ca2+ and CaM binding sites. In this ap-
pendix, we will show some predicted Ca2+ and CaM binding proteins involves in neuron system. 
The Ca2+ binding sites can be predicted based on the primary amino acid sequences and 
x-ray structures. Based on the pattern search using online server, CaPS 
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(http://chemistry.gsu.edu/faculty/Yang/Calciomics.htm), three proteins (Dicer: 
NRNQDNYVSWSD; lrrk2: DLNTEGYTSEEVAD; Cdk5: DDDDEGVPSSALRE) are predicted to have 
putitive Ca2+ binding sites. In addition, we predicted calcium binding sites in CDK5 and exportin-
5/ranGTP/pre-miRNA complex by MUG software based on the reported x-ray structure of these 
two proteins. The key residues predicted to binds Ca2+ are shown in Fig. Appendix-3, and 4. The 
predicted Ca2+ binding sites were analyzed electrostatic surface map. Both of these two pre-
dicted Ca2+ binding sits are located in the negative charge area of protein, this analysis further 
support that the predicted Ca2+ binding sites could be the real Ca2+ binding sites in these two 
proteins. We predicted another Ca2+ binding sites in x-ray structure of MEF2 using MUG. How-
ever, this predicted Ca2+ binding site is less likely to be true, because the electrostatic surface 
analysis shows that this predicted Ca2+ binding site is located in the positive charged region of 
protein (Fig. Appdendix-5).  
Since CaM is an important Ca2+ responsive protein regulating cell activities. We also 
tried to predict CaM binding proteins using CaM target database ( 
http://calcium.uhnres.utoronto.ca/ctdb/ctdb/). The prediction is based on the following crite-
ria: hydropathy, alpha-helical propensity, residue weight, residue charge, hydrophobic residue 
content, helical class and occurrence of particular residues. Three proteins (dicer, Clc7 and 
exprotin 5) with 6 putative CaM binding sites were predicted with a maxium score of 13 – 14. 
Thus, Ca2+ could regulate the function of these three proteins through CaM interaction. 
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Figure Appendix-3. The predicted Ca2+ binding site in CDK5 by MUG.  
A. X-ray structure of CDK5 with the Ca2+ binding sites highlighted in green. B. The predicted Ca2+ 
binding pocket in CDK5. C. Electrostatic map of CDK5. The Ca2+ binding site (red cycle) is located 
in the negative charged ragion of CDK5. 
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Figure Appendix-4. The predicted Ca2+ binding site in exportin-5/ranGTP/pre-miRNA complex 
by MUG. 
A. X-ray structure of exportin-5/ranGTP/pre-miRNA complex with the Ca2+ binding sites high-
lighted in green. B. C. The predicted Ca2+ binding pocket in exportin-5/ranGTP/pre-miRNA com-
plex. D. Electrostatic map of CDK5. The Ca2+ binding site (red cycle) is located in the negative 
charged ragion of exportin-5/ranGTP/pre-miRNA complex. 
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Figure Appendix-5. The predicted Ca2+ binding site in MEF2 complex by MUG. 
A. X-ray structure of MEF2 with the Ca2+ binding sites highlighted in green. B. C. The predicted 
Ca2+ binding pocket in MEF2. D. Electrostatic map of CDK5. The Ca2+ binding site (red cycle) is 
located in the negative charged ragion of MEF2. Based on the election potential map, the pre-
dicted Ca2+ binding site is less likely to be true. 
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Figure Appendix-6. The predicted calmodulin binding sites in neuronal proteins.  
The calmodulin binding sites were predicted by calmodulin targeting database. The normalized 
scores are shown below the amino acid to indicate the key residues involves in the CaM bind-
ing.  
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Appendix C. Relaxivity simulator 
As shown in chapter 1, the relaxivities of MRI contrast agents are determined by many 
parameters, such as correlation time, Gd-H distance, water cooridination number, water ex-
change rate. The factors can be described by SMB equation. For details, please see chapter 1. In 
principle, the influence of relaxivities by these factors can be simulated by SMB Equation. The 
current difficulty is SMB Equation contains more than 8 separate Equations and currently there 
is not published software to simulate the relaxivity changes influenced by these factors. There-
fore, it is very help to develop a relaxivity simulator based the SMB Equation.38-40, 42, 44  
Fig. Appendix-7 shows a relaxivity simulator generated by excel based on the SMB Equa-
tion. To simulate relaxivity values, the value of each factor is required to input into the row 4 of 
this work sheet. For example, Gd-DTPA has a τR of 100 ps, while ProCA1 has a τR of 10 ns. After 
input these values, the relaxivity under different magnetic field strength can be calculated au-
tomatically.  
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Figure Appendix-7. The relaxivity simulator to simulate the relaxivity of different MRI con-
trast agents.  
To simulate the relaxivity of a specific MRI contrast agents, τR, τm, τv, Δ
2 and Gd-H distance (RGd-
H)values required to input into this work sheet (row 4, yellow highlight). Then, the relaxivity 
under different magnetic field can be calculated based on the inputed values and SMB Equation. 
38-40, 42, 44 
 
 
